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ABSTRACT 
Particulate matter (PM) as an important part of ambient air pollution has been associated 
with increased risks of cardiovascular diseases. Fibrin clot structure alteration is an emerging 
risk factor of many cardiovascular diseases, especially thrombosis. Therefore, the aim of this 
study was to investigate whether and how air particulate matter affects fibrin clot structure 
and endothelial cell behaviour. 
Turbidity assay, turbidity lysis assay and laser scanning confocal microscopy were used to 
analyse clots formed from normal pooled plasma or purified fibrinogen, in the presence of 
varying concentrations of PM. It was found that clots formed from plasma with higher 
concentrations of particles led to prolonged lysis time compared to control. No differences 
were seen for clots formed from fibrinogen.  
In a study of clots formed from plasma samples collected as part of a previous study on the 
effects of air pollution on deep vein thrombosis (DVT), alterations were observed in clots 
formed from plasma of DVT patients exposed to high levels of PM compared to those exposed 
to low levels, but the same differences were not observed in clots formed from plasma of 
control subjects. 
To investigate the potential role of venous endothelial cells in moderating clot structure 
following exposure to PM, human umbilical vein endothelial cells (HUVEC) were treated with 
PM for 24 hours and clots subsequently formed on the cells. Clots formed from plasma on the 
treated cells were altered compared to controls. RT-PCR and ELISA results showed increased 
gene expression of tissue factor (TF), protein expression of von Willebrand Factor (VWF) and 
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plasminogen activation inhibitor-1 (PAI-1) and decreased thrombomodulin mRNA expression 
which were consistent with changes observed in clot structure.  
Engineered SiO2 nanoparticles caused denser clot structure in clots formed from normal 
pooled plasma. The gene expression of thrombomodulin was inhibited by SiO2 nanoparticles, 
but there were no significant difference in the TF mRNA expression between control and 
treated cells. Silica NPs caused increased concentrations of VWF, but not PAI-1 produced by 
endothelial cells. 
The results presented here show that PM can induce changes to clot structure and function, 
and that changes in gene expression induced in endothelial cells may be a mechanism by 
which a prothrombotic state is induced in response to PM exposure. Furthermore, some, but 
not all, similar changes were observed in clots and cells exposed to SiO2 nanoparticles, raising 
the possibility that such engineered nanoparticles may also have the potential to contribute 
to cardiovascular toxicity.  
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 Introduction  
1.1 Air Pollution 
Air pollution is a combination of gases and particulate matter (PM) varying in chemical 
compositions and concentrations that originate from man-made and natural resources  
(Brook, 2008; Gold and Samet, 2013). Air pollution is significantly associated with increased 
risk of mortality and morbidity (Franchini and Mannucci, 2012; Peters, 2005). The World 
Health Organisation described the worldwide impact of air pollution with 3.6 million 
premature deaths being attributable to ambient air pollution each year in both rural and 
urban areas (Mills et al., 2009; Newby et al., 2014; World Health Organisation, 2011). Many 
studies have shown that exposure to air pollution could lead to adverse effects on the 
pulmonary and cardiovascular systems. It is estimated that there are 80% of premature 
deaths related to ischaemic heart diseases and strokes, 14% of deaths caused by chronic 
obstructive pulmonary diseases or acute lower respiratory infections, and 6% of deaths due 
to lung cancer (World Health Organisation, 2011). Ambient air pollution ranked ninth among 
the modifiable disease risk factors, with other commonly recognized factors such as low 
physical activity, high cholesterol and drug use were all listed below air pollution (Newby et 
al., 2014). The American Heart Association writing group in 2004 illustrated that short-term 
air pollution exposure, especially to the PM, contributes to acute cardiovascular mortality and 
morbidity. For the long-term exposure, life expectancy would be reduced by a few years by 
high PM exposure (Brook et al., 2004).  
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Air pollution includes both indoor air pollution and outdoor air pollution. Indoor air pollution 
refers to the air pollution found in indoors and they are mainly from insufficient combustion 
of biomass fuels such as wood, charcoal, and animal/crop residues for cooking, lighting and 
heating, as well as fabric of buildings, and emissions from building materials such as chemical 
pollutants (Jones, 1999; Rajagopalan and Brook, 2012; World Health Organisation, 2015a, 
2014). According to the World Health Organization, there are still approximately 3 billion 
people using open fires and simple stoves burning biomass and coal for cooking and heating. 
76% of these people are from low- and middle- income countries. The house-hold air pollution 
exposure is particularly high among women and young children (Rajagopalan and Brook, 2012; 
World Health Organisation, 2015b). After exposure to the house-hold air pollution, children 
under five are susceptible to acute lower respiratory infections. And for the adults, ischaemic 
heart disease, stroke, chronic obstructive pulmonary disease and lung cancer are associated 
with the exposure. In 2012, household air pollution contributed 7.7% to global mortality 
(World Health Organisation, 2015b). Outdoor air pollution is an important cause of indoor air 
pollution, similarly, indoor air pollution also contributes to the outdoor air quality (World 
Health Organisation, 2014). In this study, we mainly focused on outdoor air pollution but 
there may be cross over for effects of indoor pollutants, especially from combustion.  
 
 Historical Perspective 
As early as 1273, the use of coal as a fuel in London raised concerns regarding the bad 
influences of air pollution on health (Routledge and Ayres, 2005). In 1872, Robert Angus Smith 
published one of the first feature length air pollution related books, which was entitled “Air 
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and Rain, The Beginning of Chemical Climatology” (Simkhovich et al., 2008; Smith, 1872). 
There were several major air pollution incidents in the 20th century that highlighted the 
impact of air pollution on human health. In the December of 1930, high atmospheric pressure 
mixed with mild winds created a thick and motionless fog in the Meuse Valley in Belgium, the 
fog caused 60 deaths. This air pollution incident was caused by the thick low fog which 
entrapped pollutants from chimney exhausts and created a toxic cloud (Nemery et al., 2001; 
Simkhovich et al., 2008). On the 26th of October, 1945, industrial pollutants from a local 
smelting plant started to accumulate in the air over Donora, Pennsylvania. This incident 
caused 20 fatalities, with approximately 5,000 to 7,000 people (of 14,000 residents) becoming 
ill (Helfand et al., 2001; Simkhovich et al., 2008). In 1952, a dramatic air pollution event, 
referred to as the Great Smog, occurred in Greater London. From 5th to 9th of December, the 
entire city was almost paralysed by the heavy fog carrying pollutants from local industrial 
plants. The PM10 level was between 3,000 to 14,000 µg/m3. The hospital admission rate was 
increased by 48%, especially the respiratory disease related admissions increased by 163%. In 
three months’ time (from December 1952 to February 1953), 12,000 more deaths induced by 
this environmental incident (Davis et al., 2002; Simkhovich et al., 2008; Utell et al., 2002).   




Figure 1-1. Great Smog in Great London, December 1952 
Source: Elliot Wagland, 2013 
After these environmental incidents, at the early 1970s, many countries started to introduce 
and enforce regulations aimed at limiting the effects of air pollutants (Simkhovich et al., 2008; 
Utell et al., 2002). 
 
 Air Pollutants 
Urban air pollution is a heterogeneous mixture of gaseous pollutants and PM (Sun et al., 2010). 
The components of the air pollutants are various depend on the meteorological conditions, 
time of the day, industrial operations, traffic density, etc. (Langrish et al., 2012). But, in 
general, the main components of gaseous pollution include ozone (O3), nitrogen oxides (NOx), 
sulphur dioxide (SO2), carbon monoxide (CO), carbonyl compounds, and organic solvents 
(Newby et al., 2014; Polichetti et al., 2009; Sun et al., 2010). The primary pollutants originate 
from the combustion of fossil fuels, releasing pollutants such as soot particles and oxides of 
nitrogen and sulphur directly into the air (Newby et al., 2014). The major sources of these 
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gaseous pollutants, NOx, SO2, and CO are from high temperature industrial processes (Brook 
et al., 2010). The secondary pollutants are recombined in the atmosphere, for example, ozone 
is formed by complex photochemical reactions of nitrogen oxides and volatile organic 
compound (Newby et al., 2014). 
The PM in air pollution is a mixture of particles, with different sizes, shapes, surface area, 
chemical composition, solubility, and different origins that are suspended in the air (Pope  3rd, 
2009). PM is categorized by aerodynamic diameter to include coarse particles with a diameter 
range less than 10 μm (PM10), fine particles with a diameter less than 2.5 μm (PM2.5), and 
ultrafine particles with a diameter less than 100 nm (PM0.1) (Brook, 2008; Polichetti et al., 
2009). Hence, PM10 contains both PM2.5 and PM0.1. PM10 and PM2.5 are measured in their mass 
per volume of air (μg/m3). However, in consideration of the particle size, ultrafine particulate 
matter are measured by their number per cubic meter (Brook et al., 2010).  
PM consists of many chemical compounds, including organic carbon species, elemental or 
black carbon, and trace metals (e.g. lead and arsenic) (Brook et al., 2010). In terms of the 
origins of PM, coarse particles are mainly from a number of human and natural activities, such 
as mechanical grinding in industries and transportation (Shah et al., 2013). Non-combustion 
surface or randomly releases that arise from agriculture emissions and industrial processes, 
as well as waste management all contribute to the production of coarse particles or even 
larger sizes (Brook et al., 2010). PM2.5 represents approximately 50-70% of the total mass of 
PM10, which is worth noting that PM2.5 can travel larger distances (over 100 km) compared to 
PM10 (Newby et al., 2014). PM2.5 is mainly originated from combustion processes of fossil and 
bio-fuels, as well as high temperature industrial processes and can contribute to smoke and 
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haze in urban areas (Pope, 2009, Brook et al., 2010). The ultrafine particulate matter is mainly 
from fresh combustion and traffic–related pollution (Brook et al., 2010). PM0.1 is very short-
lived and found mainly within only a few hundred meters of its sources (Brook, 2008). 
Ultrafine PM are included in both coarse and fine PM, nevertheless PM0.1 contribute particle 
numbers instead of the mass as they have negligible weight. For the same mass concentration 
of PM, ultrafine PM have much larger surface area and high number of particles compared to 
the larger size of PM. Ultrafine PM acts as a carrier to the lung for absorbed reactive gases, 
free radicals, and metal or organic compounds (Wichmann and Peters, 2000).  
According to the World Health Organisation statistics, the guideline values for PM10 and PM2.5 
are 50 μg/m3 and 25 μg/m3 as the 24-hour mean concentrations; 20 μg/m3 and 10 μg/m3 as 
the annual concentrations (World Health Organisation, 2011). According to the database of 
WHO in 2014, ambient air pollution was monitored in approximately 1600 cities in 91 
countries from 2008 to 2012. The world’s average level of PM10 was 71 μg/m3, region range 
from 26 to 208 µg/m3. Compared to high-income countries, middle- and low- income 
countries had higher PM10 levels, especially those in the Eastern Mediterranean reached the 
highest PM10 level, 208 µg/m3. Africa and South-East Asia also had high levels of PM10 which 
were 78 and 128 µg/m3 respectively (World Health Organisation, 2014). The details of PM10 










Figure 1-2: PM10 levels by region (2008-2012) 
* PM10 values are regional urban population-weighted. 
Afr: Africa;  
Amr: America,  
Emr: Eastern Mediterranean,  
Sear: South-East Asia,  
Wpr: Western Pacific;  
LMI: Low- and Middle-Income countries;  
HIC: High-Income Countries.  
Source: Adapted from World Health Organisation, 2014 (World Health Organisation, 2014) 
PM10 are identified as “inhalable particles” (Mills et al., 2009) as they are able to enter into 
the lung through the respiratory tract (Shah et al., 2013). Coarse particles most likely deposit 
in upper and larger airways. Fine particulate matter can transfer into deeper respiratory tract, 
with deposition in the alveolar region (Snow et al., 2014, Sun et al., 2010) then affect the 
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Due to the small size, those particles are difficult to be cleared by alveolar macrophages as 
alveolar macrophages may not be able to recognize particles with a diameter less than 500nm 
(Snow et al., 2014), hence, ultrafine PM is able to be exempted from phagocytosis. While 
PM0.1 deposits in the deeper alveolar region, particles may interfere with cells, fluids, and 
tissues of the lungs due to their large surface area. Also, the ultrafine particles may be able to 
translocate to different organs by crossing into the circulatory and/or lymphatic systems 
(Wichmann and Peters, 2000). 
Population and individual level of exposure to the air pollutants are different due to greatest 
impact on concentrations by multiple time scales, weather patterns, seasonal cycles in solar 
radiation and temperature (Brook et al., 2010). Compared to PM10 and PM0.1, PM2.5 has the 
longest atmospheric lifetime and can be spread by the prevailing winds over large geographic 
regions and leads to greater number of people being exposed to similar levels (Brook et al., 
2010). Also, actual exposure to all pollutants vary at the personal level can be various 
depending on the different microenvironments or activities an individual experiences (Brook 
et al., 2010). 
Air particulate matter could increase the risks of cardiovascular diseases through two 
pathways. Firstly, PM may have direct effects on the lung and cardiovascular system. 
Alternatively, particles may provoke either pulmonary inflammation or oxidative stress or 
both, with release of prothrombotic and inflammatory cytokines into the circulation (Chuang 
et al., 2007, Mills et al., 2009). But there are limited evidence in the specific particulate 
constituents and sources responsible (Brook et al., 2010). 
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 Routes of Exposure 
Humans are exposed to air pollutants mainly through the respiratory system. Food and water 
are contaminated by the ambient air pollutants; therefore, ingestion can be the second major 
route of air pollutants intake (Kampa and Castanas, 2008; Thron, 1996). Also, dermal contacts 
may also be taken into account as a minor route of exposure to air pollutants. To a certain 
degree, the air pollutants can be eliminated though excretion (Kampa and Castanas, 2008; 
Madden and Fowler, 2000). 
 
1.2 Cardiovascular System and Diseases  
The cardiovascular system is composed of the heart, blood vessels and blood (Aaronson and 
Ward, 2007). The heart includes two muscle pumps, the right and left ventricles (Aaronson 
and Ward, 2007; Levy et al., 2007). Each pump is connected with a contractile reservoir, the 
right or left atrium; and serves different circulations (Aaronson and Ward, 2007). The 
pulmonary circulation starts from the right ventricle. The deoxygenated blood is pumped 
through the pulmonary trunk to the lungs, four pulmonary veins return oxygenated blood 
from the lungs to the left atrium to complete the short and low pressure circulation (Aaronson 
and Ward, 2007). The left ventricle propels the oxygenated blood to all other tissues of the 
body. The tissues absorb some of the oxygen, and partly deoxygenated blood returns via two 
great veins, the superior vena cava and inferior vena cava, to the right atrium. This second, 
systemic circulation loop is under higher pressure and is longer compared to the pulmonary 
circulation (Aaronson and Ward, 2007; Levick, 2003). 
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The primary function of the cardiovascular system (CVS) is distributing oxygen, glucose, amino 
acids, fatty acids, hormones, vitamins and water to the tissues; and removing the metabolic 
by-products from the tissues (carbon dioxide, urea, creatinine) (Aaronson and Ward, 2007; 
Levy et al., 2007). Secondly, the CVS regulates the body temperature through transporting 
the heat from deep organs to the skin surface and regulate heat loss from the skin. Thirdly, 
the CVS maintains the body under homeostatic stasis by controlling the humoral 
communication throughout the body (Aaronson and Ward, 2007; Levick, 2003; Levy et al., 
2007). 
According to World Health Organisation (WHO), a group of disorders affecting the heart, brain, 
and blood vessels are classified as cardiovascular diseases (CVDs), such as coronary heart 
disease, cerebrovascular disease, raised blood pressure, venous thrombosis, pulmonary 
embolism, peripheral artery disease, rheumatic heart disease, congenital heart disease and 
heart failure (World Health Organisation, 2011). According to the WHO Statistics, CVDs are 
the number one cause of death around the world. About 17.3 million people died from CVDs 
in 2008 representing 30% of all deaths worldwide. CVDs are projected to be the single leading 
cause of death and it is estimated that 25 million people will die from CVDs by 2030 (World 
Health Organisation, 2011).  
In the UK, CVD accounted for about 180,000 deaths in 2010 – about one in three of all deaths 
that year (British Heart Foundation, 2012). In addition, the report from the Centre for Disease 
Control and Prevention (CDC) in the U.S demonstrated that CVD caused 761,085 deaths in 
1981 and 700,142 in 2001 (Brook et al., 2010). The main types of CVD are coronary artery 
disease (CAD) and stroke, of which 45% of CVD mortality is from CAD and 28% is from stroke 
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(British Heart Foundation, 2012). There are also a variety of cardiovascular diseases, but 
atherosclerosis and hypertension are the most common types (Ajjan and Ariens, 2009). Many 
factors increase the risks for developing CVDs, including tobacco use, physical inactivity, 
diabetes, obesity and raised blood pressure (Frayn et al., 2005). Modern lifestyle changes lead 
to the increase of many of these CVD risk factors.  
 
 Coronary Artery Disease 
The coronary artery disease also known as coronary heart disease, is a condition in which the 
walls of the coronary arteries supplying the oxygen-rich blood to the muscle of the heart 
become thickened, therefore, the coronary artery lumen gets narrowed and the blood flow 
reduces (Libby and Theroux, 2005). The presence of atherosclerosis plaque leads to coronary 
artery disease that is a chronic process starting from early of adolescent life and continues to 
develop throughout the life time (Libby and Theroux, 2005). 
CAD causes the highest mortality rate in the UK which is approximately 82,000 deaths per 
year. Men have higher mortality rate of CAD which is one in five compared to women’s one 
in ten (British Heart Foundation, 2012). However, after the age of 50, men and women have 
a similar risk rate. One recent study showed there were about 2.7 million people suffering 
from CAD, in which about 2 million people were affected by angina in the UK (Mahmood, 
2009). There are also two other common symptoms as well as angina, heart attacks and heart 
failure (Frayn et al., 2005).  
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 Thrombosis 
Thrombus formation is a dynamic process and in which shear stress, flow, turbulence, and the 
number of platelets in the circulation greatly impact the structure of the clot. Thrombosis 
refers to the clot formation within the vessel that reduces the blood flow or blocks the vessel 
completely therefore leading to myocardial tissue infarction (Mackman, 2012). The two most 
common types of thrombosis occur in the arteries and veins.  
Arterial thrombosis refers to the thrombus forms in the arteries. In most cases, arterial 
thrombosis is caused by the rupture of plaques. Myocardial infarction, unstable angina, 
ischemia stroke, arterial fibrillation and peripheral arterial diseases are all belonging to 
arterial thrombosis. The risk factors of arterial thrombosis include age, smoking, obesity, high 
blood pressure, lack of physical activity, high cholesterol level, and diabetes (Celinska-
Lowenhoff et al., 2011; Meltzer et al., 2007). 
Venous thromboembolic diseases include deep vein thrombosis (DVT), which occurs in the 
legs or arms, and pulmonary embolism, which occurs when a piece of the deep vein thrombus 
in the leg (or arm) breaks off (embolism) and travels to the lung through the vena cava, right 
atrium/ventricle and pulmonary artery to block a blood vessel in the lung (Mackman, 2012). 
Venous thrombosis begins at the venous valves (Esmon, 2009). A triad of causes for venous 
thrombosis was proposed by Virchow in 1856 including 1) changes in blood coagulability, 2) 
changes in vessel wall and 3) circulatory stasis (Esmon, 2009). Elevated level of coagulation 
factors and defects of natural anti-coagulants are both associated with risk of venous 
thrombosis (Esmon, 2009). However, compared to age and carcinoma, these factors are less 
frequent contributors to venous thrombosis. Cancer is able to increase the risks of venous 
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thrombosis about 6 to 10 fold through three pathways: generating tissue factor (TF) to initiate 
the coagulation, shedding procoagulant lipid microparticles, or impairing blood flow (Esmon, 
2009). Venous thrombosis is the second leading cause of death in patients with cancer (Furie 
and Furie, 2008). High levels of FVIII, FIX and FXII are able to increase the risk of venous 
thrombosis  two-fold (Bouma and Mosnier, 2006; Koster et al., 1995; Meijers et al., 2000; van 
Hylckama Vlieg et al., 2000). Factor V Leiden is a gene defect which is found in one third of 
the Caucasian patients with venous throboembolism. Factor V Leiden has a mutation Arg506 
which is between Arg to Gln mutation. This form of FV is not be able to be cleaved by activated 
protein C, thus can not support the APC-driven inactivation of FVIIIa. Subjects with 
heterozygous or homozygous FV Leiden will have 5 and 50 fold increased risks of venousm 
thrombosis, respectively (Bertina et al., 1994; Dahlbäck and Villoutreix, 2005; Rosendaal and 
Reitsma, 2009; Versteeg et al., 2013).  
 
1.3 PM Effects on Cardio-respiratory System 
Many epidemiological and experimental studies have shown that the cardiovascular system 
and the respiratory system are particularly influenced by PM (Kampa 2008, Cohen 2005, 
Huang 2006, Kunzli 2005, Sharma 2005). 
The PM in urban air pollution has been associated with cardiovascular mortality and morbidity 
in a number of studies (Brook et al., 2010; Newby et al., 2014). There are several 
cardiovascular diseases where exposure to PM has been shown to contribute to risk, including 
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ischemic heart disease, heart failure, cerebrovascular disease, cardiac arrhythmias, peripheral 
arterial and venous diseases (Brook et al., 2010; Mills et al., 2009; Newby et al., 2014).  
The epidemiological studies can be broadly categorized to short-term exposure studies and 
long-term exposure studies. Different types of effects may be expected with different 
exposure terms. For the short-term exposure, acute effects can be induced such as autonomic 
imbalance and systematic inflammation (Brook, 2008). Both initiation and aggravation of 
diseases are caused after long term air pollution exposure, for example, the progression of 
atherosclerosis. Also, carcinogenesis is another possible latent effect (Brook, 2008; Routledge 
and Ayres, 2005). Observational studies and experimental studies of different sizes of PM are 
described respectively as follows.  
 
 PM10 
There are many epidemiological studies focused on the long-term effects of PM10 on the 
cardiovascular system. Several key studies are summarised in the table 1-1.  
There is a study focused on the associations between air pollution and cardiovascular hospital 
admissions for people aged over 65 years from 1986 to 1989 in Michigan, U.S, an increase of 
32 μg/m3 of PM10 concentrations were associated with increased ischemic heart disease 
hospitalisation (adjusted relative risk (RR) = 1.018, 95% confidence interval (CI)  = 1.005--1.032) 
(Schwartz and Morris, 1995). A German cohort study carried out from 1985-2003 showed 
cardiopulmonary mortality was associated with residents living within a 50-meter radius of a 
major road (RR = 1.70; 95% CI = 1.02--2.81) and with PM10 exposure (adjusted RR = 1.34; 95% 
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CI = 1.06--1.71 for 1-year average) (Gehring et al., 2006). A 67% increase in risk of deep vein 
thrombosis for each 10 µg/m3 elevation of PM10 was observed in a large cohort study with 16 
year follow up (from 1995 to 2005) in the Lombardy region (OR = 1.70; 95% CI = 1.30--2.23) 
(Baccarelli et al., 2008). A retrospective cohort study carried out from 1998-2009 in Shenyang, 
China, reported that every 10 µg/m3 of PM10 caused a 55% increased cardiovascular mortality 
(hazard ratio HR = 1.55; 95% CI = 1.51--1.60) and 49% increase in cerebrovascular morbidity 
(HR = 1.49; 95% CI = 1.45--1.53), respectively (Zhang et al., 2011). A census mortality study 
from New Zealand from 1996-1999 showed that every 10 μg/m3 increase in average PM10 
exposure was related to a 7% (95% CI = 3%--10%) increase of all-cause mortality in adults aged 
30-74 years at census (Hales et al., 2012). According to another cohort study from 1985 to 
2008, an increase of 10 μg/m3 PM10 was associated with an increased hazard ratio for all-
cause mortality (HR = 1.15, 95% CI = 1.04--1.27), cardiopulmonary mortality (HR = 1.39, 95% 
CI = 1.17--1.64), and lung cancer mortality (HR = 1.84, 95% CI = 1.23--2.74) (Heinrich et al., 
2013). In a prospective cohort study of 71,431 middle-aged Chinese men who were studied 
from 1990 to 2006, PM10 was significantly correlated with mortality from cardiopulmonary 
diseases, with every 10 µg/m3 of PM10 increase being associated with 1.6% increased total 
mortality rate (95% CI = 0.7%--2.6%), 1.8% increased cardiovascular mortality rate (95% CI = 
0.8%--2.9%), and 1.7% increased respiratory mortality rate (95% CI = 0.3%--3.2%) (Zhou et al., 
2014). Another retrospective cohort study focused on the association between long-term 
PM10 exposure and cardiovascular mortality rate in 4 cities of China from 1998-2009. Each 
elevated 10 µg/m3 of PM10 lead to the increase of relative risk ratios (RRs) of all-cause 
mortality, 1.24 (95% CI = 1.22--1.27), cardiovascular disease mortality, 1.23 (95% CI = 1.19--
1.26), ischemic heart disease mortality, 1.37 (95% CI = 1.28--1.47), heart failure disease 
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mortality, 1.11(95% CI = 1.05--1.17), and cerebrovascular disease mortality, 1.23(95% CI = 
1.18--1.28) (Zhang et al., 2014). Every 10 µg/m3 elevation of PM10 concentration increases the 
risks of hospitalization for myocardial infarction  (Mu et al., 2014; Polichetti et al., 2009).  
This meta-analysis showed that every 10 μg/m3 elevation in PM10 concentration was 
associated with 1.63% increased heart failure hospitalisation or death rate (95% CI = 1.20%--
2.07%) (Morris, 2001). Also, a systematic review focused on the Chinese population and 1464 
articles and indicated that every 10 μg/m3 increase in PM10 results in 23–67% increase in the 
risk of total mortality (Lu et al., 2015). 
There are a few epidemiological studies focused on short-term exposure of PM10 (Table 1-1). 
Schwartz investigated admissions to all hospitals in Tucson, Arizona, for cardiovascular 
disease in people aged over 65 years. An inter-quartile range increase (23 micrograms per m3) 
in PM10 was associated with increased hospital admissions by 2.75% (95% CI = 0.52%--5.04%) 
(Schwartz, 1997). Revised Analysis of National Morbidity, Mortality, and Air Pollution Study 
(NMMAPS) recruited from 20 to 100 cities in the U.S. Data was collected from 1987 to 1994. 
The results showed that PM10 significantly increased the risks of both cardiovascular and 
respiratory deaths. Every 10 μg/cm3 elevation of PM10 increased 0.68% of death (95% 
posterior interval, 0.20 to 1.16 percent) (Samet et al., 2000). The European Approach 2 
(Agency for Public Health Education Accreditation APHEA2) project conducted in eight 
European cities (Barcelona, Birmingham, London, Milan, the Netherlands, Paris, Rome, and 
Stockholm) focused on the short-term effects of ambient PM on the mortality rate in 29 
European countries. For all ages, every daily increase of 10 μg/m3 of PM10 or black smoke 
were associated with 0.6% increase in daily deaths (95% CI = 0.4--0.8%), for the elderly it was 
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slightly higher (Katsouyanni et al., 2001). It also found that 0.5% (95% CI = 0.2--0.8) of cardiac 
hospital admissions for all ages was correlated with 10 μg/m3 of PM10, and 0.7% (95% CI = 0.4-
-1.0) for cardiac admissions over 65 years (Le Tertre et al., 2002). Another study was 
conducted in 7 United States cities from 1986 and 1999 focused on the association between 
daily levels of PM10 and the rate of hospitalization for congestive heart failure (CHF) in 
Medicare recipients (age > or = 65 years). It indicated a 10 μg/m3 increase in PM10 was 
associated with a 0.72% (95% CI = 0.35%--1.10%) increase in the rate of admission for CHF on 
the same day (Wellenius et al., 2006). From 1987 to 1993, Ponka et al. investigated the 
association between daily concentrations of SiO2, NO2, O3, and PM10, and the daily number of 
deaths from all causes and cardiovascular causes. The results showed that every 10 μg/m3 of 
PM10 were associated with 3.5% (95% CI = 1.0--5.8) and 4.1% (95% CI = 0.4--10.3) increases of 
total mortality and cardiovascular mortality respectively (Pönkä et al., 2010). Analitis et al. 
investigated the short-term effects of ambient particle concentrations (on cardiovascular and 
respiratory mortality from 29 European cities. The results showed 10 μg/m3 increase of PM10 
was associated with increases of 0.76% (95% CI = 0.47%--0.05%) in cardiovascular deaths and 
0.58% (0.21 to 0.95%) in respiratory deaths (Rajzer et al., 2012). PM10 includes particles 
derived from non-anthropogenic sources such as salt and dust particles. In a study conducted 
in 13 south-European cities the association between PM10 originating from desert and from 
other sources with daily mortality and emergency hospitalizations rate was investigated. The 
results showed that increases of 10 μg/m3 in non-desert and desert PM10 were associated 
with increases in natural mortality of 0.55% (95% CI = 0.24%--0.87%) and 0.65% (95% CI = 
0.24%--1.06%), respectively (Stafoggia et al., 2015).  
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A systemic review focused on the association between short term exposures of fine PM and 
morbidity and mortality rate of heart failure. This review contains 1146 articles in 5 databases. 
It showed every 10 μg/m3 increase in PM10 caused 1.63% (95% CI = 1.20%--2.07%) increase of 
total heart failure mortality and morbidity rate (Shah et al., 2013). Wang et al. focused on the 
short term effects of ambient particulate matter on cerebrovascular events which contained 
all observational human studies from January 1966 to January 2014. Meta-analysis was 
performed to evaluate the associations in this systematic review that each 10 μg/m3 increase 
in PM10 was associated with 0.5% (95% CI = 0.3%--0.7%) increased in total cerebrovascular 
deaths (Wang et al., 2014). Another systematic review and meta-analysis focused on the 
Chinese population and 1464 articles were included from PubMed, Web of Science, and China 
National Knowledge Infrastructure databases. For the short term effects, cardiovascular 
mortality and respiratory mortality increased 0.36% (95%CI = 0.24%--0.49%), and 0.42% 
(95%CI = 0.28%--0.55%) after 10 μg/m3 increase in PM10 (Lu et al., 2015). 
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Study Key Findings Year References 
Long-term Study: Study in 
Michigan, US 
An increase of 32 μg/m3 of PM10 concentrations were associated with 
ischemic heart disease hospitalisation (RR = 1.018, 95% CI = 1.005--
1.032) 
1986-1989 Schwartz & Morris, 
1995 
Long-term Study: German 
cohort study  
 
Cardiopulmonary mortality was associated with living within a 50-
meter radius of a major road (RR = 1.70; 95% CI = 1.02--2.81) with PM10 
(RR = 1.34; 95% CI = 1.06--1.71 for 1-year average) 
1985-2003 Gehring et al., 2006 
Long-term Study: Cohort 
Study in Lombardy, Italy 
A 70% increase in risk of deep vein thrombosis for each 10 µg/m3 
elevation of PM10 was observed with 16 year follow up (OR = 1.70; 95% 
CI = 1.30--2.23)  
1995-2005 Baccarelli et al., 2008 
Long-term Study: 
Retrospective Cohort Study 
in Shenyang, China 
An increase of every 10 µg/m3 of PM10 caused 55% increased 
cardiovascular mortality (HR = 1.55; 95% CI = 1.51--1.60) and 49% 
increase in cerebrovascular mobility (HR = 1.49; 95% CI = 1.45--1.53)  
1998-2009 Zhang et al., 2011 
Long-term Study: New 
Zealand Census Mortality 
Study 
Every 10 μg/m3 increase in average PM10 exposure increased 7% (95% 
CI = 3%--10%) of all-cause mortality in adults (aged 30-74 years at 
census) 
1996-1999 Hales et al., 2012 
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Long-term Study: German 
Women Perspective Cohort 
Study 
An increase of 10 μg/m3 PM10 was associated with an increased hazard 
ratio (HR) for all-cause (HR = 1.15, 95% CI = 1.04--1.27), 
cardiopulmonary (HR = 1.39, 95% CI = 1.17--1.64), and lung cancer 
mortality (HR = 1.84, 95% CI = 1.23--2.74) 
1985-2008 Heinrich et al., 2013 
Long-term Study: 
Retrospective cohort Study 
in 4 cities of China 
For each elevated 10 µg/m3 of PM10  lead to the increase of relative risk 
ratios of all-cause mortality, cardiovascular disease mortality, ischemic 
heart disease mortality, heart failure disease mortality, and 
cerebrovascular disease mortality were 1.24 (95% CI = 1.22--1.27), 1.23 
(95% CI = 1.19--1.26), 1.37 (95% CI = 1.28--1.47), 1.11(95% CI = 1.05--
1.17), and 1.23(95% CI = 1.18--1.28), respectively. 
1998-2009 Zhang et al., 2014 
Long-term Study: Systematic 
Review &  Meta-Analysis 
Every 10 μg/m3 elevation in PM10 concentration was associated with 
1.63% increased heart failure hospitalisation or death rate (95% CI = 
1.20%--2.07%). 
 Morris, 2001 
Long-term Study: Systematic 
Review &  Meta-Analysis in 
Chinese Population 
After the long term exposure, 10 μg/m3 increase in PM10 result in 23–
67% increase in the risk of total mortality. 
 Lu et al., 2015 
Short-term Study: Tucson An inter-quartile range increase (23 micrograms per m3) in PM10 was associated with 
increased hospital admissions by 2.75% (95% CI = 0.52%--5.04%) 
Schwartz, 1997 
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Short-term Study: NMMAPS 
Study 
PM10 significantly increased the risks of both cardiovascular and respiratory caused 
deaths. Every 10 μg/cm3 elevation of PM10 increased 0.68% of death (95% posterior 
interval = 0.20%--1.16%). 
Samet et al., 2000 
Short-term Study: APHEA2 
Study 
For all ages, every daily increase of 10 μg/m3 of PM10 or black smoke were associated 
with 0.6% of daily deaths (95% CI = 0.4--0.8%), for the elderly it was slightly higher 
Katsouyanni et al., 
2001 
Short-term Study: APHEA2 
Study 
The association between PM and cardiovascular caused hospital admissions. 0.5% 
(95% CI = 0.2--0.8) of cardiac admissions for all ages was correlated with 10 μg/m3 of 
PM10, and 0.7% (95% CI = 0.4--1.0) for cardiac admissions over 65 years 
Le Tertre et al., 2002 
Short-term Study: 7 United 
States cities 
10 μg/m3 Increase in PM10 was associated with a 0.72% (95% CI = 0.35%--1.10%) 
increase in the rate of admission for CHF on the same day  
Wellenius et al., 
2006 
Short-term Study: Helsinki, 
Finland 
Every 10 μg/m3 of PM10 were associated with 3.5% (95% CI = 1.0--5.8) and 4.1% (95% 
CI = 0.4--10.3) increases of total mortality and cardiovascular mortality respectively 
Pönkä et al., 2010 
Short-term Study: 29 
European cities 
10 μg/m3 Increase of PM10 was associated with increases of 0.76% (95% CI = 0.47--
0.05%) in cardiovascular deaths and 0.58% (0.21 to 0.95%) in respiratory deaths 
Rajzer et al., 2012 
Short-term Study: 13 South-
European Cities 
Increases of 10-μg/m3 in non-desert and desert PM10 were associated with increases 
in natural mortality of 0.55% (95% CI = 0.24%--0.87%) and 0.65% (95% CI = 0.24%--
1.06%), respectively  
Stafoggia et al., 2015 
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Every 10 μg/m3 increase in PM10 caused 1.63% (95% CI = 1.20%--2.07%) increase of 
total heart failure mortality and morbidity rate 
Shah et al., 2013 
Short-term Study: 
Systematic Review 
Every 10 μg/m3 increase in PM10 was associated with 0.5% (95% CI = 0.3%--0.7%) 
increased in total cerebrovascular deaths 
Wang et al., 2014 
Systematic Review For the short term effects, cardiovascular mortality and respiratory mortality 
increased 0.36% (95%CI = 0.24%--0.49%), and 0.42% (95%CI = 0.28%--0.55%) after 10 
μg/m3 increase in PM10 
Lu et al., 2015 
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 PM2.5 
According to the World Health Organisation, there are approximately 80,000 premature 
deaths every year caused by the long-term exposure to PM2.5, ranking it as the 13th leading 
cause of death worldwide (Brook et al., 2010). Evidence for the role of PM2.5 in cardiovascular 
disease comes from several studies of short term exposure. One of the difficulties with this 
type of epidemiological study is the accurate measurement of exposure. Some studies have 
compared health outcomes between cities based on the average exposure levels in the 
different cities (Dockery, 1993; Pope et al., 1995; C. Arden Pope et al., 2004). A large cohort 
study followed-up for 9 years on 8096 people living in 6 U.S cities from 1979 to 1988. PM2.5 
exposure measurement was based on the city-specific mean concentrations of PM2.5. Each 
elevated 10 μg/m3 in PM2.5 was associated with increased cardiovascular mortality (RR = 1.28; 
95% CI = 1.13--1.44) and lung cancer (RR = 1.27; 95% CI = 0.96--1.69) (Laden et al., 2006). 
However, these approaches miss potentially important effects of more local variations in 
exposure. To address this, Miller et al (2007) assigned exposure data from community level 
monitors (based on average yearly data from the monitor closest to the subject’s address 
based on ZIP code) to query the role of PM2.5 exposure in cardiovascular disease among a 
cohort of 65,893 postmenopausal women without previous cardiovascular diseases recruited 
in the U.S and followed up for 6 years from 1994 to 1998. The average yearly exposure 
concentrations of PM2.5 ranged from 3.4 to 28.3 μg/m3. Every increase of 10 μg/m3 of PM2.5 
was associated with a 24% increase in the risk of a cardiovascular event (HR = 1.24; 95% CI = 
1.09--1.41) and a 76% increase in the risk of death from cardiovascular disease (HR = 1.76; 95% 
CI = 1.25--2.47) (Miller et al., 2007).  
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In a study in Massachusetts, USA, conducted from 2000 to 2008, Kloog et al used more 
sophisticated geographical grid based methods for estimating exposure to PM2.5. This 
approach used air pollution prediction modelling at a solution of 50 m2 as a basis for studying 
particle related mortality. The results showed that every 10 μg/m3 increase in long-term PM2.5 
exposure was associated with an OR of 1.6 (95% CI = 1.5--1.8) for particle-related diseases 
(Kloog et al., 2013).  Using a time-series approach to study short term exposure effects, the 
same study found that for every 10 μg/m3 increase in PM2.5 exposure there was a 2.8% 
increase in PM-related mortality (95% CI= 2.3--3.5) (Kloog et al., 2013).  
 A Harvard Six Cities Extended Follow-Up study was conducted for 11 additional years. From 
2001, average PM2.5 concentration was less than 18 μg/m3. Every 10 μg/m3 elevation of PM2.5  
caused 14% (95% CI = 7--22%) increased risk of total mortality, and 26% (95% CI, 14-40%)  
cardiovascular mortality and 37% (95% CI = 7--75%) lung-cancer mortality (Lepeule et al., 
2012). A systemic review focused on 33 Chinese studies of short-term air pollution exposure, 
every 10 µg/m3 elevation of PM2.5  was associated with a 0.38% (95% CI = 0.31--0.45) increase 
in total mortality, a 0.51% (95% CI = 0.30--0.73) in respiratory mortality, and a 0.44% (95% CI 
= 0.33--0.54) in cardiovascular mortality  (Shang et al., 2013). An exposure study of PM2.5 in 
Massachusetts, United States also investigated the short-term exposure effects of on 
cardiovascular and respiratory diseases. The results indicated that every 10 μg/m3 increase in 
PM2.5 exposure there was a 2.8% increase in PM-related mortality (95% CI = 2.0--3.5) (Kloog 
et al., 2013).  
A systemic review of 33 Chinese studies of short-term air pollution exposure, included a meta-
analysis that found that every 10 µg/m3 elevation of PM2.5 was associated with a 0.38% (95% 
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CI = 0.31--0.45) increase in total mortality, a 0.51% (95% CI = 0.30--0.73) in respiratory 
mortality, and a 0.44% (95% CI = 0.33--0.54) in cardiovascular mortality (Shang et al., 2013). 
The authors calculated that reducing PM2.5 exposure average to 10 μg/m3 would lead to a 
reduction of premature deaths of between 1.7 and 6.2% in 4 Chinese megacities (Beijing, 
Shanghai, Guangzhou and Xi’an). A systemic review focused on the association between short 
term exposures of fine particulate matter and morbidity and mortality rate of heart failure. It 
showed every 10 μg/m3 increase in PM2.5 caused 2.12% (95% CI = 1.42%--2.82%) increase of 
total heart failure mortality and morbidity rate (Shah et al., 2013). Want et al. conducted a 
systematic review focused on the short term effects of ambient particulate matter on 
cerebrovascular events which contained all observational human studies from January 1966 
to January 2014. Meta-analysis was performed to evaluate the associations that after 10 
μg/m3 increase in PM2.5, total cerebrovascular deaths  increased 1.4% (95% CI = 0.9%--1.9%) 
(Wang et al., 2014). Another systematic review and meta-analysis focused on the Chinese 
population and 1464 articles were included from PubMed, Web of Science, and China 
National Knowledge Infrastructure databases. For the short term effects, after 10 μg/m3 
increase in PM2.5 cardiovascular mortality and respiratory mortality had 0.63% (95%CI = 
0.35%--0.91%), and 0.75% (95%CI = 1.39%--1.11%) increased risk, respectively (Lu et al., 2015). 
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Study Key Finding Time References 
Long-term Study: Harvard Six 
Cities Studies (Extended) 
Each elevated 10 μg/m3 in PM2.5 was associated with increased 
cardiovascular mortality (RR, 1.28; 95% CI = 1.13--1.44) and lung cancer 
(RR, 1.27; 95% CI = 0.96--1.69).  
1979-1988 Laden et al., 2006 
Long-term Study : 
Postmenopausal Women 
Cohort Study, U.S 
Every increase of 10 μg/m3 of PM2.5 was associated with a 24% increase 
in the risk of a cardiovascular event (HR, 1.24; 95% CI = 1.09--1.41) and a 
76% increase in the risk of death from cardiovascular disease (HR, 1.76; 
95% CI = 1.25--2.47). 
1994-1998 Miller et al., 2007 
Long-term Study: Study in 
Massachusetts,  U.S 
Every 10 μg/m3 increase in long-term PM2.5 exposure of 1.6 (CI = 1.5--1.8) 
for particle-related diseases. 
2000-2008 Kloog et al., 2013 
Short-term Study: Harvard Six 
Cities Extended Follow-Up 
Study 
Every 10 μg/m3 elevation of PM2.5 caused 14% (95% CI = 7%--22%) increased risk of total 
mortality, and 26% (95% CI, 14-40%) cardiovascular mortality and 37% (95% CI = 7%--75%) 
lung-cancer mortality. 
Lepeule et al., 
2012 
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Short-term Study: Systemic 
Review, China 
Every 10 µg/m3 elevation of PM2.5 was associated with a 0.38% (95% CI = 0.31--0.45) 
increase in total mortality, a 0.51% (95% CI = 0.30--0.73) in respiratory mortality, and a 
0.44% (95% CI = 0.33--0.54) in cardiovascular mortality. 
Shang et al., 2013 
Short-term Study: Study in 
Massachusetts,  U.S 
Every 10-μg/m3 increase in PM2.5 exposure there was a 2.8% increase in PM-related 
mortality (95% CI = 2.0–3.5). 
Kloog et al., 2013 
Short-term Study: Systematic 
Review 
Every 10 μg/m3 increase in PM2.5 caused 2.12% (95% CI = 1.42%--2.82%) increase of total 
heart failure mortality and morbidity rate. 
Shah et al., 2013 
Short-term Study: Systematic 
Review 
Every 10 μg/m3 increase in PM2.5 was associated with 1.4% (95% CI = 0.9%--1.9%) increased 
in total cerebrovascular deaths (Wang et al., 2014). 
Wang et al., 2014 
Short-term Study: Systematic 
Review 
For the short term effects, after 10 μg/m3 increase in PM2.5 cardiovascular mortality and 
respiratory mortality had 0.63% (95%CI = 0.35%--0.91%), and 0.75% (95%CI = 1.39%--1.11%) 
increased risk, respectively. 
Lu et al., 2015 
Table 1-2.Summary of the some important studies on both short-term and long-term effects of PM2.5 on the cardiovascular system 
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 PM0.1 
Ultrafine particles (below 0.1 µm) are small enough to be potentially taken up into the 
circulatory system. An in vivo human study has confirmed this by using inhaled technetium-
99m labelled carbon particles, which are similar in size to ambient ultrafine air pollution 
particles, to test whether such particles could translocate from the respiratory system to the 
circulatory system. Through γ-ray camera images, substantial radioactivity was found in the 
liver and other organs of the body, indicating that the inhaled particles could be able to pass 
rapidly into the systemic circulation (Nemmar et al., 2002). 
Another study showed the potential for ultrafine particles to induce oxidative damage 
investigated whether the soluble ultrafine particles could induce procoagulant responses in 
human coronary artery endothelial cells (Snow et al., 2014). The results showed that soluble 
ultrafine particles could induce procoagulant responses in human coronary artery endothelial 
cells and result in the increased production of intracellular ROS and activation of the NOX-4 
enzyme that regulates tissue factor mRNA (Snow et al., 2014).  
There is a study focused on effects of ultrafine petrol exhaust particles on human A549 lung 
cells and alveolar macrophages (murine RAW 264.7 cells). After 24 hours treatment, the 
particles induced significant oxidative stress (A549 cell line: 20 and 50 µg/ml; macrophage: 10 
and 20 µg/ml) with membrane leakage, lipid peroxidation, cell inflammation and protein 
release (Durga et al., 2014). 
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 Diesel Particles 
Diesel exhaust emission is one kind of the key sources of urban PM10 exposure, so the 
epidemiological studies discussed above have included such PM in the exposure data, as it is 
difficult to separate out the specific contribution of diesel PM in such studies. There have 
been experimental studies showing the effects of typical ambient diesel exhaust particles on 
cardiovascular and respiratory systems.  
In a randomized, double-blinded exposure study, 19 healthy young volunteers (mean age, 25 
± 3 years) were divided into three groups that respectively exposed to filtered air, diesel 
exhaust with particle trap, and diesel exhaust without particle trap for 1 hour (Lucking et al., 
2011). Compared to those volunteers who exposed to filtered air, those inhaled diesel 
exhaust had reduced vasodilatation and increased ex vivo thrombus formation under both 
low- and high- shear conditions. The diesel exhaust in the presence of particle trap had 
significantly decreased particle number (150,000 - 300,000/cm3 to 30 – 300/cm3) and mass 
(320 ± 10 to 7.2 ± 2.0 µg/m3) compared to the diesel exhaust in the absence of particle trap, 
and showed increased vasodilatation, reduced thrombus formation and increased tPA 
expression compared to the latter group (Lucking et al., 2011).  
Understanding the effects of diesel PM on the types of cells likely to be exposed is another 
approach to investigating the health effects of such PM. In one study, human primary small 
airway epithelial cells and human lung carcinoma epithelial A549 cells were treated with 
diesel particles for 2 hours. Atomic force microscope measurements indicated that short-term 
diesel particle exposure led to a significant decrease in cell elasticity and a dramatic change 
in membrane surface adhesion force. The ELISA results showed that DEP-induced 
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inflammatory responses were found in both cell types after the quantification of cytokines 
and chemokines production (Tang et al., 2012). 
An in vitro study from Solomon et al. investigated the effects of diesel particle on platelets. 
The results indicated that diesel particle physically interacted with platelets aggregation, 
induced signaling and functioning of the activation of platelets, suggesting a possible 
mechanism to link exposure to diesel particles with platelet driven thrombotic events 
(Solomon et al., 2013).  
 
 Subclinical Pathophysiological Responses 
Systemic Inflammation 
There is abundant evidence have shown that exposure to PM leads to the elevation of 
circulating pro-inflammatory biomarkers which indicates a systemic response after PM air 
pollution inhalation (Brook et al., 2010). After the short-term exposure of ambient PM, acute-
phase proteins such as C-reactive protein (CRP), fibrinogen and white blood cells counts 
increased in young overweight adults (Zeka et al., 2006), and the elderly (Pope et al., 2004); 
also the tumour necrosis factor-α (TNF-α) and interleukin (IL)-1β increase in children 
(Calderón-Garcidueñas et al., 2008). Increased ultrafine PM concentration also led to an 
immediate elevation in soluble CD40-ligand in patients with coronary artery disease (Rückerl 
et al., 2007). For the long-term PM10 exposure, elevated white blood cells count was reported 
after approximately 1-year exposure in the Third National Health and Nutrition Examination 
Survey (Brook et al., 2010). Overall, positive associations have been seen between the 
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exposure of PM and systemic inflammatory response; but there is variation in the strength of 
changes among the variety of biomarkers and populations (Brook et al., 2010).  
 
Thrombosis and Coagulation 
There have been many studies that have reported the associations between PM exposure and 
thrombosis/coagulation. Early studies demonstrated that plasma viscosity and elevated 
concentrations of fibrinogen were associated with the PM exposure (Pekkanen et al., 2000; 
Peters et al., 1997). In Taipei, PM levels were correlated with the increases in plasminogen 
activator inhibitor (PAI)-1 and fibrinogen levels in healthy adults (Chuang et al., 2007). 
Increased fibrinogen level is directly correlated with denser fibrin clot structure. 
According to Chuang et al., a penal study recruited 76 young, healthy students from University 
of Taipei to investigate whether biological mechanisms linking air pollution to cardiovascular 
events. After exposure to PM10, levels of C-reactive protein and fibrinogen were increased 
which indicated that the urban air pollution was associated with systemic oxidative stress and 
activation of blood coagulation in young and healthy volunteers (Chuang et al., 2007).  
Metassan et al. investigated the effect of filtered particulate matter (diameter less than 0.22 
µm) on fibrin clot properties in vitro. The results showed that after exposure to filtered PM, 
fibrin clot structure was altered and formed a heterogeneous network according to the 
formation of clustered fibrin fibres through the generation of reactive oxygen species (ROS). 
The formation of small clusters of fibrin fibres may break off and block small blood vessels 
and consequently led to thrombosis (Metassan et al., 2010a).  
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Atherosclerosis 
According to results from the German Heinz Nixdorf Recall Study, the subjects living near the 
major road traffic had increased coronary artery calcium scores (a surrogate marker for 
coronary atherosclerosis) compared to those living further away (Hoffmann et al., 2007; 
Langrish et al., 2012). In another study in Denmark that recruited 1223 subjects, the coronary 
artery calcium scores were significantly higher in the subjects living in a city centre 
environment (OD=1.8, 95% CI 1.3-4) who were exposed to 30%-40% higher concentrations of 
PM10 compared to those living outside of the city (Lambrechtsen et al., 2012). 
 
1.4 Haemostasis 
Haemostasis is a process which maintains the blood throughout the body under normal 
physiological conditions that include preventing loss of blood from blood vessels and removal 
of blood clots following restoration of vascular integrity (Versteeg et al., 2013). From zebra 
fish to human, the haemostatic system is a highly conserved machinery which tightly 
regulates the necessary equilibrium (Teruel-Montoya et al., 2014; Versteeg et al., 2013). 
Haemostasis encompasses four main components, firstly the endothelium, secondly the 
coagulation cascade, and thirdly platelet activation which is able to accelerate the coagulation 
cascade, and finally fibrinolysis removes the redundant clots by proteolytic mechanisms 
(Allford and Machin, 2004; Riddel et al., 2007; Versteeg et al., 2013). The Greek philosopher 
Plato described the fibres formed from blood approximately 2,000 years age. The word “fibrin” 
also originated from Plato (Versteeg et al., 2013).   
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 Coagulation Cascade 
Blood clot formation involves a cascade of two pathways which are (i) the contact pathway 
including factor (F) XII (Hageman factor), XI, IX and VIII, and (ii) the tissue factor pathway 
including FVII activated by tissue factor. In terms of the contact pathway, all the components 
are present in the blood. But for the tissue factor pathway, tissue factor as an external factor 
was required, which can be found in the extravascular tissue (Versteeg and Ruf, 2013). These 
two pathways finally merge into a common pathway involving FX, V, thrombin and fibrinogen 
(Ajjan and Grant, 2006; Ajjan and Ariens, 2009).  
The coagulation cascade can be divided roughly into three phases. In the first or initiation 
phase, there are only limited amounts of thrombin generated. Then in the second or 
amplification phase, the coagulation cascade is accelerated. Finally, in the third or 

















Figure 1-3. Coagulation Cascade 
The coagulation cascade consists of two pathways which are (i) the contact pathway including 
FXII XI, IX and VIII, and (ii) the tissue factor pathway including FVII activated by TF. These two 
pathways finally merge into a common pathway involving FX, V, thrombin and fibrinogen 
(Ajjan & Ariens, 2009; Butenas & Mann, 2002; Dahlbäck, 2000; Ajjan & Grant, 2006). 
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Initiation Phase 
The contact pathway becomes activated once blood contacts negatively charged surfaces, 
FXII starts to get activated and then cleaves prekallikrein into kallikrein, which in turn gives 
rise to a subsequent activation of FXI, FIX and FX to FXIa, FIXa and FXa respectively. According 
to Burman et al. (1994), patients with severe FXII deficiency do not have bleeding problems, 
and as a result FXII is not necessary for thrombin generation (Burman et al., 1994). Therefore, 
compared to factor XII, tissue factor is emphasized as the main physiological initiator of in 
vivo coagulation (Adams and Bird, 2009), but FXII and the contact pathway of coagulation may 
play an important role in thrombosis. In terms of the activation of the tissue factor pathway, 
classically refers to damage or activation of endothelium in the vessel wall leads to exposure 
sub-endothelial cells to the blood resulting in the exposure of tissue factor (a transmembrane 
protein expressed by sub-endothelial smooth muscle cells and fibroblasts) to the blood. 
Platelets adhere to the site of injury and then become activated by the interaction of von 
Willebrand factor (VWF) and collagen (Ajjan and Ariens, 2009). TF is a 47 kDa cell-bound 
transmembrane glycoprotein and member of the class II cytokine superfamily (Adams and 
Bird, 2009). TF is the key initiator of blood coagulation, which is expressed by sub-endothelial 
cells (e.g. smooth muscle cells) and cells surrounding blood vessels (e.g. fibroblasts). These 
two kinds of cells are located outside of the vasculature, i.e., not normally in contact with the 
circulating blood which is protected from tissue factor exposure by the intact, healthy 
endothelium (Adams and Bird, 2009; Golino, 2002).  
In the initiation phase, FVII accesses TF and is bound to TF with high affinity and specificity, 
after which FVII is rapidly converted to FVIIa via proteases and auto-activation (Ajjan and 
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Ariens, 2009; Golino, 2002). Activated TF/FVIIa complexes, on the phospholipids surface of 
the cell membrane,  catalyse the conversion of FIX to FIXa, FX to FXa and FV to FVa (Adams 
and Bird, 2009; Ajjan and Ariens, 2009; McVey, 1999). FXa and FVa cleave prothrombin to 
generate trace amounts of thrombin. The duration of the initiation phase is primarily 
dependent on the concentration of TF/FVIIa and tissue factor pathway inhibitor (TFPI) (Adams 
and Bird, 2009; Butenas and Mann, 2002).  
 
Amplification Phase 
In the amplification phase, the intrinsic tenase complex is formed by FIXa and its thrombin-
activated cofactor FVIIIa. The tenase complex FIXa/FVIIIa, aggregating on a membrane surface 
in the presence of calcium,  accelerates FXa production at a 50 to 100 fold higher rate than 
TF/FVIIa complex and generates more thrombin than FIX alone (Adams and Bird, 2009; 
Butenas and Mann, 2002). The reaction efficiency of both the intrinsic factor tenase complex 
and prothrombinase complex is accelerated in the presence of calcium by their co-localization 
on the surface of platelet with phospholipid membrane (Adams and Bird, 2009; Ajjan and 
Grant, 2006). The platelets are activated by local collagen at the site of injury in the initial 
haemostatic plug. Collagen-bond, partially activated platelets are further activated by 
thrombin through interactions with protease-activated receptor-1 (PAR-1). The fully activated 
platelets change shape and degranulate. More FVIIIa is generated by thrombin through 
liberation of FVIII from its complex with von Willebrand factor (FVIII/VWF). Thrombin also 
activates FXI to FXIa which binds to the surface of platelets. Platelet surface FXa/FVa 
complexes are the primary activator of prothrombin and lead to the efficient generation of 
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large amounts of thrombin from prothrombin (Adams and Bird, 2009; Ajjan and Grant, 2006; 
Butenas and Mann, 2002).  
 
Propagation Phase 
The propagation phase depends on the recruitment of activated platelets at the site of injury 
to generate enough thrombin through the necessary components including intrinsic tenase 
complex, the prothrombinase complex, calcium and a phospholipid surface. The sufficient 
amount of thrombin generates fibrinogen to fibrin and forms a stable fibrin clot structure 
(Adams and Bird, 2009; Ajjan and Grant, 2006; Ajjan and Ariens, 2009).  
Except FXII, all other coagulation factors deficiency are associated with bleeding disorders of 
varying severity. There are three common hereditary bleeding disorders, FVIII deficiency 
causes haemophilia A, FIX deficiency causes haemophilia B, and VWF deficiency causes von 
Willebrand diseases (Dahlbäck, 2000; Riddel et al., 2007). 
 
 Regulation of Blood Coagulation 
Apart from the deficiency of clotting factors, the coagulation cascade can be restricted by 
several coagulation inhibitors. There are at least four plasma proteins (anti-thrombin, protein 
C, protein S, and tissue factor pathway inhibitor) and one trans-membrane protein 
(thrombomodulin) that regulate the anti-coagulant process (Butenas and Mann, 2002). 
Thrombin has important roles in both pro- and anti-coagulation. As in the initiation phase, 
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the rate of thrombin generation depends on the concentration of complex TF/FVIIa. Tissue 
factor pathway inhibitor is the primary inhibitor in the initiation phase (Butenas and Mann, 
2002). In the propagation phase, TF/FVIIa complex and TFPI have little effects, while protein 
C and antithrombin start to play pronounced roles in inhibiting the FVa thus limiting thrombin 
generation (Butenas and Mann, 2002; Dahlbäck, 2000). Protein C regulates coagulation by 
restricting the activities of FVIIIa and FVa (Dahlbäck, 2000). Antithrombin can inactive a series 
of serine proteases (Norris, 2003).  
 
 Platelets 
Platelets are the smallest blood cells with diameter 2 to 3 µm, also they are the second most 
numerous corpuscles in the blood (red blood cells are the most abundant) circulating at 
between 150 x109/L and 450 x109/L. Their half-life in circulation is around ten days  (George, 
2000; Harrison, 2005). Generally, concentrations of less than 10,000 platelets/L are defined 
as extreme thrombocytopenia (Clemetson, 2012), a condition that increases the risk for 
bleeding. Platelets are biconvex discoid in shape before activation, and they are anucleated 
cells. Platelets are produced by megakaryocytes in the bone marrow, a large cell that releases 
platelets by fragmentation of the cell membrane and by packaging mitochondria, dense and 
alpha granules in the newly formed platelets (Clemetson, 2012; George, 2000; Harrison, 2005). 
Platelets are multifunctional and participate in many pathophysiological processes such as 
haemostasis, clot retraction, vessel constriction and repair, and inflammation, of which 
haemostasis (protection against blood loss) is the most important role of platelets (Clemetson, 
2012).  
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The platelets can be activated by two independent pathways which act in parallel or 
separately (Furie and Furie, 2008). One of the pathways involves the activation of platelets by 
the exposure to sub-endothelial collagen. The other pathway in platelets can be initiated by 
thrombin, generated by tissue factor or present in flowing blood. Although the platelets are 
activated by different mechanisms, the consequences are the same (Furie and Furie, 2008).  
For the first pathway, activation of the platelet by collagen is independent of thrombin. 
Platelets aggregate to the site of injury, via interactions between platelet glycoprotein VI with 
collagen and platelet glycoprotein Ib-V-IX with collagen and VWF (Furie and Furie, 2008). 
Glycoprotein VI is a collagen receptor on platelets, and glycoprotein Ib-V-IX is a cluster of 
adhesive receptors on platelets (Furie and Furie, 2008). The second pathway of platelet 
activation occurs through tissue factor driven thrombin generation without disruption of the 
endothelium. Also, this pathway is independent of VWF and glycoprotein VI. Thrombin is 
generated through tissue factor pathway that activates FVII and forms the TF/FVIIa complex, 
which then also activates IX. Thrombin activates platelets by cleaving the PAR-1 on the surface 
of platelets and causing them to release adenosine diphosphate (ADP), serotonin, and 
thromboxane A2. Afterwards, these agonists activate other platelets and amplify the signals 
for thrombus formation (Furie and Furie, 2008). 
During the activation, platelets are deformed from their discoid shape to irregular shapes with 
long dendritic extensions that helps adhesion (George, 2000). Four kinds of secretary granules 
are released from platelets in activation, but two of them are more important. Firstly the 
dense granules, also called delta granules, which produce ADP and calcium and promote the 
platelets aggregation. Secondly the alpha granules secrete a variety of proteins, P-selectin and 
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fibronectin enhance platelets activation and aggregation to the site of injury; von Willebrand 
factor, fibrinogen, and coagulation factors V and XIII  further assist in the acceleration 
platelets activation and clots formation (Clemetson, 2012; George, 2000; Harrison, 2005; 
Lindemann et al., 2007). 
 
 Fibrinogen and Fibrin Clot Structure 
The Fibrinogen Molecule 
Fibrinogen is the most abundant coagulation factor in the blood with an average 
concentration of 2 to 4 mg/ml (6 – 12 µM) (Ariens, 2013). It is mainly synthesized in the liver, 
which produces approximately 1.7g to 5g daily (Standeven et al., 2005). Fibrinogen is a 340 
kDa glycoprotein and possesses properties of both globular and fibrous proteins (Standeven 
et al., 2005). The fibrinogen molecule is composed of two sets of three polypeptide chains, 
denominated Aα, Bβ and γ, cross-linked by 29 disulfide bonds in a dimeric structure with 
bilateral symmetry (Ariens, 2013; Wolberg, 2007). The central part of the molecule includes 
the E region, which contains N-termini of all six polypeptide chains. The chains intertwine and 
connect to two distal D region via α-helical coiled-coil structure which provide elasticity to the 
molecule (Ariens, 2013; Standeven et al., 2005; Wolberg and Campbell, 2008). The C-terminal 
region of both the Bβ- and γ- chains end in the D region, however, the Aα-chain protrudes 
from the D region, form a flexible αC region and extends back to the E region (Ariens, 2013; 
Standeven et al., 2005; Weisel, 1986).  
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The Aα-chain contains 610 residues; the Bβ-chain contains 461 residues and the major γ-chain 
form, γA contains 411 residues. The complete human fibrinogen molecule is therefore made 
up of 2964 amino acids, yielding a calculated molecular weight of 329 818 (Standeven et al., 
2005). There are four carbohydrate clusters present – one on each Bβ- and γ- chain – which 
contribute another 10 000 in molecular weight, adding up to the total molecular weight of 
around 340 000 (Standeven et al., 2005). In the γ-chain, the γA chain consists of 411 amino 
acids and is composed of 10 exons and 9 introns. A minor γ-chain variant termed γ’, arises 
from alternative processing at the exon 9/exon 10 boundaries of the mRNA. The alternative 
γ′-chain arises when polyadenylation occurs at an alternative polyadenylation signal in intron 
9. In this case, intron 9 is not spliced out, leading to the substitution of 4 γA amino acids 
(γA408-411; AGDV) of exon 10 by a unique 20-amino acid extension (γ′408-427; 
VRPEHPAETEYDSLYPEDDL) encoded by intron 9 (Campbell et al., 2010; Cooper et al., 2003; 
Uitte de Willige et al., 2009). The γ′-chain occupies about 8% of the total fibrinogen γ-chain 
population and the majority of them are in heterodimeric fibrinogen molecules accounting to 
15% of plasma fibrinogen molecules. Homodimeric  γ′/γ′-molecules are present in circulating 
fibrinogen molecules in blood at less than 1% (Ariens, 2013; Campbell et al., 2010; Cooper et 
al., 2003; Uitte de Willige et al., 2009).  
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Fibrin Clot Formation 
 
Figure 1-4. Fibrin Clot Formation.  
Fibrinogen consists 2Aα, 2Bβ, and 2γ chains. Thrombin firstly cleaves fibrinopeptide A leading 
the formation of half-staggered and double-stranded twisting protofibrils. FpB is cleaved by 
thrombin at a slower rate and the cleavage of FpB facilitates the lateral aggregation of 
protofibrils (Ariens, 2013; Scott et al., 2004; Standeven et al., 2005; Undas & Ariëns, 2011). 
Thrombin first cleaves fibrinopeptide A leading to oligomers and protofibrils. Fibrinopeptide 
B is cleaved at a slower rate and is associated with the release of the αC-region and lateral 
aggregation of protofibrils into fibers and fiber bundles.  
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The final stage in the coagulation cascade is conversion of fibrinogen to fibrin and the 
formation of a fibrin clot (Standeven et al., 2005). The trigger to start the conversion is the 
thrombin catalysed cleavage of the fibrinopeptide. Thrombin binds to the central E nodule of 
fibrinogen and removes the N-terminal peptides of the Aα- and Bβ- chains. Firstly, thrombin 
cleaves the fibrinogen Aα-chain between Arg16 and Gly17, the N-terminal 16 residue peptides 
(fibrinopeptide A, FpA) are removed and expose a binding site (GPR) which is known as ‘A’ 
site in the E region. The ‘A’ site binds to the ‘a’ pocket in the γ-chain of the D region of another 
fibrinogen molecule. These interactions result in the formation of half-staggered and double-
stranded twisting protofibrils (Ariens, 2013; Campbell et al., 2010; Standeven et al., 2005; 
Wolberg, 2007). The length of fibrinogen molecule is 45nm. The half-staggered protofibrils 
maintain a periodicity of 22.5nm (half the length of the full-length fibrinogen). Fibrils branch 
out and there are two possible types of branching determining the structure of the clot. The 
first type of branching supports strength and rigidity in the clot as double-stranded 
protofibrils align side by side to form a tetra-molecular or bilateral branch-point. The second 
type of branching is tri-molecular or equilateral which is formed by the combination of three 
fibrinogen molecules in which three double-stranded protofibrils are connected to each other 
via ‘E:D’ associations (shown as figure 1-5). This situation happens when the rate of 
fibrinopeptide release is slow (Mosesson, 2005; Standeven et al., 2005). Additional fibrin 
monomers can add longitudinally to the dimer and trimer to form larger oligomers which are 
long enough for lateral aggregation. The length of a protofibril is approximately 0.5 to 0.6 µm, 
accordant with 20 to 25 half-staggered fibrin monomers (Weisel and Litvinov  I., 2013).  
  




Figure 1-5. Tri-molecular or equilateral branch point.  
The tri-molecular branch point is formed by the combination of three fibrinogen molecules in 
which three double-stranded protofibrils are connected to each other via ‘E:D’ associations 
(Mosesson, 2005; Standeven et al., 2005). 
Subsequently, the N-terminal 14 residue peptide of the Bβ-chain (fibrinopeptide B, FpB) are 
removed which expose a second binding site ’B’ with the amino acid sequence GHR in the E 
region. The ‘B’ site interacts with another specific binding pocket ‘b’ in the Bβ-chain of the D 
region of another molecule (Ariens, 2013; Campbell et al., 2010; Standeven et al., 2005; Undas 
and Ariëns, 2011; Wolberg, 2007). FpB is cleaved by thrombin at a slower rate compared with 
FpA. In the meantime of removal of FpB occurs, the αC domains are liberated but still interact 
with the distal D region in fibrinogen (Standeven et al., 2005). The αC domains originate at 
residue 220 in the D domain and end at Aα610 (Campbell et al., 2010). Interactions of αC 
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domains change from intramolecular to intermolecular, which promote the lateral 
aggregation of protofibrils.  
The cleavage of FpA is necessary for protofibril formation, nevertheless, the release of FpB in 
fibrin clot formation is highly controversial. It has been assumed that the cleavage of FpB 
facilitates the lateral aggregation of protofibrils to form thicker fibres, however, this can 
actually occur through cleavage of FpA only by several enzymes in the absence of FpB 
cleavage (Standeven et al., 2005; Wolberg, 2007).  
Fibres are twisted structure; the protofibrils need to maintain the periodicity of 22.5nm. 
When the new protofibrils are added to the growing fibres, they have to undergo a certain 
degree of stretching. The degree to which a protofibril can be stretched is the determinant of 
the thickness that the fibres can grow. The growth of the fibril ceases when the energy 
necessary to stretch an added protofibril exceeds the energy of protofibril bonding 
(Standeven et al., 2005; Weisel and Litvinov  I., 2013).  
 
 Factor XIII  
Coagulation factor XIII (FXIII), belongs to the enzyme family of transglutaminases, and is the 
last enzyme to be activated in the blood coagulation pathway (Laudano and Doolittle, 1978). 
There are two forms of FXIII, the first is a cellular of FXIII (cFXIII), which exists as a dimer (FXIII-
A2) in the cytoplasm of certain cells, particularly in platelets, monocytes, and macrophages. 
In platelets, the amount of FXIII-A2 is 46-82 fg/platelet which amounts to around 3% of total 
platelet protein. The second form of FXIII is present in the plasma (pFXIII), and is a tetramer 
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consisting of two catalytic A subunits (FXIII-A) and two carrier/inhibitor B subunits (FXIII-B). In 
plasma, FXIII circulates as a pro-enzyme (FXIII-A2B2), and the concentration in normal 
conditions is 14-28 mg/L. The A-subunit, containing the catalytic part of the enzyme, is a non-
glycosylated single polypeptide chain molecule with 731 amino acid and a molecular weight 
of 83 kDa (Ariëns et al., 2002). FXIII-A subunit is mainly synthesized in macrophages, 
megakaryocytes, and placenta with bone marrow origin. The A subunit is constituted by five 
domains, an activation peptide (AP-FXIII, residues 1-37), a β-sandwich (residues 38-183), a 
catalytic core region (residues 184-515), and two β-barrels (barrel 1, residues 516-627; barrel 
2, residues 628-731). FXIII-B subunit is secreted and synthesized by hepatocytes in liver. The 
B subunit is a typical mosaic protein which is assembled from ten short consensus repeats, 
also known as sushi domains, GP-I structure or complement control protein (CCP) module. 
FXIII-B molecule is constituted by 641 amino acids (each sushi domain contains 60 amino acid) 
and 8.5% carbohydrate, and the total molecular weight is approximately 80kDa  (Weisel & 
Litvinov, 2013; Bagoly et al., 2012; Bagoly et al., 2012; Ariëns et al., 2002). 
The main function of FXIII is the stabilization of the fibrin clot which constitutes the last stage 
in the coagulation cascade. Plasma FXIII is activated by thrombin and Ca2+. At first, thrombin 
cleaves off the AP-FXIII by hydrolysing the Arg37-Gly38 peptide bond. Then, in the presence 
of Ca2+, the carrier FXIII-B subunits dissociate from the catalytically active thrombin-cleaved 
FXIII-A subunits. The removal of B-subunits from the FXIII complex is necessary for the Ca2+-
induced transformation into an active tranglutaminase FXIIIa. The activation process is 
accelerated 80-100 fold by the presence of fibrin. The fibrin polymer is held together by non-
covalent forces at the beginning. After the activation of FXIII by thombin, Ca2+ (and fibrin), 
fibrin is covalently cross-linked by FXIIIa. FXIIIa induces intermolecular ε-(γ-glutamyl)-lysine 
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covalent bond between the γ406Lys of one γ-chain and the γ398/399Gln of another γ-chain 
in two adjacent molecules that are aligned in a longitudinal orientation. γ-Chain dimer 
formation significantly contributes to clot rigidity. α-Chain cross linking plays an important 
role in regulation of fibrinolysis and enhances fibrin stiffness and viscoelasticity (Bagoly et al., 
2012; Ariëns et al., 2002). Alpha-gamma cross-linking is negligible in quantity compared to g-
g and a-a. FXIII also cross-links between Gln2 in the amino terminus of α2 antiplasmin and 
Lys303 in the fibrin α-chains to protect the fibrin clot from lysis (Ariëns et al., 2002). In 
summary, FXIIIa is able to stabilize the fibrin clot, introducing thinner fibre formation, and 
increasing the fibre density, as well as protecting from shear stresses and producing a clot 
with increased resistance to fibrinolysis (Ariëns et al., 2002; Doolittle et al., 1998; Standeven 
et al., 2007).  
 
 Fibrinolysis 
The fibrin clot is the essential and primary product of haemostasis. The purpose of fibrinolysis 
is to remove the excess clot formed either in response to vascular damage or in pathological 
thrombosis and atherosclerosis (Adams and Bird, 2009; Chapin and Hajjar, 2015). The 
efficiency of fibrinolysis can be influenced by many factors, including the structure of the clot, 
the rate of thrombin generation, and the reactivity of thrombin-associated cells. Similarly to 
the coagulation process, fibrinolysis is also regulated by cofactors, inhibitors and receptors 
(Chapin and Hajjar, 2015). The key proteolytic enzyme in the fibrinolysis process is plasmin, 
which can be activated by the hydrolysis of plasminogen by two serine proteases, tissue-type 
plasminogen activator (tPA) and urokinase-type of plasminogen activator (uPA) (Adams and 
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Bird, 2009; Chapin and Hajjar, 2015; Lord, 2011). Whereas tPA is produced by endothelial cells, 
uPA is synthesized by monocytes, macrophages, and urinary epithelial cells (Chapin and Hajjar, 
2015). Compared with uPA, tPA has a higher affinity for plasminogen. The rate of plasminogen 
activation by tPA is increased in the presence of fibrin. Two sites of fibrin are involved in this 
process, Aα148-160 and γ312-324 (Mosesson, 2005). The cleavage of fibrin by plasmin 
initiates in the αC domain followed by cleavages in D and E regions (Ajjan and Grant, 2006).  
Both the fibrin structure and mechanical properties may affect the rate of fibrinolysis. 
Individual thicker fibres are lysed slowly compared to the thin fibres, but denser fibrin clots 
contained thinner fibres with greater number of fibres requires longer fibrinolysis time as 
denser clot had smaller port sizes which causes prolonged transportation of the fibrinolytic 
agents through the fibrin clot (Undas et al., 2006).   
Several fibrinolysis inhibitors are able to control the excess plasmin and plasminogen activator 
activities. There are three important serpins in the fibrinolysis, plasminogen activator 
inhibitor-1, plasminogen activator inhibitor-2, and α2-antiplasmin (A2AP) (Chapin and Hajjar, 
2015).  
Plasminogen activator inhibitors are produced by endothelial cells, platelets and other cells 
and released into the circulation. PAI-1 is a linear glycoprotein that consists of 379 amino acids 
with a molecular weight 48,000. It is the main inhibitor of plasminogen activators tPA and uPA 
(Binder et al., 2002; Chapin and Hajjar, 2015; Kohler and Grant, 2000). In its free, unbound, 
active form, PAI-1 is unstable with a half-life of 30 minutes, however, when bound to the 
matrix protein vitronectin in plasma, PAI-1 stabilizes at the active form and the half-life is 
prolonged over ten times (Binder et al., 2002; Kohler and Grant, 2000). Fibrinolysis is initiated 
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when tPA and plasminogen both bind to the fibrin as plasmin is formed when plasminogen is 
partially cleaved by tPA on the surface of fibrin. This process promotes the activation of 
plasminogen and acceleration of fibrinolysis (Binder et al., 2002; Chapin and Hajjar, 2015; 
Kohler and Grant, 2000). In addition, the rate of PAI-1 inhibitory activity was reduced by 80 
to 90% in the presence of fibrin. However, once fibrin monomers are cross-linked by activated 
FXIII, the binding sites for tPA are reduced. PAI-1 rapidly binds to tPA or uPA, forming a 1:1 
complex which can be cleared by hepatocytes in the circulation (Chapin and Hajjar, 2015; 
Kohler and Grant, 2000). PAI-1 can be upregulated by a number of proinflammatory cytokines, 
as well as thrombin (Binder et al., 2002; Kohler and Grant, 2000). PAI-2 is also a key inhibitor 
of tPA and uPA but mainly during pregnancy, and the concentration increases as the 
pregnancy progresses (Chapin and Hajjar, 2015).  
A2AP binds plasmin to form an irreversible complex. Once plasmin is bound to fibrin, it is 
protected from A2AP inhibition (Ajjan and Grant, 2006). There is a non-serpin fibrinolysis 
inhibitor named thrombin activated fibrinolysis inhibitor (TAFI). TAFI is a carboxypeptidase 
which removes the C-terminal lysine and arginine residues on fibrin thereby decelerating the 
plasmin generation by reducing the plasminogen binding sites (Ajjan and Grant, 2006; Chapin 
and Hajjar, 2015). 
 
 Vascular Endothelium 
The vascular endothelium is a monolayer that covers the inner surface of the entire vascular 
system, with a surface area of approximately 1 to 7 m2 in man (Cines et al., 1998; Esper et al., 
Page 73 of 265 
 
2006). The vascular endothelial surface of an adult human contains approximately 1 to 6 x 
1013 endothelial cells and the weight is almost 1kg (Cines et al., 1998; Esper et al., 2006; 
Sumpio et al., 2002). Therefore, the endothelium represents the largest and most important 
gland of the body (Ajjan and Grant, 2006). It is important to emphasize that endothelial cells 
exhibit phenotypic variation in different sections of the vasculature. Within an individual, 
endothelial cells at different locations are not only able to express different markers but can 
also react differently to the same stimulus. For different individuals, such cells vary greatly in 
the responses to stimuli (Sumpio et al., 2002). 
The endothelial cells have a similar basic structure as other cells in the human body, including 
the presence of a cytoplasm, nucleus, organelles and cell membrane. The cellular membrane 
is formed by two layers of phospholipids containing various proteins as receptor or ion 
channels (Cines et al., 1998; Esper et al., 2006). Many types of contractile proteins, such as 
actin, myosin, and tropomyosin, cross the cytoplasm and contribute to the motor activities of 
the cell (Esper et al., 2006). Some of these cells are organised as structure like cortical web 
and junction-associated actin filament system, and stress fibres (Esper et al., 2006; Sumpio et 
al., 2002). Cortical web adhering to the internal surface of the sarcolemma, controls the shape 
and elasticity of the cells, and it changes the stiffness of itself in accordance with the 
intravascular pressure. The junction-associated actin filament system exists in the 
intercellular space and the main function is controlling the intercellular space through 
contraction and dilatation. Stress fibres are myofibril-like straight filament bundles containing 
actin filaments and myosin filaments, that cross the cytoplasm in all directions. The 
contraction and relaxation of stress fibres depend on the intracellular Ca2+ concentration and 
presence of adenosine tri-phosphate (ATP). The aim of these fibres is to reduce the possibility 
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of cell lesions through adjusting the shape of cells based on the forces of blood flow and wall 
distension (Cines et al., 1998; Esper et al., 2006).  
The endothelium, as a barrier of the vessel wall, has a semi-permeable structure that controls 
the transfer of small and large molecules (Sumpio et al., 2002). The cell membrane is covered 
by “caveolae”, flask-shaped membrane invaginations which occupy 5 to 10% of total cellular 
surface area. The endothelial caveolae regulate the fluid and transport macromolecules in a 
transcellular pathway (Esper et al., 2006). 




Inhibition of leukocyte adhesion and migration 
Inhibition of smooth muscle cell proliferation and migration 
Inhibition of platelet aggregation and adhesion 
Pro-fibrinolytic effects 
Table 1-3. Healthy Endothelium Functions  
Source: adapted from Esper et al., 2006; Cines et al., 1998; Sumpio et al., 2002 
The endothelial cells are versatile and multifunctional as shown in the above figure (Sumpio 
et al., 2002). The major functions of endothelium are providing a mechanical barrier and 
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regulating the vascular tone (Ajjan and Grant, 2006). Endothelial cells are able to secrete a 
variety of molecules, vasodilators and vasoconstrictors, procoagulants and anticoagulants, 
fibrinolytics and anti-fibrinolytics, inflammatory and anti-inflammatory, oxidants and anti-
oxidants, to balance the effects of both directions to maintain the integrity of the vascular 
surface, ensure the protection of the vessel wall and provide healthy blood flow. Endothelial 
cells play a role in the coagulation process by producing a series of procoagulant agents 
including VWF, factor V, plasminogen activator inhibitor, and tissue factor  (Modena et al., 
2002). Endothelial cells also have anticoagulant effects by secreting nitric oxide (NO), 
postacyclin, tissue plasminogen activator, thrombomodulin (THBD), protein C, and protein S. 
Nitric oxide works in concert with prostacyclin to restrain the platelet adhesion and 
aggregation. The expression of THBD causes a transformation of thrombin from a pro-
coagulant converter of fibrinogen to fibrin to an anti-coagulation activator of protein C. 
Activated protein C and protein S synergistically inactivate several clotting factors. 
Furthermore, endothelial cells have proinflammatory roles through the production of a 
number of adhesion molecules (e.g. intercellular adhesion molecule-1, ICAM-1) and cytokines 
(Ajjan and Grant, 2006). Under the healthy environment, endothelium is able to maintain the 
balance of protein production. However, endothelium damage upsets the balanced secretion 
of the molecules,  reducing the ability to maintain the protection of the vessel wall and ensure 
healthy blood flow, and initiating the progression of the atherosclerotic process (Ajjan and 
Grant, 2006).  
A sign of endothelial dysfunction is the reduction of bioavailability of vasodilators, especially 
NO; in addition, the vascular contracting factors are increased (Modena et al., 2002). NO can 
be found in all tissues and due to its low molecular weight and lipophilic properties, it 
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permeates easily through cell membranes (Ajjan and Ariens, 2009). Reduced NO production 
leads to the promotion of platelet adhesion and aggregation, increased leukocytes infiltration, 
and proliferation of vascular smooth muscle cells (VSMC) (Ajjan and Grant, 2006). Endothelial 
dysfunction causes the release of VWF which mediate the platelet adhesion on damaged 
endothelium. The VWF plasma level is a marker of endothelial dysfunction (Ajjan and Grant, 
2006; Sumpio et al., 2002; Whincup et al., 2002). TF is also secreted by endothelium only if 
the cells are dysfunctional. TF cannot be found in normal endothelial cells, but can be 
detectable in atheromatous plaques, indicating TF is a risk marker of atherosclerosis in 
diseases pathogenesis (Suefuji et al., 1997). As endothelial dysfunction is characterised as pro-
coagulant, pro-inflammatory and proliferation status that contribute to the progression of 
atherosclerosis, endothelial dysfunction reflects the tendency of an individual to develop 
atherosclerotic diseases (Cines et al., 1998; Modena et al., 2002).   
 
1.5 Engineered Nanoparticles  
As described above, there is a large and growing amount of evidence showing that PM is 
associated with human health risks, including cardiovascular health risks. Consequently, there 
is concern that engineered nanoparticles (NPs) which are defined as having at least one, and 
usually two dimensions less than or equal to 100nm, may also exhibit human health risks 
(Tiede et al., 2008, Savolainen et al., 2010a, Teow et al., 2011).  
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 ENPs Definition 
Engineered nanoparticles (ENPs) are different from the ultrafine particles (UFPs) discussed 
above. Both of them have similar sizes which are less than 100nm, however, the different 
sources of these two kinds of particles have different physicochemical properties (Xia et al., 
2009). Ultrafine particles are incidental particles arising mainly from combustion. These 
particles originated from fossil fuel combustion process or through the condensation of semi-
volatile substances (Xia et al., 2009). Different from UFPs, ENPs include a variety of particles 
manufactured from various materials on an industrial scale for a variety of purposes. As a 
consequence of the small size of the nanoparticles, ENPs possess different physicochemical 
properties compared to their respective bulk material (Duffin et al., 2007). In some crucial 
respects, ENPs show different performance physically and chemically compared to UFPs 
(Kendall and Holgate, 2012). According to Xia et al. (2009), table 1-4 shows the differences 
and similarities of UFPs and ENPs (Xia et al., 2009). As the UFPs are derived incidentally and 
ENPs are engineer manufactured, the uniformity for UFPs is low and for ENPs is high. Both of 
them have high surface to volume ratio. The major exposure route of UFPs is through 
inhalation. Besides inhalation, ENPs also could be exposed through skin, ingestion, and 
injection. UFPs have been verified to have adverse health effects on humans, however, the 
effects of ENPs on humans are still unknown (Xia et al., 2009).  
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 UFPs ENPs 
Source Incidental Engineered  
Surface area to volume ratio High High 
Uniformity Low High 
Organic chemical content High Low 
Metal impurities High Varies 
ROS generation Yes Varies 
Exposure route Inhalation Inhalation, skin, ingestion, injection 
Adverse health effects Yes Unknown 
Table 1-4. Differences between ENPs and nanoparticles 
Source: adapted from Xia et al., 2009 
When studying ENPs, it is important to fully characterise the particles by measuring various 
parameters, e.g. size distribution, shape, concentration, dispersion, aggregation, structure, 
chemical composition, etc (Fanning et al., 2009, Savolainen et al., 2010a).  
 
 Functions of ENPs 
The functionality of many commercial products has been improved by the nanomaterials that 
have both novel physical and chemical properties. From the beginning of the 21st century, 
the unique physicochemical properties of nanoparticles have given rise to applications in 
many fields, including biomedical and pharmaceutical products, cosmetics, clothing, building 
materials, electronics, food packaging, food additives, and some personal care products. 
According to the Nanotechnology Consumer Products Inventory in August 2009, there are 
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more than 1000 self-claimed nano-products produced by 485 companies in 24 countries. The 
total worldwide sales revenues for nanotechnology were $11.6billion in 2009, and are 
expected to increase to more than $26 billion in 2015 (Teow et al., 2011; Xia et al., 2009). 
There are some kinds of ENPs which are frequently used, including carbon nanotubes (CNTs); 
TiO2, ZnO, CeO2, Si(O), Fe(O), Ag(O), and Au(O) nanoparticles; fullerenes; nanowires; and 
Dendrimers (Fanning et al., 2009, Stone et al., 2010). With high exploitation of nanoparticles, 
people could be exposed to ENPs through many routes. There are few studies focusing on the 
exposure measurement of ENPs. Measurement and monitoring of the engineered 
nanoparticle are needed to collect all relevant information about the amount (number, 
surface area or mass concentration), shape, chemical composition, surface charge,  and size 
distribution, as well as solubility and persistence (Savolainen et al., 2010b). Unfortunately, 
current available techniques for measuring airborne particulates are not developed enough 
to measure the exposure to particulates with nanoscale dimensions (Hubbs et al., 2011, 
Savolainen et al., 2010b).  
 
 Exposure 
Humans could be exposed to ENPs both intentionally and unintentionally. The unintentional 
exposure pathways include dermal, respiratory system, gastrointestinal tract, and ocular 
pathway  (Abbott and Maynard, 2010). The human skin could protect from nanoparticles and 
other chemicals owing to the strong stratum corneum, without sweat glands and hair follicles 
provide gaps in this barrier that NPs are able to penetrate to the dermis (Xia et al., 2009). 
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Titanium dioxide nanoparticles are added to sunscreen cream for UV protection, therefore 
TiO2 NPs is exposed to human through penetrating the skin and reaching hair follicles (Xia et 
al., 2009). Moreover, nanocrystalline silver has been reported as an anti-bacterial agent 
added in wound dressings (Hubbs et al., 2011). Where it can directly contact with the 
wounded area and reach the dermis and epidermis (Hubbs et al., 2011, Cooper et al., 2003, 
Teow et al., 2011, Savolainen et al., 2010a). The human lung consists of about 2300km of 
airways and 300 million alveoli. Particles with diameters less than 400nm have higher 
probability to penetrate the lung epithelial barrier, enter into the blood stream, and transport 
to different organs afterward (Xia et al., 2009). Nasal cilia and the action of coughing could 
get rid of coarser particulates (Li et al., 2010, Nemmar et al., 2004). Owing to the size of ENPs, 
they could easily cross the lung epithelial barrier and penetrate the alveoli. The size and shape 
of the NPs could affect the region of deposition in the respiratory system; smaller sized 
particles could penetrate deeper in the lung. Macrophages may not be able to recognize 
particles with a diameter less than 500nm, and for this reason, NPs could easily enter the 
blood or the lymphatic system and then transfer to different organs (Teow et al., 2011, 
Savolainen et al., 2010a). Nanoparticles are applied in food industries as food additives or 
anti-microbial in food packaging. Silver NPs are used in toothpaste as antibacterials and 
therefore there may be expose to gastrointestinal tract (Savolainen et al., 2010b). The 
intentional exposure to ENPs is through targeted drugs that lead to the nanoparticles 
transport and deposit in organs and tissues  (Abbott and Maynard, 2010).  
Most ENPs are used without toxicological consideration. They do not need any type of toxicity 
tests under the law even though they have some novel properties both in physical and 
chemical respects (Kendall and Holgate, 2012). Focusing on the risk assessment of ENPs, 
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nanoparticle samples were collected from 40 companies, a survey was carried out in Germany 
and Switzerland from December 2005 to February 2006. In response to the question “Does 
your company conduct risk assessments where nano-particulate materials are involved?” 26 
(65%) of them answered no, 13 companies (32.5%) implemented risk assessments sometimes 
or always, and 1 company (2.5%) did not answer the question (Savolainen et al., 2010b). Many 
of the most serious health and safety concerns about nanoparticles are due to the limited 
information of health effects and the types of exposure during the production and 
applications (Savolainen et al., 2010b). Since the increased exploitation of nanoparticles, 
there is a rising debate concerning the possible risks to human health and the environment 
(Medina et al., 2007). Therefore, research is focused on unravelling how and why the 
behaviours of engineered nanoparticles are different from the respective bulk materials. 
 
 Silicon Dioxide Nanoparticles 
As one of the most important engineered nanoparticles, silicon dioxide NPs have been 
considered as a kind of ideal material for biomedical applications and are being widely 
explored as medical diagnostics, biosensor, biomarker, cancer/gene therapy, molecule 
imaging and DNA/drug delivery (Liu and Sun, 2010). Furthermore, silica NPs are manufactured 
on an industrial scale as additives to cosmetics, food additives, paints and printer toners 
(Ahamed, 2013; Yang et al., 2014).  
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Due to the extremely small size of the SiO2 NPs widely used in many industries, a concern 
raised that SiO2 NPs may directly get into the human body and interact with cells and body 
fluids (Rim et al., 2013). The effects of SiO2 NPs were demonstrated as follows. 
As SiO2 NPs can be used as additives in cosmetics and paints, a study by Ahamed and colleges 
investigated the cytotoxicity of SiO2 NPs on human skin epithelial cells (A431) and human lung 
epithelial cells (A549). The results indicated that SiO2 NPs induced significantly cell death at 
the concentration of 25 µg/ml on both cell lines after 72 hours treatment and caused dose-
dependent cytotoxicity (Ahamed, 2013). Eom and Choi studied the cytotoxicity of SiO2 NPs on 
human bronchial epithelial cells (Beas-2B) and demonstrated that after 24 hours incubation, 
1 µg/ml of NPs caused 20% cell death compared to control (Eom and Choi, 2009). Another 
study investigated the toxicity of SiO2 NPs on human gastric epithelial cells (GES-1) and 
colorectal adenocarcinoma cells (Caco-2). There was no significant toxicity on both cell line 
after treatment with 100 µg/ml of SiO2 NPs for 24 hours incubation. But after longer time and 
high concentrations, SiO2 NPs showed dose- and time- dependent effect on these cell lines 
(Yang et al., 2014). A couple of studies have shown that NPs can translocate from the 
respiratory tract to the systemic circulation, and thus interact with endothelial cells of the 
blood vessel (Berry et al., 1977; Guarnieri et al., 2014; Nemmar et al., 2002). A study 
investigated the effects of SiO2 NPs on endothelial cells; human dermal microvascular 
endothelial cells were treated with 5 and 50 µg/ml of SiO2 NPs for 72 hours, both 
concentrations did not cause significant cell death compared to the control (Peters et al., 
2004).  
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As the small size of SiO2 NPs, particles may get into the circulation and interact with cells 
directly. The cytotoxicity of SiO2 NPs on cells were detected before, but whether SiO2 NPs 
have effects on blood coagulation were largely unknown.  
 
1.6 Aim of Study 
The overall aims of this study were to understand how diesel or urban PM can affect clot 
structure and function and to examine whether engineered nanoparticles may exhibit similar 
hazard.  
Hypotheses: 
Particulate matter and diesel particles alter fibrin network structure, mediated by 
both direct and indirect effects through modulation of endothelial cell function. 
Specific aims were to:  
1) Determine whether clot structure formed from plasma or purified fibrinogen is 
affected by presence of PM10, PM0.2, diesel particles and filtered diesel particles  
2) Determine whether exposure to PM10 was associated with changes in clot structure 
and function in samples from a susceptible population (deep vein thrombosis patients) 
3)  Determine how exposure of vascular endothelial cells to PM10, PM0.2, diesel particles 
and filtered diesel particles, affects clot formation and investigate changes induced in 
the endothelial cells as a possible mechanism of action of the particles 
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4) Determine whether engineered silica nanoparticles induce changes in clot structure 
and function similar to those induced by ultrafine particles 
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 Methods  
This chapter described the general procedures of each method that were used in this study.  
 
2.1 Materials 
Reagent Preparation/Purchasing Company 
Double distilled water Milli-Q Integral purification system 
Human Thrombin 
 
Stock concentration: 250 U/ml 
Stored at -80˚C 
(Calbiochem, Merck Chemicals, UK) 
Calcium Chloride 
 
Stock concentration: 1M (with double distilled 
water) 
Stored at room temperature 
(Sigma Aldrich, UK) 
Permeation buffer Double distilled water 
0.05 M Tris base (Fisher Scientific, UK) 
0.1 M NaCl (Sigma Aldrich, UK) 
pH 7.5 (using 5 M HCl, Sigma Aldrich, UK) 
Fluorescein isothiocyanate Alexa 
Fluor® 488 Protein (FITC) 
(Life Technology, UK) 
Purified human fibrinogen (Merck Chemicals, UK) 
Normal pooled plasma Plasma was collected from 30 healthy individuals in 
University of Leeds 
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5ml of sodium citrate and 45ml of whole blood from 
each individual were transferred to 50ml 
polypropylene tube. 
The cells were removed from plasma by 
centrifugation for at least 15 minutes at 2200-2500 
RPM at room temperature. 
After the centrifugation, all plasma was immediately 
transferred into a clean polypropylene tube and 
mixed together. 
Normal pooled plasma was apportioned into 2ml 
aliquots and stored at –80°C 
Tissue Plasminogen Activator Stock concentration: 100µg/ml 
(TechnoClone, UK) 
FXII deficiency plasma (Cambridge Bioscience, UK) 
FXII zymogen (Enzyme Research Laboratories, UK) 
Chromogenic substrate S2302 S2302 is a chromogenic substrate for plasma FXIIa 
and kallikrein. 
(Instrumentation Laboratory, US) 
Triton (Generon, UK) 
Standard Reference Material 
2787 particulate matter (<10 μm) 
(National Institute of Standards & Technology, NIST, 
USA) 
Standard Reference Material 
2975 diesel particulate matter 
(industrial forklift) 
(National Institute of Standards & Technology, NIST, 
USA) 
Silicon Dioxide nano-powder (10 
to 20 nm) 
(Sigma-Aldrich, UK) 
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µ-Slides 6 channel slides (Thistle Scientific, UK) 
µ-slide 8 well slides (ibiTreat) (Thistle Scientific, UK) 
Dulbecco's phosphate-buffered 
saline without calcium and 
magnesium (DPBS Gibco®) 
(Life Technologies, UK) 
Endothelial cell growing media 380ml of M199 Media (Sigma-Aldrich, UK) 
100 ml of Fetal Bovine Serum (FBS) 
10ml of Hepes (Life Technologies, UK) 
5ml of Antibiotic Antiomycotic Solution (Life 
Technologies, UK) 
2.5ml of Endothelial Cell Growth Supplements 
(ECGS) (Sigma-Aldrich, UK) 
2.5 ml of 1000 U/ml of Heparin (obtained from St. 
James University Hospital, Leeds) 
1ml of Sodium Pyruvate (Sigma-Aldrich, UK) 
Sodium pyruvate solution It was prepared with 2.75g of sodium pyruvate 
diluted with 50ml of double distilled water, filtered 
through 0.2mm diameter filter.  
The solution was aliquoted to 1ml and stored -20°C. 
Trypsin-EDTA It was diluted with DPBS 1:9. 
(Lonza, UK) 
Human Umbilical Vein 
Endothelial Cells (HUVEC) 
(PromoCell, Germany) 
Trypan Blue (Sigma-Aldrich, UK) 





(Life Technologies, UK) 
Dimethyl Sulfoxide (DMSO) (Lonza, UK) 
96-Well plate (Corning®) (Sigma-Aldrich, UK) 
Von Willebrand Factor ELISA Kit (Thermo Fisher Scientific, UK) 
Plasminogen Activator Inhibitor-
1 ELISA Kit 
(Abcam, UK) 
PRB322 Plasmid DNA (Thermo Fisher Scientific, UK) 
SYBR GREEN PCR Master Mix (Thermo Fisher Scientific, UK) 
Blue Juice Gel Loading Buffer 
(10x) 
(Thermo Fisher Scientific, UK) 
GelRed Nucleic Acid Gel Stain (Cambridge Bioscience, UK) 
Tips and tubes (DNase/RNase 
free) 
(Roche, UK) 
96-well plate and 384-well plate 
for PCR 
(Roche, UK) 
DNA ladder (100bp and 1kb) (Thermo Fisher Scientific, UK) 
 
 Turbidity Method 
Plasma Samples 
The kinetics of fibrin formation was evaluated by turbidimetry. The fibrin clot formation is 
characterised by three parts, which are lag phase, followed by lateral aggregation, and finally 
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a plateau of maximum absorbency (Metassan et al., 2010a). The lag phase is the time that the 
optical density value increases up to 0.01. The lag phase of the turbidity curve reflects the 
time required for fibrin protofibrils to grow up to sufficient length to allow lateral aggregation 
to occur (Undas et al., 2010). The lag phase starts from the moment that the activation 
mixture is added. Lateral aggregation is the slope of the turbidity curve, which is determined 
by the rate of fibrin polymerization. Maximum absorbance at the plateau phase reflects the 
number of protofibrils per fibre. Polymerisation rate can also be analysed by measuring the 
slope of the turbidity curve at its steepest or inflexion point. 
An aliquot of 25 µl of plasma samples and 75 µl of permeation buffer were transferred in 
triplicate to the 96-well microplate. Activation mixture contained 0.3 U/ml human thrombin 
and 15 mM CaCl2. Immediately on addition of 50 µl of activation mix, absorbency was read 
every 12 seconds at 340 nm for 30 minutes with a Kinetic Plate Reader (Spectramax Plus 384, 
Molecular Devices, UK). The temperature of the reaction was set at 37 °C. The final 











Figure 2-1. Turbidity Assay – Fibrin Clot Formation 
The fibrin clot formation is characterised by three parts, which are lag phase, followed by 
lateral aggregation, and finally a plateau of maximum absorbency (Metassan et al., 2010). 
 
Normal Pooled Plasma 
To set up the clot, 25 µl of normal pooled plasma and 25 µl of permeation buffer were added 
to the 96-well microplate. Four types of particles were used which were PM10, PM0.2, total 
diesel particles and filtered diesel particles.  Particles were diluted with permeation buffer to 
the working concentrations 150 µg/ml, 30 µg/ml, 3 µg/ml, 0.3 µg/ml, and 0.03 µg/ml. 50 µl 
of different concentrations of particle suspensions were added in triplicate to the microplate. 
The activation mixture contained 0.3 U/ml human thrombin and 15 mM CaCl2. Immediately 
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on addition of 50 µl of activation mix, absorbency was read every 12 seconds at 340 nm for 
60 minutes with a Kinetic Plate Reader (Spectramax Plus 384, Molecular Devices, UK). The 
temperature of the reaction was set at 37˚C. The final concentrations of thrombin and CaCl2 
were 0.1 U/ml and 5 mM respectively. The concentrations of particles were 50 µg/ml, 10 
µg/ml, 1 µg/ml, 0.1 µg/ml, and 0.01 µg/ml. 
 
Purified Human Fibrinogen 
50 µl of the human purified fibrinogen was added to each well of the 96-well plate. Same 
concentrations of particle suspension were used. 50 µl of each concentration of particle 
suspension were added in triplicate to the microplate. Activation mixture contained 0.3 U/ml 
human thrombin and 15 mM CaCl2. Immediately on addition of 50 µl of activation mix, 
absorbency was read every 12 seconds at 340 nm for 30 minutes with a Kinetic Plate Reader 
(Spectramax Plus 384, Molecular Devices, UK). The temperature of the reaction was set at 
37˚C. The final concentration of fibrinogen, thrombin and CaCl2 was 1 mg/ml, 0.1 U/ml and 5 
mM. The concentrations of particle suspension were 50 µg/ml, 10 µg/ml, 1 µg/ml, 0.1 µg/ml, 
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 Turbidity Lysis Assay 
Normal Pooled Plasma 
33.3 µl of normal pooled plasma and 16.7 µl of permeation buffer were added to the 96-well 
microplate. Particles were diluted with permeation buffer to the working concentrations 200 
µg/ml, 40 µg/ml, 4 µg/ml, 0.4 µg/ml, and 0.04 µg/ml. 50 µl of different concentrations of 
particle suspension were added in triplicate to the microplate. The lysis mixture was consisted 
of 0.4 µg/ml tPA. The activation mixture contained 0.4 U/ml human thrombin and 20 mM 
CaCl2. Immediately on addition of 50 µl of lysis mixture and 50 µl of activation mix, absorbency 
was read every 12 seconds at 340 nm for 60 minutes with a Kinetic Plate Reader (Spectramax 
Plus 384, Molecular Devices, UK). The temperature of the reaction was set at 37˚C. The final 
concentrations of tPA, thrombin and CaCl2 were 0.1 µg/ml, 0.1 U/ml and 5 mM respectively. 
The concentrations of particle suspension were 50 µg/ml, 10 µg/ml, 1 µg/ml, 0.1 µg/ml, and 
0.01 µg/ml.  
 
Purified Human Fibrinogen 
50 µl of 3 mg/ml of purified fibrinogen was added to the 96-well microplate. Particles were 
diluted with permeation buffer to the working concentrations 150 µg/ml, 30 µg/ml, 3 µg/ml, 
0.3 µg/ml, and 0.03 µg/ml. 50 µl of different concentrations of particle suspension were 
added in triplicate to the microplate. The lysis mixture was consisted of 1.5 µM of 
Plasminogen. The activation mixture contained 0.6 µg/ml tPA, 0.6 U/ml human thrombin and 
30 mM CaCl2. Immediately on addition of 25 µl of lysis mixture and 25 µl of activation mix, 
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absorbency was read every 12 seconds at 340 nm for 60 minutes with a Kinetic Plate Reader 
(Spectramax Plus 384, Molecular Devices, UK). The temperature of the reaction was set at 
37˚C. The final concentrations of plasminogen, tPA, thrombin and CaCl2 were 0.25 µM, 0.1 
µg/ml, 0.1 U/ml and 5 mM respectively. The concentrations of particle suspension were 50 
µg/ml, 10 µg/ml, 1 µg/ml, 0.1 µg/ml, and 0.01 µg/ml.  
 
2.2 Laser Scanning Confocal Microscopy 
Laser Scanning Confocal Microscopy (LSCM) allows direct quantification of fibrin clot 
structure by image.  
 
 
Figure 2-2: Laser Scanning Confocal Microscopy 700 T-PMT ZEISS 
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 Clot Preparation 
Plasma Samples 
30 µl of plasma samples was added to the microtube. 30 ul of activation mixture which 
contained 100 µg/ml of human fibrinogen amino terminal labelled with Fluorescein 
Isothiocyanate (FITC), 0.2 U/ml of human thrombin and 10 mM CaCl2 were introduced into 
the microtube and mixed with the plasma sample. Fibrin clots were prepared in a total volume 
of 60 µl, immediately upon the addition of activation mixture, 30 µl was slowly transferred to 
the channel of µ-slide VI0.4. Care was taken to ensure there were no bubbles in the channel. 
The slides were stored in a humidity chamber to prevent dehydration of the clot and stored 
at room temperature for 30 minutes. The final concentrations of FITC, thrombin and CaCl2 
were 50 µg/ml, 0.1 U/ml and 5 mM respectively.  
 
     
Figure 2-3: 6 channel µ-slide VI0.4 (Ibidi, Martinsried, Germany)  
Source: Ibidi Official Website µ-Slide VI 0.4 
 
 




Figure 2-4: Fibrin clot in µ-slide VI 
 
Normal Pooled Plasma 
An aliquot of 15 µl of normal pooled plasma mixed with 15 µl of permeation buffer were 
added to microtube. Silica nanoparticle suspension was prepared to concentrations 150 
µg/ml, 30 µg/ml, 3 µg/ml, 0.03 µg/ml, and 0.0003 µg/m. 30 µl of each concentration of SiO2 
nanoparticle suspension was added to the plasma sample. 24 µl of activation mixture which 
contained 150 µg/ml of human fibrinogen amino terminal labelled with Fluorescein 
Isothiocyanate (FITC) and 15 mM CaCl2 were introduced into the microtube. Finally, 6 µl of 
0.3 U/ml of human thrombin added to the tube and mixed with the plasma and nanoparticle 
suspension in the microtube. Fibrin clots were prepared in a total volume of 90 µl, 
immediately upon the addition of thrombin 30 µl of solution was slowly transferred to the 
channel of µ-slide VI0.4 (Ibidi, Martinsried, Germany). There should be no bubbles in the 
channel. The slides were stored in a humidity chamber to prevent dehydration of the clot. 
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The final concentrations of FITC, thrombin and CaCl2 were 50 µg/ml, 0.1 U/ml and 5 mM 
respectively. The concentrations of nano-silica suspension were 100 µg/ml, 10 µg/ml, 1 µg/ml, 
0.01 µg/ml, and 0.0001 µg/ml. 
 
Purified Human fibrinogen 
An aliquot of 30 µl of purified human fibrinogen was introduced into each eppendorf tube. 
30 µl of nanoparticle suspensions with concentrations 150 µg/ml, 30 µg/ml, 3 µg/ml, 0.3 
µg/ml, and 0.03 µg/ml were added into the eppendorf in duplicate and mixed with the 
fibrinogen. Activation mixture contained 150 µg/ml of human fibrinogen amino terminal 
labelled with Fluorescein Isothiocyanate (FITC), 1.5 U/ml of human thrombin and 45 mM CaCl2. 
24 µl of activation mixture which contained 150 µg/ml of human fibrinogen amino terminal 
labelled with Fluorescein Isothiocyanate (FITC) and 15 mM CaCl2 were introduced into the 
microtube. Finally, 6 µl of 0.3 U/ml of human thrombin added to the tube and mixed with the 
plasma and nanoparticle suspension in the microtube. Fibrin clots were prepared in a total 
volume of 90 µl, immediately upon the addition of thrombin 30 µl of solution was slowly 
transferred to the channel of µ-slide VI0.4 (Ibidi, Martinsried, Germany). Care was taken to 
ensure there were no bubbles in the channel. The slides were stored in a humidity chamber 
to prevent dehydration of the clot. The final concentrations of FITC, thrombin and CaCl2 were 
50 µg/ml, 0.1 U/ml and 5 mM respectively. The concentrations of nano-silica suspension were 
50 µg/ml, 10 µg/ml, 1 µg/ml, 0.1 µg/ml, and 0.01 µg/ml. 
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 Image Analysis 
The 3D structure of the clot was visualized by confocal microscopy on a LSM 700 T-PMT ZEISS 
microscope (ZEISS, Jena, Germany). Clot structure was viewed using 63x oil immersion lens 
with a 5-W argon laser and 488nm laser filter. The images were collected in the format of 512 
x 512 pixels. Fibre density was calculated as the number of fibres crossing a straight line of 




Figure 2-5: Fibrin clot image under LSCM 
Structure of fibrin clots can be visualized through confocal microscope.  
 
2.3 Permeation Method 
 Permeability Experimental Apparatus 
Fibrin clot permeation involves a gravity-driven tube system as shown in figure 2-6. 




Figure 2-6: Permeability Experimental Apparatus 
There are four parts of this apparatus, syringe (A), plastic tube (B), plastic pipette tip (C), and 
a small plastic microtube (D). The syringe was filled with permeation buffer. The plastic tube 
was the connection between syringe and the plastic pipette tip. The plastic pipette tip was 
cut from a disposable plastic pipette. 4.5cm from the tip of the disposable plastic pipette was 
sheared as the plastic pipette tip. The interior surface of the pipette tip was roughened. The 
screw cap of the microtube was drilled in the middle with the diameter of the plastic pipette 
tip. The pipette tip could pass through the cap. The pipette tip and microtube were linked.  
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The fibrin clot permeation method is used to measure the flow rate of liquid through the fibrin 
clot. The flow rate represents the pore size of fibrin clot structure.  
 
 Clot Preparation 
Plasma Samples 
Plasma samples were defrosted in the water bath at 37˚C for 3 minutes just before use. After 
defrosting, plasma samples were agitated briefly to ensure thorough mixing. 100 µl of plasma 
was transferred to each eppendorf tube. Activation mixture contained 176 mM of CaCl2 and 
11 U/ml of thrombin. 10 µl of activation mixture was transferred to each eppendorf tube and 
mixed with plasma. Fibrin clot started to form. 100 µl of clotting mixture was carefully and 
immediately transferred from the eppendorf tube to the plastic pipette tip. There should not 
be any bubbles in the clotting tip. The final concentrations of thrombin and CaCl2 were 1 U/ml 
and 16 mM. Then the pipette tip was kept in the humidity chamber horizontally for two hours 
at room temperature. During this time, fibrin gel cross-linking started to occur and stabilise 
the fibrin clot structure in the humidity chamber horizontally. The humidity chamber was 
prepared, as follows, before making the fibrin clot, a folded piece of paper towel was soaked 
with distilled water and placed in the petri dish. After the 2 hours, the plastic pipette tip was 
connected to the syringe through a plastic tube. The syringe was filled with permeation buffer. 
The height of the buffer was 4 cm from the bottom of the plastic pipette tip (Fig 2-6). Pressure 
was created on the clot due to the buffer. The clot was washed by the permeation buffer for 
90 to 120 minutes. 




Figure 2-7: The graphical representation of the pressure to the clot 
 
 Pore Size Measurement of Fibrin Clot  
After 90 to 120 minutes washing, the volume of the permeation buffer through the fibrin clot 
was measured for the next 120 minutes. The permeation buffer was collected and measured 
every 30 minutes. To avoid evaporation, the buffer through the fibrin clot dropped into a 
closed microtube. The microtubes were weighed prior to use, in order to calculate the drops 
weight accurately. After every 30 minutes, the old microtube was removed and replaced with 
a new one. After 120 minutes, 4 microtubes were collected. The volume of the permeation 
buffer through the fibrin clot was calculated (1 g=1 ml). 
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The permeation coefficient (Darcy constant [Ks]), which indicates the pore size of fibrin clot 
and represents the surface of the gel allowing flow, was calculated from the equation:  
 
Ks = Permeability Coefficient 
Q = volume of liquid (1ml = 1cm3) 
L = the length of fibrin clot gel (1.7cm) 
η = viscosity of the liquid (10-2 poise = 10-7 N.s.cm-2) 
T = time (second) 
A = cross-sectional area (0.071 cm2) 
ΔP = pressure drop (density x weight x height = 1 x 980 x 4 = 3920 dyne/cm2 = 0.03920 N.cm-
2)  
 
As the constants are substituted, L = 1.7 cm, η = 10-7 N.s.cm-2, A = 0.071, and ΔP = 0.03920 
N.cm-2 
Ks = Q/T x 6.108 x 10-5 
Q = Volume (ml) 
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2.4 Factor XII Activation Test 
Method A 
Silicon dioxide nanoparticles was diluted with double distilled water and the working 
concentrations were 150 µg/ml, 30 µg/ml, 3 µg/ml, 0.3 µg/ml, and 0.03 µg/ml. 50 µl of silica 
suspensions, 25 µl of FXII deficiency plasma and 25 µl of permeation buffer were added in the 
96-well plate in triplicates.  
The stock concentration of FXII zymogen is 4.1 µg/ml. FXII plasma concentration is 375 nM 
(30 µg/ml). 1 µl of FXII zymogen was diluted with 136.67 µl of double distilled water. 3.42 µl 
of FXII zymogen was mixed with 996.58 µl of FXII deficiency plasma. 50 µl of silicon dioxide 
nanoparticle suspension were added in triplicate. 25 µl of FXII deficiency with plasma FXII 
zymogen and 25 µl of permeation buffer were added into the 96 well-plate. 50 µl of silica 
suspensions, 25 µl of normal pooled plasma and 25 µl of permeation buffer were added in 
triplicate in the 96-well plate as control. 
Activation mixture contained 0.3 U/ml human thrombin and 15 mM CaCl2. Immediately on 
addition of 50 µl of activation mix, absorbency was read every 12 seconds at 340 nm for 60 
minutes with a Kinetic Plate Reader (Spectramax Plus 384, Molecular Devices, UK). The 
temperature of the reaction was set at 37˚C. The final concentrations of thrombin and CaCl2 
were 0.1 U/ml and 5 mM respectively. The concentrations of nano-silica suspension were 50 
µg/ml, 10 µg/ml, 1 µg/ml, 0.1 µg/ml, and 0.01 µg/ml. 
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Method B 
Silicon dioxide nanoparticles was diluted with double distilled water and the working 
concentrations were 500 µg/ml, 100 µg/ml, 10 µg/ml, 1 µg/ml, and 0.1 µg/ml. 10 µl of 
different concentrations of SiO2 NPs were added to 96-well plate. 0.25% Triton, 625 nM of 
FXII zymogen, 10 mM S2302 (a kind of chromogenic substrate for plasma kallikrein, factor XIa 
and factor XIIa) and permeation buffer was added into each well. For a positive control of FXII, 
PTT automate was added and mixed with 625 nM of FXII zymogen. Absorbency was read every 
12 seconds at 340 nm for 180 minutes with a Kinetic Plate Reader (Spectramax Plus 384, 
Molecular Devices, UK). The temperature of the reaction was set at 37˚C. The final 
concentrations of Triton, FXII zymogen, and S2302 were 0.05%, 125 nM, and 2 mM 
respectively. The concentrations of nano-silica suspension were 50 µg/ml, 10 µg/ml, 1 µg/ml, 
0.1 µg/ml, and 0.01 µg/ml. 
 
2.5 Endothelial Cell Culture 
Endothelial cell growth media (ECGM) was prepared before defrosting the cells. 500 ml of 
ECGM consisted of 380 ml of M199 media, 100 ml of fetal bovine serum, 10 ml of 1 M Hepes, 
5 ml of antibiotic antiomycotic solution, 2.5 ml endothelial cell growth supplements solution, 
2.5 ml of 1000 U/ml Heparin, and 1 ml of sodium pyruvate solution. ECGM was stored at -4 
degree and prewarmed before use. 
Frozen human umbilical vein endothelial cells (HUVEC) were purchased from PromoCell. The 
vial containing the cells was thawed in a water bath and gently shook for 2 or 3 minutes. Once 
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the cells were defrosted, they were immediately transferred into a T25 flask containing 9ml 
pre-warmed ECGM. 
Cells were cultured and underwent passaging after 80-90% confluent in the flask. HUVEC were 
used only between passage 3 to passage 7. 
 
 Passaging 
When the cells were 80-90% confluent in the T25 flask, they were prepared for passaging. All 
media was removed completely. The cells were washed once with 5 ml DPBS. Then 1 ml of 
Trypsin-EDTA (10 fold diluted) was added to the T25 flask which was enough to cover the 
whole bottom surface of the flask. Cells were incubated for 2 to 3 minutes. Afterwards, all 
cells should detached from the bottom surface of the flask, 8 ml of pre-warmed ECGM was 
added to flask to stop trypsinization. Cells were transferred into a sterile 15 ml tube and 
centrifuged for 5 min at 1000 x g. Then, the supernatant was discarded and the cell pellet was 
re-suspended with 1 ml of ECGM. Based on the experiment requirements, different number 
of cells were seeded to either flasks, plates, or slides.  
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 Counting Cells  
After the cells were re-suspended with 1 ml fresh ECGM, 10 µl of cell suspension was taken 
transferred into a small eppendorf and 30 µl of Trypan Blue was added. The haemocytometer 
was prepared for counting cells by placing cover slip onto the grooves on the glass slide. 10 µl 
of mixed cell suspension was transferred to one side of the slide under the cover slip. Cells 





Figure 2-8: Image Showing Haemocytometer 
The cells were counted in the area A. For each light blue square, the number of cells in 4 A 
parts were added up which refers to ‘the number of cells counted’ in the formula. The number 
of cells per ml was calculated following the formula. 
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 Freezing Cells 
The freezing media was prepared with 90% fetal bovine serum and 10% of sterile DMSO. After 
passaging the cells, 200 μl of cell suspension was transferred to a cryotube (Nunc) containing 
800 μl of the freezing mixture. The cell number would be approximately 1.0 x 106 cells per ml. 
The vials were placed into Nalgene Mr Frosty (Sigma-Aldrich, UK) which is a polycarbonate 
container holding isopropanol. Isopropanol controls the cooling at a constant rate of 1°C per 
minute which was required for successful cryopreservation of cells. The Mr Frosty container 
was placed in the -80°C freezer overnight. Then the vials were moved to the liquid nitrogen 
storage tank for long term storage. Cells were only frozen until passage three.  
 
2.6 Cytotoxicity Test 
The particles cytotoxicity was measured by using the 3-(4, 5-dimerthylthia-zol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) reduction assay. MTT is a water soluble tetrazolium salt, 
which can be converted to a purple formazon product by enzymes in living cells. MTT assay is 
a colorimetric method for cytotoxicity detection that measures the reduction of MTT by 
mitochondrial succinate dehydrogenase. The MTT entered cells and passed into the 
mitochondria. Then it became an insoluble, dark purple formazan product. After adding 
solubilising solution (an organic solvent), the formazan reagent was solubilised and released. 
Reduction of MTT reagent only occurs in live cells. More mitochondria activities induced the 
darker colour of cells and indicated more viable cells. The colour was measured 
spectrophotometrically  (Supino, 1995). 
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For the treatment, cells were seeded into a 96-well plate. Each well contained 2x104 cells at 
the beginning. After the cells were 80 to 90% confluent, cells were ready to be treated with 
nano-silica. All the media was removed from the well completely. Particle solution was diluted 
with ECGM without fetal bovine serum. The concentrations were 50 µg/ml, 10 µg/ml, 1 µg/ml, 
0.1 µg/ml, 0.01 µg/ml and 0 µg/ml. 100 µl of different concentrations of particle suspension 
was added to each well in triplicate. The cells were incubated for 24 hours at 37˚C with 5% 
CO2. 
To prepare the MTT, 100 mg of MTT powder was added into a 50 ml falcon tube covered with 
aluminium foil containing 20 ml of tissue-culture DPBS. The MTT solution was mixed well and 
incubated in the water bath for 15 minutes at 37˚C. The MTT solution was filtered by a 0.2 
µm filter in the flow hood without light. The tube containing filtered MTT solution was 
wrapped with aluminium foil.  
The whole process should be conducted in the flow hood without the light on. 10 µl of MTT 
solution was added to each well without taken the previous treatment solution. 96-well plate 
was covered with aluminium foil and transferred into the incubator for 4 hours. After 
incubation, all media was removed completely. 100 ul of sterile DMSO was added to each well 
for solubilising the MTT reagent. The plate was incubated overnight. The plate was read at 
540 nm and 690 nm (reference absorbance) with 10 seconds shaking on the ASCENT software.  
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2.7 Fibrin Clot Formation on HUVEC 
To set up the fibrin clot structure, 300 µl of cell suspension containing 5 x 104 cells were 
seeded on the µ-slide. After 80 to 90% confluent in the µ-slide, the cells were ready for 
treatment. The particle suspension was prepared with ECGM without fetal bovine serum for 
treatment. The concentrations were 50 µg/ml, 10 µg/ml, 1 µg/ml, 0.1 µg/ml, 0.01 µg/ml and 
0 µg/ml. 300 µl of each concentration and control were added in duplicate to each well of the 
slide. The treatment lasted for 24 hours. Then, all solution was removed completely by 
vacuum pump.  
 
 Purified Human fibrinogen 
Clot formation were performed on the cells after the treatment. 1 mg/ml of purified 
fibrinogen was mixed with the activation mixture consisted of 50 µg/ml of FITC, 15mM of 
CaCl2, 5 U/ml of thrombin and ECGM without fetal bovine serum. 300 µl of the clotting 
mixture was immediately introduced into the well. The slides were kept in the incubator for 
15 to 30 min for the clot to form. The final concentrations of fibrinogen, FITC, thrombin and 
CaCl2 were 1 mg/ml, 50 µg/ml, 0.5 U/ml and 15 mM respectively.  
 
 Normal Pooled Plasma 
To set up the clot, 100 µl of normal pooled plasma was mixed with the 200 µl of activation 
mixture consisted of 0.5 mg/ml of FITC, 150 mM of CaCl2, 5 U/ml of thrombin and M199 media. 
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300 µl of the clotting mixture was immediately introduced into each well. The slides were 
kept in the incubator for 30 min allowing the clot formation. The final concentrations of FITC, 
thrombin and CaCl2 were 50 µg/ml, 0.5 U/ml and 15 mM respectively. 
This method was confirmed after trying different concentrations of thrombin and CaCl2, also 
different reagents (DPBS, permeation buffer, ECGM without serum, M199 media) were used 
to dilute the activation mixture. M199 media was the most appropriate reagent to mix with 
thrombin and CaCl2 and setting up the clots.  
 
2.8  Enzyme-Linked Immunosorbent Assay (ELISA)  
Enzyme-Linked Immunosorbent Assay (ELISA) was used to measure the concentrations of 
VWF and Plasminogen Activator Inhibitor-1 (PAI-1) which are secreted by endothelial cells 
and released into the circulation afterwards. 
 
 Von Willebrand Factor 
Enzyme-Linked Immunosorbent Assay (ELISA) was used to measure the concentration of 
Human VWF in the cell culture supernatant. We purchased the Human VWF ELISA Kit from 
Abcam. 96-well plate had been coated with VWF antibody. The brief procedures were as 
following. The Standards and samples were added to the wells, incubated and then washed 
with wash buffer. The VWF biotinylated detection antibody was then added, incubated, and 
washed by wash buffer. Thirdly, Streptavidin-Peroxidase Conjugates was added, incubated, 
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and washed with wash buffer. Chromogenic substrate (TMB, 3,3', 5,5;-tetramethylbenzidine) 
is catalyzed by Streptavidin-Peroxidase to produce a blue color product which was added to 
visualize Streptavidin-Peroxidase enzymatic reaction. Finally, an acidic stop solution was 
added and the chromogenic substrate produce color changed to yellow. The density of yellow 
was measured by a microplate reader and indicated the amount of VWF captured on the plate.  
 
Cell Treatment 
HUVEC was treated with different particles with different concentrations 0 μg/ml, 0.01 μg/ml, 
0.1 μg/ml, 1 μg/ml, 10 μg/ml, and 50 μg/ml, respectively. The cells were incubated with 
particle suspension for 24 hours.  
 
Reagent Preparation 
All reagents were warmed up to room temperature (18-25°C) prior to use. Diluent N 
Concentration was diluted 1:10 with MilliQ water and mixed well. Wash Buffer Concentrate 
was diluted with MilliQ water 1:20 and mixed well.  
Von Willebrand Factor Standard was prepared. The stock concentration was 240 mU/ml. The 
standard were diluted to concentrations 80 mU/ml, 40 mU/ml, 20 mU/ml, 10 mU/ml, 5 
mU/ml, 2.5 mU/ml and 0 mU/ml. 50x Biothinylated Von Willebrand Factor Detector Antibody 
was diluted with Diluent N.  
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Cell Culture Supernatants Preparation 
After the cells were treated for 24 hours, the cell supernatants were transferred to 
microtubes. The supernatants were centrifuged at 3,000 x g for 10 minutes to remove debris.  
 
ELISA 
All materials and prepared reagents were warmed up to room temperature prior to use. 50 
μl of standards, controls and samples were added into the wells in triplicate. The plate was 
covered by a sealing tape and incubated for 2 hours. Each well was inverted and washed five 
times using 200 μl of 1X Wash Buffer, tapped 4 to 5 times on absorbent paper towel to 
completely remove the liquid. 50 μl of 1X Biotinylated Von Willebrand Factor Antibody were 
added to each well and incubated for 2 hours. Plate was washed as described above. Then, 
50 μl of 1X SP Conjugate were added to each well and incubated for 30 minutes, followed by 
plate washing as described above. 50 μl of Chromogen Substrate were added to each well 
and incubated for 20 minutes and finally 50 μl of Stop Solution were added. The color changed 




To generate the standard curve, the graph used the standard concentrations on the x-axis and 
the corresponding mean 450 nm absorbance on the y-axis. The samples concentrations were 
calculated from the standard curve.  
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 Plasminogen Activator Inhibitor - 1 
Enzyme-Linked Immunosorbent Assay (ELISA) was used to measure the concentration of 




HUVEC was treated with different particles with different concentrations from 0 to 50 μg/ml. 
The cells were incubated with the suspension for 24 hours.  
 
Standard Preparation 
PAI-1 Standard was prepared. Each well was added 100 μl of standard. The stock 
concentration was 4,000 pg/ml. The standard was diluted to 2,000 pg/ml, 1,000 pg/ml, 500 
pg/ml, 250 pg/ml, 125 pg/ml, and 0 pg/ml.  
Streptavidin-HRP (100X) is in 50% glycerol. Streptavidin-HRP was diluted with Streptavidin-
HRP Diluent 1:100. This reagent was prepared within 15 minutes of usage.  
Wash Buffer Concentrate (25X) was diluted with MilliQ water 1:25.   
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Cell Culture Supernatants Preparation 
After the cells were treated for 24 hours, the cell supernatants were transferred to 
microtubes. The supernatants were centrifuged at 3,000 x g for 10 minutes to remove debris.  
 
ELISA 
All materials and prepared reagents were warmed up to room temperature prior to use.  
All standards, controls and samples were in triplicates. 100 μl of standards were added to 
each well. Controls and samples were diluted with Standard Diluent Buffer 1:1 (50 μl : 50 μl) 
and added into each well in triplicate. The plate was covered by a sealing tape and incubated 
for 2 hours at room temperature. Then, each well was washed with 300 μl of 1X Wash Buffer 
for four times, tapped 4 to 5 times on absorbent paper towel to completely remove the liquid. 
100 μl of Biotinylated Human PAI-1 Biotin Conjugate Solution was added into each well and 
incubated for another 2 hours at room temperature with sealing tape. The plate was washed 
as described above. Then 100 μl of Streptavidin-HRP Working Solution was added to each well 
and incubated for 30 minutes at room temperature with plate cover. The plate was washed 4 
times as described above. 100 μl of Stabilized Chromogen was added to each well and 
incubated for 30 minutes at room temperature in the dark. Finally, 100 μl Stop Solution was 
added to each well. Read the plate immediately at 450nm.  
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Calculation 
To generate the standard curve, the graph was plotted using the standard concentrations on 
the x-axis and the corresponding mean 450 nm absorbance on the y-axis. The samples 
concentrations were calculated from the standard curve.  
 
2.9 Real Time Polymerase Chain Reaction (RT-PCR) 
The real time polymerase chain reaction is one of the most useful technologies in molecule 
biology which can be used to quantify the DNA or RNA in a sample. Specific sequences in a 
DNA or cDNA template can be amplified thousands to millions fold using sequence specific 
oligonuceotides. PCR amplifies DNA exponentially, doubling the number of target molecules 
in each amplification cycle. Fluorescent DNA-binding dyes and real time PCR machine are used 
to quantify the amplified products by measuring the fluorescence dyes that yield increasing 
fluorescent signal in direct proportion to the number of PCR product molecules generated.  
RT-PCR method was used to quantify the gene expression of tissue factor and 
thrombomodulin as both of them are membrane proteins secreted by endothelial cells.  
 
 Cell Treatment 
Human umbilical vein endothelial cells were seeded in T25 flasks with 0.7x106. When the T25 
flasks were 80 to 90% confluent, cells were treated with different concentrations of particles. 
Each particles were diluted to six concentrations for cell treatment which were 0 µg/ml, 0.01 
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µg/ml, 0.1 µg/ml, 1 µg/ml, 10 µg/ml and 50 µg/ml respectively. Cell were treated for 24 hours 
in the incubator at 37 ᵒC with 5% CO2. After the treatment, the cells were trypsinzed and 
collected in the tubes. Then, those cells were washed with DPBS one more time to remove 
the serum completely. Afterwards, the cells were ready for total RNA extraction.  
 
 RNA Extraction 
RNeasy Mini Kit from Qiagen (Germany) was used for total RNA extraction from endothelial 
cells. After treatment, the harvest cell number was approximately 1 – 1.5 x105 per flask. Cells 
were mixed with 350 µl of RLT buffer for 15 minutes with gentle shaking which allowed the 
cells to be lysed completely. Then, 350 µl of 70% of ethanol was added to the lysate and mixed 
well by pipetting. 700 µl of each sample was transferred to an RNeasy Mini spin column placed 
in a 2 ml collection tube. The tubes were centrifuged for 1 min at 4,000 x g, and 5 seconds at 
6,000 x g. The flow through was discarded. 700 µl of Buffer RW1 was added to each RNeasy 
Mini spin column. The tubes were centrifuged for 1 min at 4,000 x g, and 5 seconds at 6,000 
x g. The flow through was discarded. 500 µl of Buffer RPE was added to each RNeasy Mini spin 
column. The tubes were centrifuged for 1 min at 4,000 x g, and 5 seconds at 6,000 x g. The 
flow through was discarded. Another 500 µl of Buffer RPE was added to each spin column. 
The tubes were centrifuged for 2 min at 4,000 x g, and 15 seconds at 6,000 x g. The flow 
through was discarded. The tubes were centrifuged again for 2 min at the maximum speed to 
dry the membranes.  The 2 ml collection tubes were discarded and replaced by the new 1.5 
ml collection tubes. Finally, 30 µl of RNase/DNase Free water was added to each spin column 
membrane. The tubes were centrifuged for 1.5 min at 6000 x g to elute the total RNA. 
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The quantity and quality of total RNA from each sample was measured by NanoDrop 1000 
Spectrophotometer (UK).  
 
 Reverse Transcription 
For reverse transcriptase from totol RNA to cDNA, we used Taqman Reserve Transcription 
Reagents (Life Technologies, UK). The total RNA samples were diluted to 100 ng/ul. Each 
reaction was made up to 20 µl of the reaction volume (as shown below). The enzymes should 
be kept in the freezer until immediately prior to use.  
Component Volume Final Concentrations 
DNase/RNase Free H2O 1.6 µl - 
10x RT Buffer 2 µl 1x 
25 mM MgCl2 1.4 µl 1.75 mM 
10 mM dNTP mix 1 µl 0.5 mM 
100 mM DTT 1 µl 5mM 
RNase Inhibitor (20 U/µl) 1 µl 1 U/µl 
MultiScribe RT (50 U/µl) 1 µl 2.5 U/µl 
50 µM Random Hexamers 1 µl 2.5 µM 
Template RNA (100 µg/µl) 10 µl 50 µg/ul 
 Figure 2-9. Reverse Transcription Reagents Preparation 
 
Page 117 of 265 
 
After making up the reaction, the tubes were moved to the PCR machine for incubation in a 
thermal cycle (as shown below). 
Temperature Time 
25 ᵒC 10 minutes 
37 ᵒC 30 minutes 
95 ᵒC 5 minutes 
4 ᵒC Indefinitely 
Figure 2-10. Reverse Transcription thermal cycle setup 
After the incubation, the total RNA was reverse transcript to the cDNA and ready for real time 
PCR. 
 
 Primer Design 
Good primer design is an important parameter in real time PCR. The primers should be 18 to 
24 nucleotides in length and the amplicon length should be between 50 to 150 bp. The primer 
pairs should have compatible melting temperature (Tm) (within 1 ᵒC) and contain 
approximately 50% GC content.  
We needed to choose primers for housekeeping genes and target genes. There are many 
common used housekeeping genes. According to the literatures, we chose glyceraldehydes-
3-phosphate dehydrogenase (GAPDH) and beta actin (ACTB) as the housekeeping gene. The 
two target genes were TF and THBD. We found the adaptive primers for each gene from 
national centre of biotechnology institute (NCBI).  
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Gene Primer Sequence (5’ – 3’) Tm GC% Amplicon Length 
GAPDH 
NM_001256799.2 
Forward AAGCCTGCCGGTGACTAAC 60 ᵒC 57.89 111 bp 
Reverse GCATCACCCGGAGGAGAAAT 59.82 ᵒC 55% 
ACTB 
NM_001101.3 
Forward TCGAGCAAGAGATGGC 62 ᵒC 56% 194 bp 
Reverse TGAAGGTAGTTTCGTGGATG 66 ᵒC 45% 
TF 
NM_001178096.1 
Forward AAACCTCGGACAGCCAACAA 60.11 ᵒC 50 116 bp 
Reverse CCCGGAGGCTTAGGAAAGTG 60.11 ᵒC 60 
THBD 
NM_000361.2 
Forward AGCCCCTGAACCAAACTAGC 59.96 ᵒC 55 176 BP 
Reverse GAAACCGTCGTCCAGGATGT 60.04 ᵒC 55 
Figure 2-11. Details of primers of housekeeping genes and target genes 
To confirm the specificity of the primers, BLAST® search was used to be sure that the primers 
were only recognized in the target of interests.  
 
 RT-PCR 
There were three main steps of real time PCR and the reaction ran for 40 cycles. Before 
making up the reactions, the LC480 RT-PCR instrument was set up as following. 
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Program Analysis Mode Cycle Segment Temperature Time Acquisition 
Mode 
Denaturation None 1  95 °C 10 min None 
Amplification Quantification 40 Denaturation 95 °C 15 s None 
Annealing/ 
Extension 
60 °C 1 min Single 
Melting Curves Melting Curves 1 Denaturation 95 °C 5 s None 
Annealing/ 
Extension 
60 °C 1 min None 
Melting 95 °C  Continuous 
Cooling None 1  40 °C 30 s None 
Figure 2-12. Real Time PCR thermal cycle setup 
 
After setting up the instrument, the reactions were prepared as following. SYBR Green Master 
Mix (Thermo Fisher, UK) was used in the RT-PCR for fluorescence quantification after double 
stranded DNA binding to the SYBR® Green. 
Component Volume (96-well Plate) Final Concentrations 
2x SYBR Green PCR Master Mix 10 μl 1x 
Forward Primer 1 μl 500 nM 
Reverse Primer 1 μl 500 nM 
cDNA Template 8 μl 40 ng 
Figure 2-13. Real Rime PCR reagents preparation 
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After making up the reactions, the plate was covered by the foil and centrifuged for 2 min at 
1,500 x g. Then, the plate was transferred into the instrument LC480 to start the progress 
immediately.  
 
2.10 Plasmid Strand Break Assay 
The plasmid strand break assay was used to investigate the strand breaks in the plasmid DNA 
caused by exogenous agents such as ionizing radiation, or by endogenously generated reactive 
oxygen species (Lodge et al., 1989; Schnaith et al., 1994; Smiałek et al., 2009). The pBR supercoiled 
plasmid DNA was incubated with different concentrations of particles for 12 hours allowing the 
single strand or double strand breaks to occur and generating nicked or relaxed plasmid DNA. pBR 
plasmid DNA is 4,361 bp in length. But supercoiled plasmid DNA travels faster than nicked DNA, 
the relaxed DNA travels the most slowly through an agarose gel during electrophoresis. 
  
  Plasmid DNA Precipitation 
PBR 322 Plasmid DNA was purchased from Thermo Fisher Scientific and stored in the buffer 
with 10 mM Tris-HCl and 1mM EDTA. The plasmid need to be precipitated to remove the 
chelating agent, EDTA, completely. 
The pBR 322 supercoiled plasmid DNA was transferred to the RNase/DNase free 1.5 ml tube 
and then 20 µl of 3M Sodium Acetate buffer was added to the tube. After adding another 500 
µl of cold 100% ethanol, the tube was placed in -20 °C freezer for one hour. The plasmid DNA 
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was centrifuged for 15 minutes at the highest speed (13000 rpm) in a 4°C.  The supernatant 
was removed as much as possible and 250 µl of cold 70% ethanol was added. The plasmid 
was centrifuged again for 5 minutes in a 4 °C centrifuge at maximum speed. The supernatant 
was discarded completely. The remaining ethanol was evaporated by using SpeedVac for 10 
min. The plasmid DNA pellet was resuspended in 100 µl of DNase/RNase free water. The stock 
concentration of plasmid DNA was 1 µg/µl and stored in -20°C freezer.  
 
  Plasmid Strand Break Assay 
PBR322 plasmid was diluted with DNase/RNase free water to 0.2 µg/µl. Different 
concentrations of particles were prepared for treatment. 5 µl of plasmid DNA was incubated 
with 5 µl of treatment at room temperature in dark (avoid UV damage of plasmid).  
After 12 hours incubation, the gel was prepared with 1 g agarose in 100 ml 1x TBE buffer 
(0.5M EDTA, Tris Base, Boric Acid), adding 1 µl of gel red. After the gel cooled down, the 
samples were added. Each sample was mixed with 1 µl of 10x blue juice gel loading buffer and 
10 µl of sample was loaded into the gel. Gel electrophoresis was run at 60V for 2 hours with 
1x TBE buffer. The gel was visualized. The strand breaks were able to be quantified using 
BioRad QuantityOne software (Bio-Rad, Hercules, CA) by calculating the proportion of 
supercoiled plasmid DNA remaining of each sample compared to the control.  
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 Effects of Particulate Matter and Diesel Particles 
on Fibrin Clot Structure  
3.1 Introduction 
PM has been associated with cardiovascular diseases in many epidemiological studies. Some 
studies have shown air pollution is associated with increased risks of cardiovascular diseases, 
such as myocardial infarction, deep vein thrombosis and coronary artery diseases (Franchini 
and Mannucci, 2007; Langrish et al., 2012; Newby et al., 2014). An epidemiological study from 
Kloog et al. investigated the short-term and long-term PM2.5 exposure effects, the results 
indicated that every 10 µg/m3 of PM2.5 caused 0.63% (95% CI = 0.03%--1.25%) increase in DVT 
admissions in short-term exposure and 6.98% (95% CI = 5.65%--8.33%) in long-term exposure. 
In terms of the pulmonary embolism, 0.38% (95% CI = −0.68%--1.25%) and 2.67% (95% 
CI = 5.65%--8.33%) increased risks were induced by PM2.5 short- and long-term exposure 
respectively (Kloog et al., 2015). Some studies also confirmed that the alterations in fibrin clot 
structure, its mechanical properties and resistance to lysis were correlated with different 
cardiovascular diseases and diseases of both arterial and venous thrombosis. Altered fibrin 
clot structure with compact, highly branched networks, reduced permeability and prolonged 
lysis time has been associated with several thromboembolic events, e.g. ischemic stroke and 
venous thrombosis. The patients with those CVD had altered fibrin clot structure with greater 
number of fibres and more compact arrangement fibre network (Hooper et al., 2012; Undas 
and Ariens, 2011; Weisel, 2007). However, the underpinning mechanisms were still unclear. 
Therefore, in view of the association between exposure to particulate matter and thrombosis, 
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and of the association between thrombosis and abnormal fibrin clot structure, the aim of this 
study was to investigate whether particulate matter and diesel particles could induce fibrin 
clot structure alteration in vitro. Normal pooled plasma samples and purified fibrinogen 
samples were used as in vitro models to detect the effects of PM.  
 
3.2 Methods 
PM10 (SRM 2787) and diesel particles (SRM 2975) was purchased from the National Institute 
of Standard and Technology (NIST). PM10 was collected from an air intake filtration system of 
a major exhibition centre in Prague, Czech Republic, and generally represents the 
atmospheric particulate matter obtained from an urban area, which contains polycyclic 
aromatic hydrocarbons (PAHs), nitro-substituted PAHs (nitro-PAHs), polybrominated 
diphenyl ether (PBDE) congeners, hexabromocyclododecane (HBCD) isomers, sugars, 
polychlorinated dibenzo-р-dioxin (PCDD) and dibenzofuran (PCDF) congeners, inorganic 
constituents, and particles-size characteristics in atmospheric particulate material. Total 
diesel particles was collected from an industrial diesel-powered forklift and contained PAHs 
and nitro-PAHs in diesel particulate matter.  
Both particles were diluted with double distilled water, with a stock concentration of PM10 of 
1 µg/ml. Both particles were then diluted to 1 µg/ml and centrifuged for 30 min at maximum 
speed, and then filtered through a 0.2 μm membrane filter respectively. The diameters of the 
filtered particles were less than 0.2 μm. The mass fraction of PM0.2 is 30% of the PM10. And 
filtered diesel particles is 35% of the total diesel particles. 
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Five concentrations of particle suspension were used in the experiments; 50 µg/ml, 10 µg/ml, 
1 µg/ml, 0.1 µg/ml and 0.01 µg/ml. Different concentrations of PM and diesel particles were 
added to the normal pooled plasma and fibrinogen samples, respectively. Three methods, 
turbidity assay, turbidity-lysis assay and laser scanning confocal microscope assay, were used 




 Turbidity Assay 
The results of the turbidity assay are shown in the following figure (Fig. 3-1 and 3-2). The four 
types of particles used in experiments in which fibrin clots were formed with 1) normal pooled 
plasma and 2) purified fibrinogen.  
 
Normal Pooled Plasma Samples 
Clots were formed from normal pooled plasma samples in the presence of particles. 
Compared to the control, the clots formed with particles had no significantly higher 
absorbance. But, there was a trend that as the concentrations of particles increased, the 
maximum OD values increased as well (Fig. 3-1). 
 




Figure 3-1. Turbidity Assay -- Maximum Absorbance of Plasma Samples Exposed to Different 
Concentrations of Particles (n=5) 
The normal pooled plasma samples were mixed with particle suspension from 0 to 50 µg/ml. 
The final concentrations of thrombin and CaCl2 were 0.1 U/ml and 5 mM respectively. The 
maximum absorbance of the clots formed with different concentrations of particles were 
shown in the figure. 
 
Fibrinogen Samples 
In terms of the fibrinogen samples, after the incubation with increased concentrations of 
PM10, there were no significant differences compared to controls. The total diesel particles 
showed similar results as PM10. However, for the PM0.2 and filtered diesel particles, the 
maximum fluorescence intensity of the clots showed no changes, even after treatment with 
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Figure 3-2. Turbidity Assay -- Maximum Absorbance of Fibrinogen Samples Exposed to 
Different Concentrations of Particles (n=5) 
The purified fibrinogen samples were mixed with particle suspension from 0 to 50 µg/ml. The 
final concentrations of fibrinogen, thrombin and CaCl2 were 1 mg/ml, 0.1 U/ml and 5 mM 
respectively. The maximum absorbance of the clots formed with different concentrations of 
particles were shown in the figure. 
 
 Turbidity Lysis Assay 
Normal Pooled Plasma Samples 
In the presence of particles, as the concentrations of particles increased, the t50% was 
increased in a dose-dependent manner. Clot lysis time was the time in which absorbance 
decreased by 50% of the peak value (t50%) (Undas et al., 2014). Higher concentration of 
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longer at 10 µg/ml of PM10 and total diesel particles. PM0.2 and filtered diesel particles only 
caused statistically longer t50% at 50 µg/ml which were 13.8 and 14.3 min. The results 
indicated that fibres formed in the presence of particles, especially at the high concentrations, 
were much less sensitive to fibrinolysis compared to control.  
Figure 3-3. Turbidity Lysis Assay – T50% of Normal Pooled Plasma Samples Exposed to 
Different Concentrations of Particles (n=3)  
*p<0.05; **p<0.001 
The clot lysis time was shown based on the concentrations and particle types. The final 
concentrations of tPA, thrombin and CaCl2 were 0.1 µg/ml, 0.1 U/ml and 5 mM respectively. 
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Fibrinogen Samples 
In terms of the fibrinogen samples, t50% had no significantly difference between control and 
high concentrations of particles. The clot lysis time was similar and around 10 to 12 minutes. 
Figure 3-4. Turbidity Lysis Assay – T50% of Purified Fibrinogen Samples Exposed to Different 
Concentrations of Particles (n=3) 
The clot lysis time was shown based on the concentrations and particle types. The final 
concentrations of fibrinogen, plasminogen, tPA, thrombin and CaCl2 were 1 mg/ml, 0.25 µM, 
0.1 µg/ml, 0.1 U/ml and 5 mM respectively. As the concentrations of particles increased, the 























PM10 PM0.2 Total Diesel Particles Filtered Diesel Particles
Page 129 of 265 
 
 Laser Scanning Confocal Microscopy 
Normal Pooled Plasma Samples 
Fully hydrated fibrin clot structure was analysed under the laser scanning confocal 
microscope.  The four kinds of particles were incubated with plasma samples and the clots 
formed with 0.1 U/ml of thrombin and 5 mM CaCl2. Fig 3-5 to 3-8 represents the fibrin clot 
structure of plasma samples with different concentrations of different particles. 
Coarse particulate matter were added to the normal pooled plasma samples. The effects of 
different concentrations of PM10 after clots formed from plasma samples were shown in the 
figures below. Six different concentrations of PM10 were incubated with the plasma samples. 
From 0 µg/ml to 50 µg/ml of PM10 (Fig 3-5), the clot structure showed similar fibrin clot 
structure with similar fibre numbers per μm. Compared to the control, there were no 
differences after incubation with PM10. The same concentrations of PM0.2 were incubated with 
plasma samples (Fig 3-6). The figures showed fibrin clots formed from plasma samples were 
similar. The average fibre numbers per um were between 3.10 and 3.43 after treatment with 
different concentrations of PM0.2.  
In the normal pooled plasma samples, total diesel particles had almost no effects on fibrin 
clot structure. Compared to control, 50 µg/ml of total diesel particles lead to slightly denser 
clot formation but there was no significantly difference (Fig 3-7). In figure 3-8, filtered diesel 
particles also had no significant effects on alteration of fibrin clot structure formed from 
normal pooled plasma samples. From 0 µg/ml to 50 µg/ml of filtered diesel particles, the 
number of fibres was similar. 
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Fig 3-9 shows that fibre numbers per μm of the clots formed from plasma samples after 
exposure to different concentrations of particle suspensions. Compared to the control, fibre 
numbers of the clots with all these four different particles had no difference even at the 
highest concentration of 50 μg/ml. These four particles did not cause significantly denser 
fibrin clot structure in the plasma samples.  
  




               Control                                          0.01 µg/ml of PM10 
  
              0.1 µg/ml of PM10                                   1 µg/ml of PM10 
  
              10 µg/ml of PM10                                 50 µg/ml of PM10 
Figure 3-5. LSCM--Effects of PM10 on Plasma Samples 
The structure of clots formed from plasma samples with PM10 from 0 to 50 µg/ml. 




                 Control                                           0.01 µg/ml of PM0.2 
  
                 0.1 µg/ml of PM0.2                                 1 µg/ml of PM0.2 
  
                    10 µg/ml of PM0.2                                  50 µg/ml of PM0.2 
Figure 3-6. LSCM--Effects of PM0.2 on Plasma Samples 
The structure of clots formed from plasma samples with PM0.2 from 0 to 50 µg/ml. 




            Control                           0.01 µg/ml of Total Diesel Particles 
  
              0.1 µg/ml of Total Diesel Particles            1 µg/ml of Total Diesel Particles 
  
10 µg/ml of Total Diesel Particles          50 µg/ml of Total Diesel Particles 
Figure 3-7. LSCM—Effects of Total Diesel Particle on Plasma 
The structure of clots formed from plasma with total diesel particles from 0 to 50 µg/ml. 




Control                             0.01µg/ml of Filtered Diesel Particles 
  
               0.1µg/ml of Diesel Particles                       1µg/ml of Diesel Particles 
  
               10µg/ml of Diesel Particles                      50µg/ml of Diesel Particles 
Figure 3-8. LSCM—Effects of Filtered Diesel Particle on Plasma 
The structure of clots formed from plasma with total diesel particles from 0 to 50 µg/ml. 




Figure 3-9. Fibre Bundles of Fibrin Clots Formed from Plasma Samples with Different 
Concentrations of Particles (n=9) 
The clots formed from plasma samples with particles from 0 to 50 µg/ml was shown. The final 
concentrations of thrombin, CaCl2 and FITC were 0.1 U/ml, 5 mM and 50 µg/ml respectively. 
There were no significant differences in the fibre numbers between the clots with and without 
particles.  
 
Purified Fibrinogen Samples 
Compared to fibrin clots formed from plasma samples, purified fibrinogen samples had looser 
clot structure with a lower number of fibres per μm (Fig 3-14). To form the clots, the same 
concentrations of thrombin and CaCl2 were used in plasma and fibrinogen samples. In the 
normal pooled plasma, there are coagulation factors which may improve the thrombin 
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fibre number of the control was around 2 per µm in the fibrinogen samples, however, in the 
plasma samples, the fibre number was approximately 3 per µm. In the fibrinogen samples, 
from 0.1 µ/ml to 50 µg/ml of the particles, there were no significant differences from control. 
For the purified fibrinogen samples, same concentrations of PM10 were used. In the following 
figures, it can be seen that there were no significantly differences in the fibrin clot structure 
formed with or without participation of PM10. The fibre numbers per µm were around 2 (Fig 
3-10). Similar as the PM10 results, when the clots were formed with PM0.2, the clot structure 
was similar among different concentrations (Fig 3-11). 
For the purified fibrinogen samples, the fibrin clot structure was not altered after adding 
different concentrations of total diesel particles compared to control. The fibre numbers were 
similar at low and high concentrations of total diesel particles (Fig 3-12). Figure 3-13 shows 
that filtered diesel particles added in the purified fibrinogen samples did not increased or 
reduce the fibre numbers per µm compared to the control.  
  




Control                                       0.01 µg/ml of PM10 
  
0.1 µg/ml of PM10                                     1 µg/ml of PM10 
  
10 µg/ml of PM10                               50 µg/ml of PM10 
Figure 3-10. LSCM--PM10 Effects on Fibrinogen 
The structure of clots formed from fibrinogen samples with PM10 from 0 to 50 µg/ml. 




Control                                                0.01 µg/ml of PM0.2 
  
0.1 µg/ml of PM0.2                                    1 µg/ml of PM0.2 
  
10 µg/ml of PM0.2                                     50 µg/ml of PM0.2 
Figure 3-11. LSCM--PM0.2 Effects on Fibrinogen 
The structure of clots formed from fibrinogen samples with PM0.2 from 0 to 50 µg/ml. 




Control                              0.01 µg/ml of Total Diesel Particles 
  
0.1 µg/ml of Total Diesel Particles               1 µg/ml of Total Diesel Particles 
  
10 µg/ml of Total Diesel Particles           50 µg/ml of Total Diesel Particles 
Figure 3-12. LSCM—Effects of Total Diesel Particle on Fibrinogen 
The structure of clots formed from fibrinogen with total diesel particles from 0 to 50 µg/ml. 




Control                                0.01 µg/ml of Filtered Diesel Particles 
  
0.1 µg/ml of Filtered Diesel Particles      1 µg/ml of Filtered Diesel Particles 
  
10 µg/ml of Filtered Diesel Particles      50 µg/ml of Filtered Diesel Particles 
Figure 3-13. LSCM—Effects of Filtered Diesel Particle on Fibrinogen 
The structure of clots formed from fibrinogen with filtered diesel particles from 0 to 50 µg/ml. 




Figure 3-14. Fibre Bundles of Fibrin Clots Formed from Purified Fibrinogen Samples with 
Different Concentrations of Particles (n=9) 
The number of fibres bundles per µm of the clots formed from purified fibrinogen samples 
with particles from 0 to 50 µg/ml was shown. The final concentrations of fibrinogen, thrombin, 
CaCl2 and FITC were 1mg/ml, 0.1 U/ml, 5 mM and 50 µg/ml respectively. Figure 3-14 showed 
that there were no significant differences in the fibre bundles between the clots with and 
without particles.  
 
3.4 Discussion 
In this study, the effects of PM10, PM0.2, total diesel particles and filtered diesel particles on 
fibrin clot structure were investigated. The concentrations chosen were from 0.01 to 50 µg/ml 
which was different from the other study (Metassan et al., 2010a). In the realistic 
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which is equal to 0.014 µg/ml in H2O. Also, as the people keep exposed to particulate matter, 
it is able to accumulate in the body and the concentrations will increase. Therefore, I chose 
the start concentration was 0.01 µg/ml and hypothesized that the highest concentration 
people may have was 50 µg/ml. Three methods were applied to study the effects of particles 
from air pollution, turbidity assay, turbidity lysis assay and laser scanning confocal microscopy 
in both normal pooled plasma and purified fibrinogen system. The experiments results from 
turbidity assay and LSCM assay showed that these four particles did not significantly alter 
fibrin clot structure formed from normal pooled plasma samples. But the clot lysis time was 
significantly longer as the concentrations of particles increased. The fibres formed from 
plasma were getting more resistance to fibrinolysis and t50% were significantly longer at 50 
µg/ml of these four particles compared to control. In terms of the purified fibrinogen system, 
the clots had similar structure as control even at the highest concentration 50 µg/ml of those 
particles. In summary, PM10 and total diesel particles had more effects on the fibrin clot 
structure alterations compared to PM0.2 and filtered diesel particles. This was because both 
filtered particles were extracted from the total particles, the mass fraction of PM0.2 and 
filtered diesel particles were only 30% and 35% of PM10 and total diesel particles which 
represented the percentages of filtered particles occupied in the total particles realistically. 
In other words, at the concentration 10 µg/ml of PM10 and total diesel particles, the 
concentrations of PM0.2 and filtered diesel particles were 3 and 3.5 µg/ml respectively.  
Fibrin clot structure has been associated with several thromboembolic diseases (Undas and 
Ariëns, 2011). A large number of case-control studies have reported the associations. Undas 
et al. (2008) investigated the fibrin clot structure of 40 patients with acute coronary 
syndromes and 40 controls. The results showed that the patients had faster fibrin 
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polymerization (p=0.008) and prolonged fibrinolysis time (p<0.001) than controls (Undas et 
al., 2008).  Undas and her collages also measured the fibrin clot structure and functions of the 
patients with idiopathic venous thromboembolism and their first-degree relatives. The ex vivo 
plasma was used to form the clots. Compared to healthy controls, those patients with DVT 
and their relatives were characterized by lower clot permeability (p<0.001), lower compaction 
(p<0.001), higher maximum clot absorbency (p<0.001), and prolonged clot lysis time (p < 
0.001) (Undas et al., 2009). These studies indicated that denser fibrin clot structure with 
prolong clot lysis time may represent an emerging risk factor for arterial and venous 
thromboembolism.  
A study from the Leeds laboratory showed that PM was able to alter fibrin clot structure and 
functions in human plasma and purified systems (Metassan et al., 2010a). The concentrations 
used in the study from Metassan et al. were 100 and 200 µg/ml which were higher than the 
concentrations used in this study. But in this study, the particle did not significantly alter fibrin 
clot structure. The concentrations used in this study were lower (0.01 µg/ml to 50 µg/ml) 
compared to the concentrations in the study of Metassan et al (100 µg/ml to 200 µg/ml). 
There was still a trend that as the concentrations of particles increased, the clot structure was 
getting denser in a dose-dependent manner. In addition, the clot lysis time were significantly 
longer compared to control. These results showed that particles from air pollution caused 
altered fibrin clot structure which possessed similar properties as the clots formed from the 
plasma of thromboembolic patients. Therefore, air pollution may increase the risks of 
thrombosis.  
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The mechanisms of how air pollution increases the risk of thrombosis are not clear. So, for 
the further investigation, more studies were performed.  
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 Italian Cohort Study of Long-term Air Particulate 
Matter Exposure 
4.1 Introduction 
Exposure to air pollution is associated with adverse effects on the pulmonary and 
cardiovascular systems, as reviewed in chapter 1. In particulate, the PM in urban air pollution 
has been associated with cardiovascular mortality and morbidity, as discussed. 
A range of possible mechanisms by which PM may damage the cardiovascular system have 
been proposed, including atherogenesis and thrombosis as a result of activation of 
inflammation, oxidative stress, endothelial dysfunction and increased levels of circulating 
coagulation proteins (eg. factor VIII [FVIII], VWF and fibrinogen) (Baccarelli et al., 2007a, 
2007b; Vermylen et al., 2005). Exposure to air pollution particles induces pulmonary 
inflammation with release of cytokines that are capable of mediating acute-phase proteins 
and leading to hypercoagulability (Baccarelli et al., 2007a; Esmon, 2004; Seaton et al., 1999). 
However, the mechanisms underpinning the increased risk of thrombosis after exposure to 
ambient air pollution are still poorly understood. 
In view of these associations between thrombosis and fibrin structure, the effects of 
particulate matter on fibrin clot structure have previously been investigated in this laboratory. 
It was found that diesel PM caused changes in fibrin clot structure and function in clots 
formed from both purified fibrinogen and from human plasma (Metassan et al., 2010a). 
However, no changes in fibrin clot structure were observed in clots formed from plasma taken 
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from healthy individuals after 2 hours exposure to PM while performing moderate exercise 
(Metassan et al., 2010b). The exposure in the latter study was of short duration, so the 
possibility remained that fibrin clot structure could be affected by long-term exposure to high 
levels of air pollution, or that susceptible subjects, such as patients with thrombosis could 
respond differently to the healthy young subjects in the earlier study.  
To test this possibility, a sub-study was based on samples from a large cohort study in the 
Lombardy Region of Italy (Baccarelli et al. 2007; Baccarelli et al. 2009; Baccarelli et al. 2008), 
which had reported that every 10 μg/m3 elevation of PM10 exposure was associated with a 
67% increase of DVT. The aim of this study was to determine the effects of PM10 on patient 
with DVT and healthy controls.   
 
4.2 Methods 
Stored plasma samples from an existing large epidemiological study in the Lombardy Region, 
North Italy (Baccarelli et al., 2007; Baccarelli et al., 2008; Baccarelli et al., 2007; Baccarelli et 
al., 2009) were used for this study. 224 subjects were randomly chosen from this study. The 
previous study examined the association between PM10 and the risk of deep vein thrombosis. 
The main result showed that every 10 μg/m3 elevation of PM10 was associated with 67% 
increased risk of DVT. This sub-study was to investigate the fibrin clot structure alteration 
after exposure to different concentrations of PM10 by analysing the fibrin clot structure 
formed from the plasma samples of each subject.  
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 Study Population 
The study population of patients and controls has been previously described in detail 
(Baccarelli et al., 2007; Baccarelli et al., 2008; Baccarelli et al., 2007; Baccarelli et al., 2009). 
Briefly, patients from the Lombardy region, Northern Italy were referred to the Angelo Bianchi 
Bonomi Thrombosis Centre in Milan from January 1995 to September 2005 for a 
thrombophilia screening after a first episode of objectively confirmed lower-limb deep vein 
thrombosis with or without pulmonary embolism. Controls were healthy individuals, friends 
or partners of the patients referred to the same Thrombosis Centre, who were residents in 
the Lombardy region and volunteered to undergo thrombophilia screening. All patients and 
controls provided informed written consent and the duty was approved by the local ethics 
committee. General characteristics of patients and controls including age, BMI, gender, 
education, and smoking status, and fibrinogen and FVIII levels were provided by Angelo 
Bianchi Bonomi Thrombosis Centre. Methods for exposure assignment were previously 
described in detail (Baccarelli et al., 2008; Baccarelli et al., 2007). Hourly concentrations of 
PM10 were obtained from the Regional Environmental Protection Agency (ARPA Lombardia) 
which recorded the hourly air pollution data from January 1994 to September 2005 using 
monitors located at 53 different sites throughout the Lombardy region (Baccarelli et al. 2007). 
 
 Method 
Three methods were used to analyse the fibrin clots structure formed from ex vivo plasma 
samples of the patients and controls, permeability assay, turbidity assay and laser scanning 
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confocal microscope assay. Permeability assay was applied to measure the average pore size 
of the fibrin clot structure formed from the plasma samples. Fibres arrangements in the clots 
can be detected through turbidity assay. Laser scanning confocal microscopy method 
provided a direct 3D visualisation of the clots. The details of each method were as described 
in chapter 2. 
 
4.3 Results 
There were significant correlations between maximum absorbance and the number of fibres 
(r = 0.4, p < 0.001), maximum absorbance and Ks (r = -0.5, p < 0.001), and number of fibres 
and Ks (r = -0.5, p < 0.001). Maximum absorbance and fibre number were both positively 
correlated with age, body mass index (BMI), fibrinogen concentration and plasma level of FVIII, 
whereas Ks was negatively correlated, indicating that with increasing age, BMI, fibrinogen 
concentrations and FVIII levels, the fibrin fibres grew thicker, and were more compactly 
woven in the three-dimensional clot network, and that the clot was less permeable. Except 
for Ks, both fibre thickness (r = 0.1, p = 0.04) and fibre number (r = 0.2, p = 0.001) were 
associated with PM10 concentrations. 
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 Maximum Absorbance Fibre Number Ks 
Coefficient P-value Coefficient P-value Coefficient P-value 
Case 0.12 0.07 0.16 0.02 -0.12 0.25 
Age (years) 0.23 0.001 0.24 <0.0001 -0.37 <0.0001 
Male 0.09 0.18 0.07 0.30 -0. 17 0.12 
Non-Smokers -0.002 0.98 -0.08 0.32 0.06 0.60 
BMI 0.33 <0.0001 0. 30 <0.0001 -0. 36 0.001 
Fibrinogen (mg/dl) 0.70 <0.0001 0.26 <0.0001 -0. 45 <0.0001 
Factor VIII (%) 0.22 0.00 0.17 0.02 -0.33 0.003 
PM10 Concentration (µg/ml) 0.14 0.04 0.22 0.001 -0.03 0.76 
Maximum Absorbance (mOD) 1.00  0.41 <0.0001 -0.51 <0.0001 
Fibre Number (per µm) 0.41 <0.0001 1.00  -0. 48 <0.0001 
Ks (x10-10 cm2) -0.51 <0.0001 -0.48 <0.0001 1.00  
Table 4-1. Pearson’s and Chi-Square Correlations of Clot Parameters to Other Variables 
Correlations between continuous parameters were tested using Pearson’s, and between clot structure and categorical variables (case, sex, and 
smoking) using Chi-Square analysis. 




Figure 4-1. Representative fibrin clot structure formed from plasma samples of patients and 
controls 
The fully hydrated fibrin clot were formed with the plasma samples from patients and healthy 
controls and visualized under laser scanning confocal microscope.  
 
Page 151 of 265 
 
General characteristics, fibrinogen level, factor VIII, thrombophilia abnormalities and fibrin 
clot structure parameters of patients and controls are shown in Table 4-2. In terms of the 
general characteristics of these subjects, age was similar between patients and controls. But 
the BMI and gender were significantly different, the patients had higher BMI compared to 
healthy controls; and there were more males than females. Fibrinogen concentrations in 
patients plasma were slightly higher than those in healthy controls (p = 0.070). The patients 
with DVT had significantly higher FVIII plasma levels compared to controls (p < 0.001). There 
were more subjects with thrombophilia abnormalities in the patients group (p < 0.001). In 
terms of the clot structure, only fibre number was significantly different between patients 
and controls (p = 0.018). However, there was a tendency showed that patients possessed 
denser fibrin clot structure with thicker fibres, more number of fibres per clot area and less 
permeable clots compared to controls. 
Patients exposed to high levels of air pollution showed higher concentrations of fibrinogen 
compared to those exposed to low levels, whereas thrombophilia factors did not differ 
between exposure groups (Table 4-3). We also compared the fibrin clot structure parameters 
by exposure levels in patients and controls. Patients in the high exposure group had more 
compactly arranged fibres and less permeable structure compared to those in the low 
exposure levels. However, in controls only plasma levels of coagulation FVIII were different 
between the two exposure groups (p = 0.029). 
Table 4-4 shows logistic regression analysis of risk factors for DVT. The continuous data age, 
BMI, fibrinogen concentration, FVIII level were categorized into high and low groups, the cut-
off points being 51.9 for age, 24.7 for BMI, 299.7 for fibrinogen, and 125.3 for FVIII, 
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respectively. The model showed that increased age, BMI and fibrinogen concentrations did 
not contribute to the development of DVT in this study. Male sex was a risk factor for DVT, as 
well as FVIII, thrombophilia abnormalities and high level of PM10.




Mean ±SD or percentage% 
Controls 
Mean ±SD or percentage% 
P-Value 
Number of subjects 103 121  
Age (years) 53.7 ±14.7 50.4 ±13.9 0.085 
Male % 48.5% 25.6% <0.001 
BMI 25.5 ±4.2 24.0 ±4.3 0.014 
Non-Smokers % 81.0% 76.9% 0.584 
Primary education or below % 70.9% 77.7% 0.187 
Fibrinogen (mg/dl) 309.4 ±80.7 290.7 ±50.9 0.070 
Factor VIII (%) 141.6 ±43.1 108.1 ±27.4 <0.001 
Thrombophilia^ % 40.8% 14% <0.001 
Ks (x10-10 cm2) 28.8 ±8.8 31.4 ±12.2 0.248 
Fibre Number (per µm) 22.5 ±3.5 21.3 ±3.8 0.018 
Maximum Absorbance (mOD) 719.2 ±175.2 679.3 ±156.9 0.073 
Table 4-2. Characteristics of patients with DVT and controls 
^ Thrombophilia was classified as being positive for at least one of the following: factor V Leiden, prothrombin G20210 mutation, 
antithrombin-, protein C-, protein S-deficiency, antiphospolipids antibodies and hyperhomocysteinemia. 
 




Low Exp (n=23) High Exp (n=80) P-Value Low Exp (n=72) High Exp (n=49) P-Value 
Age (years) 55.3 ±16.5 53.3 ±14.3 0.420 48.7 ±13.7 53.0 ±14.0 0.768 
Male˄ 39.1% 51.2% 0.060 29.2% 20.4% 0.027 
BMI 24.9 ±3.9 25.7 ±4.3 0.202 24.5 ±4.5 23.4 ±3.8 0.684 
Non-Smokersᴓ 84.6% 79.3% 0.416 77.8% 75.5% 0.569 
PM10 Levels (µg/m3) 39.3 ±8.5 48.9 ±2.6 <0.001 41.61 ±4.8 49.20 ±3.0 <0.001 
Thrombophilia≠ 47.8% 38.8% 0.435 12.5% 16.3% 0.552 
Factor VIII (%) 132.2 ±38.0 144.2 ±44.3 0.260 114.2 ±30.2 101.7 ±22.9 0.029 
Fibrinogen (mg/dl) 277.2 ±81.3 320.4 ±78.1 0.026 283.8 ±64.9 300.4 ±45.3 0.168 
Maximum Absorbance (mOD) 626.4 ±155.5 745.8 ±172.2 0.003 675.9 ±171.2 684.2 ±134.7 0.776 
Fibre Number (per µm) 20.4 ±3.9 23 ±3.1 0.001 21 ±4 21.7 ±3.4 0.307 
Ks (x10-10 cm2) 33.7 ±11.2 26.3 ±6.1 0.006 30.1 ±11.4 35.2 ±14.5 0.236 
Table 4-3. General characteristics and clotting parameters (mean ± SD) in patients and controls of high and low PM10 exposure 
˄The percentage of male subjects in each group 
ᴓThe percentage of non-smokers in each group 
≠The percentage of subjects with positive thrombophilia in each group 
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Determinants or Variables OR 95% CI p-value 
Age > 51.9 years 0.70 0.32-1.52 0.368 
Men 3.02 1.36-6.74 0.007 
BMI > 24.73 0.88 0.39-1.95 0.748 
Thrombophilia 2.65 1.16-6.05 0.020 
FVIII > 125.27% 5.52 2.52-12.10 <0.001 
Fibrinogen > 299.73 mg/dl 1.44 0.65-3.17 0.371 
PM10 Exposure Level > 45.6 µg/m3 3.85 1.79-8.28 0.001 
Table 4-4. Logistic regression analysis of risk factors for DVT
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Finally, we analysed the relative contributions of age, sex, BMI, thrombophilia abnormalities, 
PM10 and interaction of thrombophilia abnormalities and PM10 with the variation in maximum 
absorbance, fibre number and Ks by linear regression in patients and controls, respectively 
(Table 4-5). In the maximum absorbance model, BMI and PM10 exposure both significantly 
contributed to the formation of thicker fibres in patients only, whereas age was significantly 
correlated with maximum absorbance in controls. In the fibre number model, PM10 and BMI 
were risk factors for more branched fibre formation for both patients and controls. In the Ks 
model, exposure to PM10 did not contribute to the alterations of clot structure in patients or 
controls. Permeability of the clot reduced with BMI increased in patients but not in controls. 
Neither thrombophilia abnormalities nor the interaction of thrombophilia abnormalities and 
PM10 contributed to the alteration of fibrin clot structure in this study. Neither thrombophilia 
abnormalities nor the interaction of thrombophilia abnormalities and PM10 were contributing 
to the alteration of fibrin clot structure in this study. The reason for the absence of an effect 
of thrombophilia on clot structure likely reflects the large degree of heterogeneity of the 
causes of thrombophilia in this group, including deficiencies of antithrombin, protein C, and 
protein S, hyperhomocysteinemia, antiphospholipids, FV Leiden mutation or prothrombin 
mutation (table 4-6). Each of these could have differential effects on fibrin clot structure. 
When we compared the larger subgroups of thrombophilia (i.e. FV Leiden, prothrombin 
mutation or hyperhomocysteinemia) to patients without thrombophilia there were also no 
differences in clot structure, likely due to the small sample size. The number of patients with 
other causes of thrombophilia (i.e. antithrombin, protein C or protein S deficiency, or 
antiphospholipid syndrome) were too small to perform any meaningful statistical analysis. 
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Table 4-5. Multiple regression analysis of risk factors for Maximum Absorbance, Fibre Number and Ks (cases/controls) 
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Patients With/Without Thrombophilia Abnormalities 
Clotting Parameters 
Maximum Absorbance (mOD) 
Mean (±SD) 
Fibre Number (per µm) 
Mean (±SD) 
Ks (x10-10 cm2) 
Mean (±SD) 
Patients without Thrombophilia Abnormalities (n=42) 721.5 (±169.5) 22.2 (±3.8) 29.3 (±9.7) 
Patients with Thrombophilia Abnormalities (n=61)¶ 715.7 (±185.2) 22.8 (±3.0) 28.3 (±7.4) 
Patients with Antiphospholipid Antibodies (n=4) 755.0 (±109.3) 25.2 (±1.9) 23.0 (±2.8) 
Patients with Antithrombin Deficiency (n=3) 581.0 (±86.7) 22.4 (±2.5) 27.3 (±9.0) 
Patients with Factor V Leiden (n=13) 778.8 (±226.5) 21.9 (±3.8) 33.9 (±9.7) 
Patients with Hyperhomocysteinemia (n=13) 762.0 (±187.9) 22.9 (±2.4) 27.3 (±7.7) 
Patients with Protein C Deficiency (n=2) 558.5 (±1.1) 20.2 (±3.6) 30.4 (±2.9) 
Patients with Protein S Deficiency (n=3) 700.3 (±59.6) 23.1 (±2.6) 26.2 (±2.9) 
Patients with Prothrombin G20210A (n=10) 620.5 (±141.8) 22.3 (±3.3) 33.9 (±8.8) 
Table 4-6. Clotting parameters (mean ± SD) in patients with/without different thrombophilia abnormalities 
¶Some patients had more than one thrombophilia abnormality. 
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4.4 Discussion 
According to World Health Organisation statistics, air pollution causes 3 million premature 
deaths each year (World Health Organisation, 2011). So far, it is still very difficult to determine 
the approximate concentrations of particles that reach the human blood in circulation. The 
only available data related to PM exposure is the PM mass concentration measured by PM 
monitors (Baccarelli et al. 2008; Baccarelli et al. 2009; Metassan et al. 2010a).  
Consistent with a larger previous study on the association between air pollution and venous 
thrombosis (Baccarelli et al., 2008), PM10 exposure in the current study was a strong risk factor 
for DVT and men had higher risk of DVT than women. Baccarelli et al. (2008) showed that DVT 
risk was associated with the concentrations of PM10 measured during the year before 
diagnosis. In the current study, sex, levels of factor VIII, thrombophilia abnormalities, and 
PM10 exposure level were all significantly associated with the risk of DVT. Increased levels of 
coagulation factors, such as factor VIII, have previously been associated with increased risk of 
thrombosis (Undas et al., 2009). Thrombophilia abnormalities are also contributing factors 
that modulate fibrin clot structure. The prothrombin G20210 mutation leads to the increase 
plasma level of prothrombin which triggers the formation of denser clot structure composed 
of more branched thinner fibres (Wolberg and Campbell, 2008). Age, BMI and fibrinogen 
concentrations were not significantly associated with DVT. 
In table 4-2, it can be seen that the gender and BMI were not balance between patients and 
healthy controls. There were more women than men, and more subjects with higher BMI in 
patients compared to controls. Women have higher risks of DVT. Subjects with higher BMI 
contribute increased risks of thrombosis. Therefore, the group with more women and 
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subjects with higher BMI may both contribute to the increased risk of DVT and denser clot 
structure.  
Some differences in clot structure between patients and controls were also observed. Clots 
formed from plasma of patients had denser, less permeable fibrin clot structure containing 
more, thicker fibres compared to controls, although the differences did not reach statistical 
significance, possibly due to the relatively small number of subjects studied. These data 
provide some support to previous studies by Undas et al. (2009), in which plasma from 
patients with DVT and pulmonary embolism formed clots with lower clot permeability and 
higher maximum absorbency than controls (Undas et al., 2009). From this study, it also has 
been found that after long-term and high-level exposure to PM10 (concentrations over 45.6 
µg/m3), patients with deep vein thrombosis had significantly denser fibrin clot structure 
compared to those living in areas with lower levels of exposure (PM10 less than 45.6 µg/m3). 
In the high exposure group, clots from patients possessed more compact fibre arranged fibre 
networks with thicker fibres and less permeable structure. However, in healthy subjects group, 
there were no significant differences found in clot structure between high and low exposure 
levels.  
The mechanisms underpinning this difference between patients and healthy controls are 
unknown but may be related to the differences in susceptibility of fibrin clot structure to air 
pollution PM exposure. Susceptibility means there will be an aggravating risks of a particular 
cardiovascular end point or event may occur in a certain group of population (such as subjects 
with diabetes or old ages) compared to the general population when all of them expose to 
same concentration of PM to occur for a particulate cardiovascular end event compared with 
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the general population after the exposure to same concentration of PM (Brook et al., 2010). 
In the first American Heart Association scientific statement, the susceptibility factors include  
the elderly; individuals with diabetes; patients with pre-existing coronary heart disease, 
chronic lung disease, or heart failure; and individuals with low education or social economic 
status (Brook et al., 2010). The effects of transient exposure (2 hours) to diesel particle air 
pollution were previously investigated in a controlled environment in healthy, young 
individuals. This study provided similar results that fibrin clot structure in plasma from 
subjects after short-term diesel exhaust exposure was not significantly different compared to 
those who were exposed to filtered air (Metassan et al., 2010b). It is possible that healthy 
subjects are more resistant to oxidative stress than patients with venous thrombosis, since 
the latter may have an enhanced inflammatory state (Franchini and Mannucci, 2011), that 
increases oxidative stress. Alternatively, due to increased levels of inflammatory proteins and 
coagulation activation in patients with venous thrombosis, any additional oxidative effects 
caused by air pollution on fibrin clot structure could be more pronounced, perhaps due to a 
threshold effect, or a minimum level of oxidative stress needed for effects on clot structure 
to become apparent. Finally, due to the inflammatory state, pulmonary function may be 
impaired, leading to translocation of ultrafine PM into the circulation. However, these 
considerations remain speculative as there currently are no reliable methods to analyse PM 
in the blood, nor do we have detailed information regarding the pulmonary function in our 
patients. 
Mills et al. reported that diesel exhaust inhalation causes vascular dysfunction and impaired 
endogenous fibrinolysis (Mills et al., 2005). Furthermore, previous studies have shown that 
denser fibrin clot structure was associated with prolonged lysis time (Ajjan and Grant, 2006; 
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Ariens, 2013; Scott et al., 2004; Undas and Ariens, 2011). Therefore, as patients exposed to 
high levels of air pollution had denser fibrin clot structure, the lysis time compared to those 
patients exposed to low levels of air pollution is likely to be longer. In Chapter 3, it has been 
found that after normal pooled plasma exposed to air pollution particles, the clots were 
getting denser with more compact arrangements and prolonged lysis time. Future studies will 
be needed to further evaluate the effects of air pollution exposure on fibrinolysis in patients 
with venous thrombosis. 
Possible limitations of this study include the relatively small study sample size (due to the 
time-consuming nature of fibrin structure analysis), and that we had no information regarding 
personal levels of air pollution exposure for the participants. The concentrations of PM10 in 
this study were measured according to the area of residence for the subjects, which were 
different for each subject and spanned several residential areas in Lombardy. Therefore, 
although exposure to air pollution was not measured with personal monitors, the data 
obtained did provide average daily, specific and long-term individual exposure to air pollution.  
In conclusion, this study shows that patients with venous thrombosis exposed to high level of 
air pollution had denser fibrin clot structure with thicker fibres (higher maximum absorbance), 
decreased permeability (lower Ks value) and higher fibre numbers compared to those in the 
low exposure group, indicative of a prothrombotic clot structure. There were no differences 
in fibrin clot structure measurements between the two exposure groups in controls, 
suggesting that air pollution may trigger differences in fibrin clot structure only in patients 
predisposed to thrombotic diseases.  
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 Effects of PM and Diesel Particles on Human 
Umbilical Vein Endothelial Cells  
5.1 Introduction 
According to the Italy cohort study in the previous chapter, the results have shown that 
people exposed to PM10 had increased risk of deep vein thrombosis, and that those patients 
with DVT had denser fibrin clot structure after long term exposure to high level of PM10. 
Several other epidemiological studies also indicated associations between air pollution and 
cardiovascular diseases as indicated in the previous chapters. There are a few mechanisms 
that have been proposed for underpinning this increased cardiovascular risk, which include 
pulmonary and systemic inflammation, enhanced coagulation, reduced fibrinolysis, and 
autonomic system dysfunction.  
In chapter 3, the effects of PM and diesel particles on plasma or fibrinogen samples were 
investigated through in vitro experiments. The results showed that particles were not able to 
alter fibrin clot structure formed from plasma and fibrinogen. But the clot lysis time was 
significantly longer with particles (50 µg/ml) compared to control. In chapter 4 the Italy ex 
vivo study showed that after high level PM exposure, patients with DVT had significantly 
denser fibrin clots structure compared to those patients exposure to low level of exposure. 
Both in vitro and ex vivo studies have shown that particles from air pollution were able to 
influence the fibrin clot structure formed from plasma samples. Therefore, the possible 
mechanisms why air pollution particles altered the fibrin clot structure needs to be 
investigated.  
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To assess whether air pollutant particles can pass into the systemic circulation, Nemmar et al. 
measured the distribution of radioactivity after 5 healthy volunteers inhaled the aerosol 
contains technetium-99m labelled carbon particles (<100 nm). Gamma camera images 
showed radioactivity was detected in the liver and bladder indicating that ultrafine PM is able 
to pass into the circulation and directly interfere with endothelial cells (Nemmar et al., 2002). 
This chapter would focus on the human umbilical vein endothelial cells. It is hypothesized that 
particulate matter and diesel particles may interfere with the endothelial cells directly and 
lead to altered fibrin clot structure.  
 
5.2 Methods 
HUVECs were cultured as described in chapter 2.3.3. Briefly, cells were treated for 24 hours 
with different concentrations of PM. Cytotoxicity of the cells was measured by the MTT assay. 
The same concentrations of PM10 and diesel particles were used as for the previous plasma 
and fibrinogen in vitro study (Chapter 3). The concentrations of particles were chosen which 
caused less than 20% cell death for further investigation. Cells were seeded on the ibidi µ-
slide and incubated with chosen concentrations of particles for 24 hours. The treatment was 
removed, after which fibrin clots were formed with thrombin and CaCl2 on the cells. Laser 
scanning confocal microscopy method were used to measure the fibre number of the clots 
through images. Then, we used Enzyme-linked immune-sorbent assay (ELISA) to quantify the 
proteins produced by HUVEC after incubation with PM. Some transmembrane proteins may 
be produced by endothelial cells as well after exposure, but they were not able to be 
measured by ELISA. To assess changes to gene expression after exposure to the PM for the 
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genes coding these proteins real time polymerase chain reactions (RT-PCR) were used. The 




HUVECs were treated with PM10, PM0.2, total diesel particles and filtered diesel particles at 6 
different concentrations for 24 hours. The toxicity of these four particles is shown in the 
following figure. At the highest concentration 50 μg/ml, these four particles caused less than 
10% cell death. Compared to diesel particles, PM10 and PM0.2 had more cytotoxicity. PM10 had 
the most toxicity on HUVEC, but even at the highest concentration this effect was not 
significant harmful (Fig 5-1).  
  




Figure 5-1. Cytotoxicity of Endothelial Cells after 24 hours Particles Exposure (n=10) 
HUVEC were treated with different concentrations of different particles for 24 hours. MTT 
assay was performed to detect the particle cytotoxicity. The results showed that there was 
no significantly cell death even at the highest concentration 50 µg/ml. 
 
 LSCM of Particulate Matter 
After the cytotoxicity test, all concentrations of particles could be used in the following 
experiments as the cell viability was over 80%. 
Cells were treated with different concentrations of particles for 24 hours. Then the cell 
supernatant was removed completely. The fibrin clots were formed from either normal 
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treated cells. The clots were incubated at 37 °C for 30 minutes for analysis. The number of 
fibres was measured through LSCM image. 
 
Normal Pooled Plasma Samples 
The fibrin clot structure formed from normal pooled plasma samples with cells exposed to 
PM10, PM were shown as following. After the cells were treated with particles at 
concentration of 0.01 μg/ml, 0.1 μg/ml, 1 μg/ml 10 μg/ml and 50 μg/ml, the fibrin clot 
structure was altered compared to control. These four particles showed a similar trend that 
as the concentrations of particles increased, the clot structure became denser as the number 
of fibre per μm increased gradually in a dose-dependent manner. 
The following figures represent the fibrin clot structure formed on the cells after treatment 
with different particles at different concentrations. As the concentrations of PM10 increased, 
the clots were getting much more complex. The clots started to have significantly denser 
structure after cells treated with 10 µg/ml of PM10 compared to control (Fig 5-2). 
Figure 5-3 shows that the fibre number increased as the concentration of particles increased. 
Clots were similar as control after cells were treated with 0.1 μg/ml of PM0.2. The fibre number 
of the clots was significantly higher at 10 μg/ml. 
In figure 5-4, it can be seen that when the cells were treated with 0.01 μg/ml of total diesel 
particles, the clots had similar fibre numbers as control. The increased concentrations of total 
diesel particles led to increased number of fibres formed in the clots. At 50 μg/ml, total diesel 
particles caused the densest clots with highest number of fibres. 
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In terms of the filtered diesel particles, from 10 µg/ml, the fibre numbers were significantly 
higher compared to control. The clots were getting denser with more branched networking 
as the concentration of filtered diesel particles increased (Fig 5-5).   




                  Control                                       0.01 µg/ml of PM10 
  
            0.1 µg/ml of PM10                                   1 µg/ml of PM10 
  
10 µg/ml of PM10                                                  50 µg/ml of PM10 
Figure 5-2. LSCM—Effects of PM10 on HUVEC (Normal Pooled Plasma) 
The fibrin clots were formed with plasma samples in the presence of cells exposed to PM10.  




           Control                                              0.01 µg/ml of PM0.2 
  
                     0.1µg/ml of PM0.2                                 1µg/ml of PM0.2 
  
              10µg/ml of PM0.2                                         50µg/ml of PM0.2 
Figure 5-3. LSCM—Effects of PM0.2 on HUVEC (Normal Pooled Plasma) 
The fibrin clots were formed with plasma samples in the presence of cells exposed to PM0.2.  




            Control                              0.01 µg/ml of Total Diesel Particles 
  
                0.1 µg/ml of Total Diesel Particles          1 µg/ml of Total Diesel Particles 
  
                10µg/ml of Total Diesel Particles          50µg/ml of Total Diesel Particles 
Figure 5-4. LSCM—Effects of Total Diesel Particles on HUVEC (Plasma) 
The fibrin clots were formed with plasma in the presence of cells exposed to total DEP. 




Control                           0.01 µg/ml of Filtered Diesel Particles 
  
              0.1 µg/ml of Filtered Diesel Particles     1 µg/ml of Filtered Diesel Particles 
  
10 µg/ml of Filtered Diesel Particles      50 µg/ml of Filtered Diesel Particles 
Figure 5-5. LSCM—Effects of Total Diesel Particles on HUVEC (Plasma) 
The fibrin clots were formed with plasma in the presence of cells exposed to filtered DEP. 
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As can be seen from figure 5-2 to 5-6, the clots had significantly denser structure than control 
at the concentration of 10 μg/ml. The fibre bundles were around 3 per µm after the cells 
treated with different particles at same concentration. PM0.2 and filtered diesel particles had 
less fibre bundles compared to PM10 and total diesel particles (Fig 5-6). The fibre bundles were 




Figure 5-6. Fibre Bundles of Clots Formed from Plasma Samples with Different 
Concentrations of Particles on HUVEC (n=9) 
*p<0.05; **p<0.001 
Laser scanning confocal microscope assay was used to measure the fibrin clot structure. After 
the cells were treated with different concentrations of particles for 24 hours, the fibrin clots 
were set up with plasma samples in the presence of treated cells. As the concentrations of 
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Fibrinogen Samples 
For the fibrinogen samples, the clots were set up with purified fibrinogen samples in the 
presence of endothelial cells exposed to different concentration of particles.  The following 
four figures (5-7 to 5-10) represent the fibrin clot structure formed from purified fibrinogen 
in the presence of endothelial cells treated with different concentrations of PM10, PM0.2, total 
diesel particles and filtered diesel particles, respectively. The clot structure was similar as 
control even the cells exposed to the highest concentration of particles. The data (figure 5-
11) showed even after the cells treated with the highest concentration of those particles, the 
fibrin clot structure was still similar as the control. In contrast to the clots formed from plasma, 
there wasn't any significant difference of the structure between treated and untreated cells. 
  




  Control                                              0.01µg/ml of PM10 
  
0.1µg/ml of PM10                                            1µg/ml of PM10 
  
10µg/ml of PM10                                    50 µg/ml of PM10 
Figure 5-7. LSCM—Effects of PM10 on HUVEC (Purified Fibrinogen) 
The fibrin clots were formed with fibrinogen samples in the presence of cells exposed to PM10.  




         Control                                                 0.01µg/ml of PM0.2 
  
    0.1µg/ml of PM0. 2                                        1µg/ml of PM0.2 
  
    10µg/ml of PM0.2                                         50µg/ml of PM0.2 
Figure 5-8. LSCM—Effects of PM0.2 on HUVEC (Purified Fibrinogen) 
The fibrin clots were formed with fibrinogen samples in the presence of cells exposed to PM0.2.  




Control                                   0.01µg/ml of Total Diesel Particles 
  
0.1µg/ml of Total Diesel Particles            1µg/ml of Total Diesel Particles 
  
10µg/ml of Total Diesel Particles              50µg/ml of Total Diesel Particles 
Figure 5-9. LSCM—Effects of Total Diesel Particles on HUVEC (Purified Fibrinogen) 
The fibrin clots were formed with fibrinogen in the presence of cells exposed to total DEP.  




Control                            0.01µg/ml of Filtered Diesel Particles 
  
0.1µg/ml of Filtered Diesel Particles        1µg/ml of Filtered Diesel Particles 
  
10µg/ml of Filtered Diesel Particles     50µg/ml of Filtered Diesel Particles 
Figure 5-10. LSCM—Effects of Filtered Diesel Particles on HUVEC (Purified Fibrinogen) 
The fibrin clots were formed with fibrinogen in the presence of cells exposed to filtered DEP.  




Figure 5-11. Fibre Bundles of Clots Formed from Purified Fibrinogen Samples with Different 
Concentrations of Particles on HUVEC (n=9) 
Laser scanning confocal microscope assay was used to measure the fibrin clot structure. After 
the cells were treated with different concentrations of particles for 24 hours, the fibrin clots 
were set up with purified fibrinogen samples in the presence of treated cells. Compared to 




Real time polymerase chain reaction was used to quantify the genes of interests that 
expressed by endothelial cells after incubation with air pollution particles for 24 hours. Two 































PM10 PM0.2 Total Diesel Particles Filtered Diesel Particles
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Tissue Factor 
Tissue factor is a transmembrane glycoprotein which is produced by endothelial cells only 
while exposed to stimuli that activate the endothelial cells such as cytokines. After endothelial 
cells were incubated with different types and concentrations of particles for 24 hours, the 
gene of tissue factor was quantified by RT-PCR.  
After the cells were treated with PM10 and total diesel particles at 0.1 μg/ml, gene expression 
of tissue factor were significantly higher compared to control. PM0.2 caused significantly 
increased expression of tissue factor gene from 1 μg/ml. Filtered diesel particles had less 
effect on TF gene expression in comparison with the other three types of particles as shown 
in the figure. Until 50 μg/ml, all four kinds of particles induced TF mRNA expression 
significantly more than control. PM10 caused three times more tissue factor gene expression 
compared to control, the other three particles induced 1.85, 1.72, and 1.49 times elevation 
of TF mRNA, respectively (Fig 5-12).  
  




Figure 5-12. Gene Expression Level of Tissue Factor (TF) in Human Umbilical Vein Endothelial 
Cells after Treatment with the Different Particles (n=3)  
*p<0.05; **p<0.001; ***p<0.0001 
Relative gene expression level of tissue factor was determined by real-time polymerase chain 
reaction. As the concentrations of particles increased, the TF mRNA expression level increased 
as well.  
 
Thrombomodulin 
Thrombomodulin is also a membrane protein expressed by endothelial cells. 
Thrombomodulin binds thrombin and alters its substrate activity so that it activates Protein C 
(a naturally occurring anticoagulant) rather than fibrinogen. Activated Protein C in turn 
inactivates activated Factors V and VIII reducing thrombin generation. Therefore, 
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without particle treatment had the highest level of THBD mRNA expression. As the 
concentration of particles increased, the gene expression of THBD decreased in a dose-
dependent manner. PM10, PM0.2 and total diesel particles significantly suppressed THBD 
mRNA expression by endothelial cells at 1 μg/ml, and followed by filtered diesel particles at 
10 μg/ml. At 50 μg/ml, PM10 and total diesel particles inhibited the THBD gene expression by 
70% reduction compared to control, PM0.2 and filtered diesel particles led to approximately 
55% less THBD mRNA secretion by HUVECs. 
 
 
Figure 5-13. Gene Expression Level of Thrombomodulin (THBD) gene in Human Umbilical 
Vein Endothelial Cells after Treatment with the Different Particles (n=3) 
*p<0.05; **p<0.001; ***p<0.0001 
Relative gene expression level of thrombomodulin was determined by real-time polymerase 
chain reaction. As the concentrations of particles increased, the THBD mRNA expression level 
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 ELISA 
Enzyme-linked immunosorbent assays were used to quantify the levels of proteins secreted 
by endothelial cells after incubation with different concentrations of PM. Two proteins were 
chosen to be measured as both of them were closely correlated with alteration fibrin clot 
structure and clot fibrinolysis, von Willebrand factor and plasminogen activator inhibitor-1. 
 
Von Willebrand Factor 
Endothelial cells were treated for 24 hours, then the cell supernatant was taken for measuring 
the concentration of VWF. As the concentrations of PM increased, the levels of VWF 
expressed by treated HUVECs increased in a dose-dependent manner (Fig 5-14). At 50 µg/ml, 
PM10 caused highest concentration of VWF secretion compared to the other three particles, 
followed by PM0.2, total diesel particles and filtered diesel particles. 
  




Figure 5-14. Concentrations of Von Willebrand Factor (VWF) from Human Umbilical Vein 
Endothelial Cells after 24h Treatment with Different Concentrations of Particles (n=5) 
*p<0.05; **p<0.001; ***p<0.0001 
ELISA was used to measure the VWF protein levels. After the cells were treated with different 
concentrations of particles for 24 hours, the cell supernatants were taken for measuring the 
concentrations of VWF secreted by endothelial cells. Compared to control, the VWF 
concentrations were increased as the concentrations of particles increased in a dose-
dependent manner. 
 
Plasminogen Activator Inhibitor–1  
PAI-1 as the main inhibitor of tPA was expressed more when endothelial cells were stimulated 
by PM. At 0.1 μg/ml of PM10, the concentration of PAI-1 increased to approximately 250 pg/ml 
which was significantly higher compared to control 200 pg/ml. Total diesel particles induced 
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Figure 5-15. Concentrations of Plasminogen Activator Inhibito-1 (PAI-1) from Human 
Umbilical Vein Endothelial Cells after 24h Treatment with Different Concentrations of 
Particles (n=5) 
*p<0.05; **p<0.001; ***p<0.0001 
ELISA was used to measure the PAI-1 protein levels. Compared to control, the concentrations 
PAI-1 were increased as the concentrations of particles increased in a dose-dependent 
manner. 
 
 Plasmid Strand Break Assay 
Plasmid strand break assay was used to detect the free radicals released from the particles 
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After 12 hours incubation in the dark, there were more single strand breaks in pBR322 DNA 
as the concentrations of particles increased (Fig 5-16). PM had more free radicals released 
compared to the diesel particles. Over 60% of supercoiled plasmid changed to the nicked form 
induced by PM10 and PM0.2. In terms of both diesel particles, there were only 35% of nicked 
plasmid. PM10 released the most free radicals and caused significantly more strand breaks at 
concentration of 10 µg/ml. The other three types of particles caused the significantly nicked 
DNA at 50 µg/ml. 
 
Figure 5-16. Induction of Single Stand Breaks in pBR322 DNA Following Incubation with 
Different Particles (n=3) 
Figure 5-16 showed that gel electrophoresis results of strand breaks induced by different 
concentrations of particles. 
  




Figure 5-17. Induction of Single Stand Breaks in pBR322 DNA Following Incubation with 
Different Particles (n=3) 
*p<0.05; **p<0.001; ***p<0.0001; 
Plasmid DNA was incubated with different concentrations of particles from 0 to 50 µg/ml for 
12 hours in the darkness. The induction of strand breaks were assessed and expressed as the 
percentage of nicked DNA observed. The results indicated that PM10 started to induce 
significantly stand breaks at 10 µg/ml. The other three particles caused damage to plasmid 
DNA at 50 µg/ml. 
 
5.4 Discussion 
In this chapter, the effects of air pollution on human umbilical vein endothelial cells were 
investigated using five methods, MTT cytotoxicity test, laser scanning confocal microscope, 
Real-Time PCR, ELISA, and plasmid strand break assay. The results indicated that the particles 
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But, the fibrin clots formed on the treated cells were altered compared to the control in 
plasma samples. In terms of the purified fibrinogen samples, there were no significant 
differences between treated and untreated cells on the clot structure.  
 
 Components of Particles 
There were some differences between PM and diesel particles effects on HUVEC as PM had 
more critical effects compared to the diesel particles due to the differences on the 
components of these particles. Total diesel particles (SRM 2975) were collected from an 
industrial diesel-powered forklift and mainly contained PAHs and nitro-PAHs. However, PM10 
(SRM 2787) contained not only PAHs, nitro-PAHs, but also polybrominated diphenyl ether 
(PBDE) congeners, hexabronocyclododecane (HBCD) isomers, sugars, polychlorinated 
dibenzo-р-dioxin (PCDD) and dibenzofuran (PCDF) congeners, inorganic constituents, 
especially metals, such as Zn, Fe and Cu. The differences of the components may account for 
the different effects on endothelial cells and clot structure.  
 
 Cytotoxicity 
Cells were treated with endothelial cell growth media without fetal bovine serum. The serum 
contains albumin which could act as a metal chelator and thus reduce the effects of PM as 
both PM10 and PM0.2 contained metals. After 24 hours treatment, these four particles did not 
cause any significant cell death. PM10 and total diesel particles were more toxic than their 
own filtered particles, but PM10 is the most toxic particle (PM10 > PM0.2 > Total Diesel Particles > 
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Filtered Diesel Particles). Similar results were seen by Akhtar et al. (2010), although in a 
different cell line. In that study, human alveolar epithelial cells (A549) exposed to two 
particles, SRM 2795 and SRM 1648a (another type of urban particles from NIST), for 24 hours 
treatment from concentration 10 to 1000 μg/ml. MTT results showed SRM 1648a total urban 
particles lead to more cell death compared to SRM 2795 total diesel particles. At 50 μg/ml, 
SRM 2795 had no significant cytotoxicity compared to control (Akhtar et al., 2010). Snow et 
al. demonstrated ultrafine particles had no toxicity to human coronary artery endothelial cells 
at 50 μg/ml after 24 hours treatment. Ultrafine particles had similar sizes as PM0.2 and filtered 
diesel particles (Snow et al., 2014). Another study investigated diesel particles cytotoxicity on 
human aortic endothelial cells and after 50 μg/ml concentration and 24 hours treatment, 
there was no significant cell death induced by diesel particles (Wu et al., 2012). However, PM 
and diesel particles can cause cellular death at high concentration and long term treatment; 
but in these experiments, the concentrations of PM and diesel particles used were non-toxic 
(cell viability > 80%) which indicated that the endothelial cells changed from normal 
physiological condition to procoagulant and anti-fibrinolytic status caused by endothelial 
dysfunction after treatment with PM and diesel particles rather than cell apoptosis.  
It has been confirmed that after HUVECs 24 hours exposure to particulate matter and diesel 
particles, fibrin clots formed from normal pooled plasma samples were significantly denser 
compared to the controls. These four types of particles caused significantly denser fibrin clot 
structure from 10 µg/ml compared to control. Increased evidence supports that air pollution 
is linked with different CVD, and the patients with CVD have altered fibrin clot structure which 
was mentioned in Chapter 3 that patients with thromboembolic diseases had denser fibrin 
clot structure with more compact arranged network and prolonged lysis time. A study showed 
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that patients with peripheral artery disease were characterised by thrombotic fibrin clot 
phenotype with 32% lower clot permeability (Ks) (P <0.001) and 7% longer clot lysis time (t50%) 
(P = 0.004) compared with controls (Okraska-Bylica et al., 2012). The other study from Palka 
et al. also indicated that patients with chronic heart failure predisposed thromboembolic 
complications with 23% lower permeability (p < 0.0001), 13% less clot compaction (p < 0.001), 
15% faster fibrin polymerisation ( p < 0.0001) and prolonged lysis time (p = 0.1) compared to 
control (Palka et al., 2010). 
As HUVECs formed denser fibrin clot structure after air pollution particles exposure, several 
methods were used to detect the underpinning mechanisms of fibrin clot structure alteration 
which were enzyme-linked immunosorbent assays, real time polymerase chain reaction 
assays and strand break assays. After 24 hours cells treatment, the gene expression of tissue 
factor and thrombomodulin were quantified in the RT-PCR experiments. Tissue factor gene 
expression by endothelial cells significantly increased after exposed to particles compared to 
control. The level of thrombomodulin mRNA decreased after particles exposure in a dose-
dependent manner. ELISA results showed that both von Willebrand factor and plasminogen 
activator inhibitor-1 increased compared to the control. Through the plasmid strand break 
assay, free radicals were detected after the plasmid DNA was incubated with particles for 12 
hours. The particles induced endothelial dysfunction with increased levels of von Willebrand 
factor, plasminogen activator inhibitor-1 and tissue factor mRNA expression, decreased level 
of thrombomodulin mRNA expression and oxidative stress may be caused by free radicals.  
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 Tissue factor & Thrombomodulin 
Tissue factor and thrombomodulin both are transmembrane proteins which were measured 
by using real time PCR.  
Tissue Factor, formerly known as thromboplastin, is a key initiator of the coagulation cascade. 
TF is 47 kDa transmembrane glycoprotein containing 263 amino acids expressed in vascular 
and non-vascular cells (Napoleone et al., 1997). The TF gene is located on chromosome 1 and 
consists of 6 exons. Under normal physiological conditions, TF is only expressed in 
subendothelial cells such as vascular smooth muscle cells in response to the initiation of 
coagulation cascade when the vessel wall is damaged.  
The tissue factor pathway of coagulation cascade is initiated when TF contacts with Factor VII 
and form the TF/FVIIa complex. Activated TF/FVIIa complexes convert FIX to FIXa, FX to FXa 
and FV to FVa. FXa and FVa cleave prothrombin to generate thrombin, thereby the fibrin clot 
is formed (Adams and Bird, 2009; Ajjan and Ariens, 2009; McVey, 1999; Steffel et al., 2006).  
Endothelial cells and monocytes only express TF when the cells are exposed to stimuli such as 
cytokines (Steffel et al., 2006). Endothelial cells express TF when in contact with cytokines, 
e.g. tumor necrosis factor (TNF) -α, interleukin (IL) -1, or CD40 ligand; or biogenic amines, e.g. 
serotonin, or histamine; or mediators, e.g. thrombin, oxidized low density lipoprotein, or 
vascular endothelial growth factor (Steffel et al., 2005; Napoleone et al., 1997; Steffel et al., 
2005; Kawano et al., 2001; Drake et al., 1991; Camera et al., 1999; Bavendiek et al., 2002).  
The coagulation cascade is activated to protect from blood loss when the vessel wall is injured. 
Tissue Factor is the key initiator of coagulation cascade. However, heightened activation of 
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coagulation due to TF expression on endothelial cells and monocytes can cause thrombophilia 
and atherosclerosis (Steffel et al., 2006). In the RT-PCR experiments, tissue factor mRNA 
increased in a dose dependent manner. It indicated that air pollution particles act as stimuli 
when the endothelial cells were treated with particles, cells expressed more TF mRNA, and 
increased concentrations of particles triggered increased TF gene expression. Increased level 
of TF mRNA thereby increased the availability for exposure to FVII/FVIIa and more likely to 
activate the coagulation cascade. Tissue factor as the pathway initiator, forms complex 
TF/FVIIa with FVII, then in turn activates FIX, FX and FVIII. FXa and FVa cleave prothrombin to 
thrombin and sufficient amount of thrombin generates fibinogen to fibrin. There were also a 
few studies focused on the TF gene expression from endothelial cells after exposure to air 
pollution. Snow et al. Studied the effects of air pollution particles on human coronary arterial 
endothelial cells. Their results showed that soluble ultrafine particulate matter (diameter less 
than 0.1 µm) induced a significant 3.8 and 5.1 fold increased gene expression of TF after 50 
and 100 µg/m3 treatment respectively (Snow et al., 2014). Another study demonstrated the 
TF gene expression after human pulmonary arterial endothelial cells treated with ultrafine 
particulate matter. Four concentrations of PM0.1 were used in this study, 0, 1, 10 and 100 
µg/m3, after treatment for 4 hours, expression level of TF was upregulated in a dose-
dependent manner. In the Western blot analysis, as well as the results in RT-PCR, the protein 
expression of TF was increased after 18 hours particle treatment (Karoly et al., 2007). Milano 
et al. focused on different cell lines, macrophages, after exposure to different concentrations 
of PM10, TF mRNA levels were consistantly increased from 10 to 100 µg/m3 compared to the 
control in a dose-dependent manner (Milano et al., 2015).  
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Increased levels of TF expression is associated with elevated risks of procoagulability and 
increased tendency of thrombosis (Chu, 2005). Tissue factor initiates the extracellular 
coagulation which provokes the intracellular inflammation signalling. The coagulation factors 
(FVIIa, FXa, and thrombin) and fibrin are proinflammatory, all of which can activate the cells 
independently (Chu, 2005). Inflammation boosts coagulation through feedback upregulation 
on TF expression that sustains the coagulation TF pathway and coagulation dependent 
inflammation to refuel the coagulation-inflammation cycle. Therefore, regulation of TF 
expression is crucial in inhibition of coagulation-dependent inflammation (Chu, 2005).  
Thrombomodulin, a transmembrane protein produced by endothelial cells, causes a 
transformation of thrombin from a pro-coagulant converter of fibrinogen to fibrin to an anti-
coagulation activator of protein C. Activated protein C synergistically deactivates the 
coagulation cascade by supressing the activities of FVa and FVIIIa (Fuentes-Prior et al., 2000; 
Li et al., 2012). In this study, after endothelial cells were treated with different concentrations 
of PM, the results showed the mRNA level of thrombomodulin decreased in a dose-
dependent manner. The reduced level of thrombomodulin may cause low level of activated 
protein C. In a cross-sectional study conducted in 2009-2010, after the healthy subjects were 
exposed to different levels of air pollution over 6 months, mRNA of THBD was measured. It 
indicated that the participants who exposed to high levels of PM10 had reduced level of THBD 
compared to those exposed to low levels of PM10, although the difference was not significant 
(Poursafa et al., 2011). In an in vitro study, human coronary artery endothelial cells were 
incubated with 10, 50, and 100 µg/ml of soluble Ultrafine PM for 6 and 24 hours. The results 
showed that even after 24 hours and highest concentration of PM treatment, the level of 
THBD produced by treated cells were similar as untreated cells (Snow et al., 2014). 
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Besides the anti-coagulant function, thrombin-thrombomodulin complex also inhibits 
fibrinolysis by activating the thrombin activatable fibrinolysis inhibitor (TAFI) (Fuentes-Prior 
et al., 2000). TAFIa is activated by thrombin from TAFI. TAFIa removes COOH-terminal lysine 
residues from partially degraded fibrin and causes impaired fibrinolysis (Versteeg et al., 2013). 
 
 Von Willebrand Factor & Plasminogen Activator Inhibitor-1 
Von Willebrand factor is a large glycoprotein which plays a pivotal role in haemostasis, 
circulating in human plasma at concentrations of 10 µg/ml. VWF is synthesized by vascular 
endothelial cells and encoded by a gene on chromosome 12 (Lenting et al., 2012; Mannucci, 
1998; Vischer, 2006). VWF is secreted from endothelial cells in a bipolar manner, through 
both the luminal and abluminal membranes. When secreted through the luminal membrane, 
VWF directly reaches the bloodstream; when it is secreted through the abluminal membrane, 
VWF is deposited on the sub-endothelium as an extracellular matrix protein that helps to 
aggregate and activate platelets when the endothelium is disrupted (Mannucci, 1998).  
VWF mediates platelet aggregation and adhesion to the site of vascular injuries, which is 
particularly important under high shear stress (Mannucci, 1998; Vischer, 2006). There are two 
platelets receptors for VWF in the platelets which are glycoprotein (GP) Ibα in the GP Ib-IX-V 
complex and the integrin αIIbβ3 (GP IIb-IIIa complex) (Ruggeri and Ruggeri ZM, 2003). VWF also 
acts as a plasma carrier for factor VIII and protects it from degradation and cellular uptake, 
when not bound to VWF the plasma half-life of FVIII is reduced from 12  hours to 1 to 2 hours 
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(Meyer et al., 2009; Ruggeri and Ruggeri ZM, 2003; Vischer, 2006). Pro-VWF is expressed in 
endothelial cells and platelets and stored in Weibel-Palade bodies and α-granules respectively. 
An animal study investigated the effects of diesel particles on rats after exposed to 5 
hours/day, 1 day/week for 16 weeks, the results demonstrated that as the mRNA levels pf TF, 
PAI-1 and VWF as the biomarkers of thrombosis were increased in the aorta (Kodavanti et al., 
2011).  
VWF contributes with atherothrombotic diseases and venous thromboembolism (Lenting et 
al., 2012).  The connection between VWF and these two diseases was related to FVIII. VWF as 
the FVIII protein carrier, the levels of VWF and FVIII were closely correlated that high level of 
VWF induce high level of FVIII, which, contributes to atherothrombotic diseases and venous 
thromboembolism (Koster et al., 1995; Lenting et al., 2012, 1998). Several animal studies also 
provided evidence that inhibition and genetic deficiency of VWF protects against venous 
thrombosis (Brill et al., 2011; Chauhan et al., 2007; Lenting et al., 2012; Yamamoto et al., 
1998). 
Plasmin is the main fibrinolytic enzyme which can be activated by two serine proteases, tPA 
and uPA. PAI-1 supresses the fibrinolysis by inhibiting tPA and uPA. High plasma PAI-1 
concentration is associated with many thrombotic disorders, thus it is considered as astrong 
marker of reduced fibrinolytic function (Kohler and Grant, 2000; Su et al., 2006). In this study, 
the results showed that, after endothelial cells were treated with those particles, the protein 
levels of PAI-1 increased in a dose-dependent manner. All types of particles, PM10, PM0.2, total 
diesel particles and filtered diesel particles induced significantly increased levels of PAI-1 
expression from 10 µg/ml.  
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In an animal study, Budinger et al. indicated that after exposed to PM2.5, mice had increased 
levels of PAI-1 mRNA and protein compared to the mice only exposed to filtered air (Budinger 
et al., 2011).  In a panel study from Taiwan investigated the effects of urban air pollution on 
human. The results showed that after exposure to PM10 or PM2.5 in single-pollutant models, 
healthy young humans had increased high-sensitivity C reactive protein, PAI-1, fibrinogen, 
and decreased heart rate variability, which indicated the potential mechanisms that urban air 
pollution was associated with inflammation, oxidative stress, blood coagulation and 
autonomic dysfunction (K. Chuang et al., 2007). However, Su et al. showed slightly different 
results that compared to the patients, PAI-1 levels were significantly elevated in the patients 
with CHD exposed to high level of air pollution. However, the PAI-1 levels in the participants 
with multiple CHD risk factors were not different whether exposed to high or low level of air 
pollution. This may suggest that urban air pollution probably caused adverse effects in plasma 
fibrinolytic function in the susceptible population (Su et al., 2006).   
Fibrinolysis initiates when tPA and plasminogen both bind to the fibrin as plasmin is formed 
when plasminogen is partially cleaved by tPA on the surface of fibrin. The elevated level of 
PAI-1 effectively supresses fibrinolysis through inhibiting tPA and uPA, less plasmin is 
activated and impair fibrinolytic function, resulting in fibrin deposition in the vessel wall, thus 
facilitating thrombosis (Kohler and Grant, 2000). An impaired fibrinolytic system also 
contributes to thrombosis formation and propagation. Mills et al. recruited 30 healthy men 
in a double-blind, randomized, cross-over study to study the effects of diluted diesel particles. 
The level of tPA secreted from endothelial cells showed significant reductions after exposure 
to the diluted diesel exhaust compared with controls. The fibrinolytic function was impaired 
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and persisted for 6 hours after the exposure (Franchini and Mannucci, 2011; Mills et al., 2007, 
2005). The reduction of tPA was possibly due to the increased secretion of PAI-1.  
Elevated levels of PAI-1 are an independent risk factors for cardiovascular diseases in large 
prospective studies such as Northwick Park Heart Studies (Carter, 2005; Kohler and Grant, 
2000). 
 
 Oxidative Stress 
Plasmid strand break assay was used to test whether there were free radicals released from 
particles. Free radicals refer to the molecules possessing one or more unpaired electron 
(Bahorun et al., 2006; Halliwell and Gutteridge, 2007; Pham-Huy et al., 2008). Air pollutants 
are able to induce oxidative stress and inflammatory responses as pro-oxidants of lipids and 
proteins or as free radicals generators (Kampa and Castanas, 2008; Menzel, 1994; Rahman 
and MacNee, 2000). A previous study from this lab showed that diesel particles released free 
radicals. Therefore, plasmid strand break assay was used to detect whether particles triggered 
the free radicals. In accordance with the literature, the results showed that PM10, PM0.2, total 
diesel particles and filtered diesel particles released different amounts of free radicals in a 
dose-dependent manner that higher concentrations of particles lead to more plasmid DNA 
strand breaks. The free radicals released from those particles may be formed via the breakage 
of a chemical bond or via redox reactions (Halliwell and Gutteridge, 2007; Pham-Huy et al., 
2008). Free radicals have adverse effects on cellular lipids, proteins, and also interfere with 
signalling pathways within the cells (Kampa and Castanas, 2008; Valko et al., 2007). PM and 
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diesel particles cause oxidative stress mainly through oxidant hydrogen peroxide (H2O2), free 
radical superoxide (•O2-), and free radical hydroxyl radical (OH•) (Akhtar et al., 2010).  
Free radicals are not only released from the air pollutants but also continuously produced 
during human normal metabolism and in response to exogenous environmental exposure. 
The cells used oxygen to generate energy, adenosine triphosphate (ATP) and free radicals are 
produced by the mitochondria as the consequence (Kampa and Castanas, 2008; Pham-Huy et 
al., 2008). The human body is able to produce antioxidants either in situ or externally supplied 
by food or supplements to neutralize the oxidative stress (Pham-Huy et al., 2008). As the 
concentration of free radicals increases and the imbalance between the two antagonistic 
effects comes into being, oxidative stress is generated and gradually plays the major role in a 
range of diseases, such as atherosclerosis, chronic inflammatory diseases, central nervous 
system disorders, age related disorders and finally cancer (Kampa and Castanas, 2008; Pham-
Huy et al., 2008). As the components of these particles were different, among those 
components, PM were enriched in metals, such as Cu, Fe, and Zn which induced high 
concentrations of free radicals than diesel engine particles (Akhtar et al., 2010). Heavy metals 
also can induce free radical release and cause DNA damage (Kampa and Castanas, 2008).  
 
 Summary 
This chapter focused on the effects of air pollution on human umbilical vein endothelial cells. 
These cells are in contact with blood and more likely to receive air pollution components 
when they get into the blood stream. These results provide a potential pathogenic role of PM 
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and diesel particles in endothelial cell system and imply that PM had more adverse effects 
compared to diesel particles. Furthermore, PM and diesel particles can cause cellular death 
at high concentration and long term treatment; but in these experiments, the concentrations 
of PM and diesel particles used were non-toxic (cell viability > 80%) which indicated that the 
endothelial cells changed from normal physiological condition to procoagulant and anti-
fibrinolysis status were caused by endothelial dysfunction after treatment with PM and diesel 
particles rather than cell apoptosis. 
This is the first study that investigated the structure of fibrin clots setting upon on the HUVEC 
after cells exposed to PM and diesel particles. The procoagulant and proinflammatory 
proteins and fibrinolysis inhibitors released from endothelial cells after 24 hours treatment 
with exposure to air pollution all contribute to endothelial dysfunction, fibrin clot structure 
alteration and prothrombotic tendency. The results in this study demonstrated that both PM 
and diesel particles caused impaired endothelial function with pro-inflammatory and 
oxidative state, thus induced the changes of fibrin clot structure formed from plasma samples.  
Healthy endothelial cells have several functions such as anti-coagulation, anti-inflammation, 
anti-oxidation and pro-fibrinolysis. However, after the cells were exposed to air pollution 
particles, the endothelial cells were pro-inflammatory with increased TF gene expression, 
anti-fibrinolysis with increased levels of PAI-1 and decreased thrombomodulin mRNA 
expression and pro-oxidation. Also, as the increased VWF expression, platelets were 
promoted to aggregate. The significant elevation and reduction of levels of protein or gene 
expression expressed by HUVEC after exposed to air pollution particles not only indicated 
endothelial dysfunction but also contributed to the denser fibrin clot structure formation. 
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Many studies have confirmed that patients with thrombotic diseases had abnormal fibrin clot 
structure such as thinner fibres, more compact arrangements and prolonged lysis time. These 
features are in accordance with the clots formed from plasma samples on HUVEC after 
exposed to air pollution particles. Therefore, air pollution may contribute to the denser fibrin 
clot structure formation, thereby inducing a prothrombotic state.   
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 Effects of Silicon Dioxide Nanoparticles on Fibrin 
Clot Structure 
6.1 Introduction 
Silicon dioxide nanoparticles (SiO2 NP) are one the most widely applied engineered 
nanoparticles. SiO2 NPs can be used as additives to cosmetics, printer toners, and varnishes. 
In addition, silica NPs are applied in biotechnological applications such as gene therapy, drug 
delivery, DNA transfection, and enzyme immobilization (Duan et al., 2014a; Napierska et al., 
2010).  
Owing to the wide applications, the cytotoxicity and other effects of SiO2 NP were worth to 
be investigated. Some studies had shown that SiO2 NP had does- and time- dependent 
manner on cell cytotoxicity (Ahamed, 2013; Eom and Choi, 2009; Napierska et al., 2010; 
Peters et al., 2004; Yang et al., 2014). Malvindi et al. documented that silica NPs had good 
biocompatibility when applied in a reasonable concentration, under 2.5 nM (Guo et al., 2015; 
Malvindi et al., 2012). However, as the diameter of nanoparticles are less than some of the 
cellular organelles, particles may penetrate the plasma membrane, deposit in mitochondria 
or nucleus, and finally lead to cell death (Guo et al., 2015; Liang et al., 2014; Zhu et al., 2013). 
The cardiovascular system may be affected by nanoparticles through direct interaction with 
vasculature, blood, and the heart (Guo et al., 2015; Nemmar et al., 2002). However, there 
were few related research focused on SiO2 NPs. Therefore, this chapter would either confirm 
or deny that SiO2 NPs was able to alter fibrin clot structure and cause endothelial dysfunction.  
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6.2 Methods 
Silicon dioxide nanoparticle powder with size 10-20 nm was purchased from Sigma Aldrich. 
Particles were diluted with double distilled water, and the stock concentration was 1 mg/ml. 
Different concentrations of particle suspensions were used in the experiments which included 
50 µg/ml, 10 µg/ml, 1 µg/ml, 0.1 µg/ml and 0.01 µg/ml. Different concentrations of SiO2 NPs 
were added to normal pooled plasma and purified fibrinogen samples, respectively. Three 
methods, turbidity assay, turbidity lysis assay and laser scanning confocal microscope assay 
were used to analyse the fibrin clot structure formed with or without SiO2 NPs. The details of 
the methods were as described in chapter 2.  
Human umbilical vein endothelial cells were also used to investigate the effects of SiO2 NPs. 
Particle cytotoxicity was firstly measured using MTT assay. Then, the clots were formed with 
plasma or fibrinogen samples on the cells. LSCM was used direct visualisation of fibrin clot 
structure. 
To detect the mechanisms that how SiO2 NP affected the fibrin clot structure, coagulation 
factors activation test, plasmid strand break assay, ELISA and RT-PCR were used. 
 
6.3 Results  
 Effects of SiO2 NPs on Fibrin Clot Structure 
Three methods, turbidity assay, turbidity lysis assay, and laser scanning confocal microscope 
assay, were used to investigate the effects of SiO2 NPs on fibrin clot structure.  
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Turbidity Assay 
These figures represent the kinetic curves of the clots formation from plasma samples and 
purified fibrinogen samples with different concentrations of SiO2 NPs. The curves showed a 
lag period before clots started to form (in some cases is this very short), an exponential 
growth phase during the clot rapidly formed and finally a plateau when the clots formed 
completely and reached the maximum OD value. 
 
Normal Pooled Plasma Samples 
In the normal pooled plasma samples, control had highest OD value and SiO2 NPs caused 
decreased OD value as the concentration increased. But it is hard to say whether the fibre is 
thicker or thinner, as clots formed from plasma sample can lead to same OD value with either 
more number of thinner fibres or less number of thicker fibres. 
  




Figure 6-1. Turbidity Assay of SiO2 NPs with Plasma Samples (n=5) 
*p<0.05; **p<0.001 
Fibrin clots were formed with plasma samples in the presence of silica nanoparticles. The final 
concentrations of thrombin and CaCl2 were 0.1 U/ml and 5 mM respectively. The figure shows 
the maximum absorbance of the clots with different concentrations of particles.  
 
Fibrinogen Samples 
In the purified fibrinogen samples, there were no differences in the fibrin clot structure 
between different concentrations of SiO2 NPs. The highest concentration of SiO2 NPs and 
control had similar maximum OD value. The clots were formed similar structure even with 
different concentrations of SiO2 NPs. This figure illustrated that silica nanoparticles had no 
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Figure 6-2. Turbidity Assay of SiO2 NPs with Purified Fibrinogen Samples (n=5) 
Fibrin clots were formed with purified fibrinogen samples in the presence of silica 
nanoparticles. The final concentrations of fibrinogen, thrombin and CaCl2 were 1 mg/ml, 0.1 
U/ml and 5 mM respectively. The figure shows the kinetic curve of the clots formation and 
maximum absorbance with different concentrations of particles. 
 
Turbidity Lysis Assay 
Normal Pooled Plasma Samples 
The rate of clots degradation was measured by turbidity lysis assay. In the presence of 
particles, the maximum OD value was decreased as the concentrations of particles increased; 
but the time to 50% fibrinolysis (t50%) was similar between control and other concentrations 
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Figure 6-3. Turbidity Lysis Assay of SiO2 NPs with Plasma Samples (n=3) 
The T50% were shown in the figure. The final concentrations of tPA, thrombin and CaCl2 were 
0.1 µg/ml, 0.1 U/ml and 5 mM respectively.  
 
Purified Fibrinogen Samples 
Similar results was found in the purified fibrinogen samples in that t50% was similar between 
control and other concentrations of particles (figure 6-4). The silica nanoparticles did not 
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Figure 6-4. Turbidity Lysis Assay of SiO2 NPs with Purified Fibrinogen Samples (n=3) 
The clot lysis time was shown based on the concentrations and particle types. The final 
concentrations of fibrinogen, plasminogen, tPA, thrombin and CaCl2 were 1 mg/ml, 0.25 µM, 
0.1 µg/ml, 0.1 U/ml and 5 mM respectively. 
 
LSCM 
Fibrin clots were formed with either plasma or fibrinogen samples with different 
concentrations of SiO2 NPs. The clot structure was visualised by LSCM and measured using 
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Normal Pooled Plasma Samples 
In the normal pooled plasma samples, after adding the nanoparticles suspension, fiber 
bundles was increased as the concentration of particles increased. From 10 µg/ml, SiO2 NPs 
caused significantly denser fibrin clot structure formation with increased numbers of fibers. 
Combined with the turbidity assay results, lower OD value indicated the denser fibrin clot 








                   Control                                         0.01 µg/ml of SiO2 NPs 
  
            0.1 µg/ml of SiO2 NPs                               1 µg/ml of SiO2 NPs 
  








Figure 6-5 (A): LSCM—Clot Structure Formed from Plasma Samples with Different 
Concentrations of SiO2 NPs;  
Figure 6-6 (B): LSCM—Number of Fibre Bundles from Plasma Samples with Different 
Concentrations of SiO2 NPs (n=9) 
**p<0.001 
The clots formed from plasma samples with SiO2 NPs from 0 to 50 µg/ml. The final 
concentrations of thrombin, CaCl2 and FITC were 0.5 U/ml, 15 mM and 50 µg/ml respectively. 
 
Purified Fibrinogen Samples 
In the purified fibrinogen samples, there were no significant differences between the clots 
with and without SiO2 NPs which indicated that silica had no effects on purified fibrinogen 
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                 Control                                         0.01 µg/ml of SiO2 NPs 
  
           0.1 µg/ml of SiO2 NPs                              1 µg/ml of SiO2 NPs 
  









Figure 6-6 (A): LSCM—Clot Structure Formed from Purified Fibrinogen with Different 
Concentrations of SiO2 NPs;  
Figure 6-6 (B): LSCM—Number of Fibre Bundles from Purified Fibrinogen with Different 
Concentrations of SiO2 NPs (n=9) 
**p<0.001 
The clots formed from purified fibrinogen with SiO2 NPs from 0 to 50 µg/ml. The final 
concentrations of fibrinogen, thrombin, CaCl2 and FITC were 1 mg/ml, 0.5 U/ml, 15 mM and 
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Factor XII Activation Test 
The results of fibrin clot formed from plasma showed that the clots had become denser as 
the concentrations of silicon dioxide nanoparticles increased. A possible mechanism could be 
that the coagulation factors in plasma caused the dose-dependent effects which needed to 
be further investigated. Factor XII was tested to explore the reasons for denser fibrin clot 
formation as FXII is activated by negatively charged surfaces.  
In the first method, FXII deficient plasma was used. In figure 6-7, the fibrin clots were formed 
from FXII deficient plasma with different concentrations of silicon dioxide nanoparticles and 
activation mixture. There was a trend that increased concentrations of SiO2 NPs caused 
decreased OD value which were similar as the clot structure formed from normal pooled 
plasma. In figure 6-8, FXII zymogen was added to the clots with the presence of FXII deficient 
plasma, different concentrations of silicon dioxide nanoparticles and activation mixture. 
Similar trend was found as the clots formed from FXII deficient plasma without FXII zymogen. 
But in the presence of FXII zymogen, the clots were getting into the maximum absorbance 
faster with higher OD value. However, FXII zymogen seemed no effect on fibrin clot structure 










Figure 6-7: Turbidity Assay -- SiO2 NPs with FXII deficient plasma (n=3) 
The clots were formed with FXII deficient plasma and SiO2 NPs 0 to 50 µg/ml.  
 
 
Figure 6-8: Turbidity Assay -- SiO2 NPs with FXII deficient plasma and FXII zymogen (n=3) 
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In the second method, different concentrations of silica NPs were mixed with and without 
FXII zymogen. PTT automate as the positive control was added to FXII zymogen. Compared to 
the positive control in figure 6-9 (C), figure 6-9 (A) and 6-10 (B) illustrated silicon dioxide 
nanoparticle were not able to activate FXII zymogen. The OD value for the positive control 
was approximately 3.5 at 30 min. However, after 1 hour’s interaction, the OD value was only 
0.5 even with the highest concentration, 50 µg/ml. This method also showed the SiO2 NPs 






































Figure 6-9 (A): Turbidity Assay -- SiO2 NPs without FXII Zymogen (n=3);  
Figure 6-10 (B): Turbidity Assay -- SiO2 NPs with FXII Zymogen (n=3);  
Figure 6-11 (C): Turbidity Assay -- SiO2 NPs with PTT Automate and FXII Zymogen (n=3) 
In Figure 6-9 (A), there were no clots formed as only SiO2 NPs were added into the plate. In 
Figure 6-9 (B), SiO2 NPs were mixed with FXII zymogen, the final concentration of FXII zymogen 
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Therefore, these two methods confirmed that silica NPs did not react with FXII, thus FXII was 
not the reason for denser fibrin clot structure in the presence of SiO2 NPs. 
 
Plasmid Strand Break Assay 
Plasmid strand break assay was used to detect the free radicals released from the silicon 
dioxide nanoparticles when they were incubated with supercoiled plasmid DNA.  
After 12 hours incubation in the dark, silica NPs did not have more free radical released 
compared to control (Fig 6-10). The nicked plasmid was between 10 to 20% after the plasmid 
pBR322 incubated with 0 to 50 µg/ml of SiO2 NPs. This result indicated that silicon dioxide 









Figure 6-12. Induction of Single Stand Breaks in pBR322 DNA following Incubation with SiO2 
NPs (n=6) 
Plasmid DNA was incubated with SiO2 NPs from 0 to 50 µg/ml for 12 hours in the darkness. 
The induction of strand breaks were assessed and expressed as the percentage of nicked DNA 
observed. The results indicated that there were no significantly higher number of stand 
breaks caused by SiO2 NPs. 
 
 Effects of SiO2 NPs on HUVEC  
To investigate the effects of SiO2 NPs on fibrin clot structure formed from plasma and 
fibrinogen samples were not enough, which was not able to represent the in vivo 
environment. Human umbilical vein endothelial cells were used to develop mechanisms of 
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Endothelial Cell Cytotoxicity 
Human umbilical vein endothelial cells were treated with 50 µg/ml, 10 µg/ml, 1 µg/ml, 0.1 
µg/ml, and 0.01 µg/ml of silicon dioxide nanoparticles for 24 hours. 
 
 
Figure 6-13. Cytotoxicity of Endothelial Cells after 24 hours SiO2 NPs Treatment (n=9) 
Cells were treated for 24 hours with different concentrations of SiO2 NPs. After the cells 
exposed to 10 µg/ml of particles, there were approximately 10% cell death which was 
significantly more compared to control. 
 
Fibrin Clot Formation on Endothelial Cells 
After the cell cytotoxicity test, LSCM was used to investigate the fibrin clot structure. The clots 
were set up on the cells after HUVECs were treated with different concentrations of SiO2 NPs 
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either normal pooled plasma samples or purified fibrinogen with thrombin and CaCl2 upon 
the treated cells. The slides were incubated at 37 degree for 30 minutes which allowing the 
clots for form completely. The structure of the fibrin was analysed through confocal 
microscope. 
 
Normal Pooled Plasma Samples 
The fibrin clot structure formed from normal pool plasma samples in the presence of treated 
cells are shown below. After the cells were treated with SiO2 NPs at concentration of 0.01 
μg/ml, 0.1 μg/ml, 1 μg/ml 10 μg/ml and 50 μg/ml, the fibrin clot structure was altered 
compared to control. As the concentration of particles increased, the clot structure became 
much denser with increased number of fibres per μm in a dose-dependent manner. The clots 
had significant denser structure from the concentration of 1 μg/ml.  
 
  




               Control                                         0.01 µg/ml of SiO2 NPs 
  
0.1 µg/ml of SiO2 NPs                                 1 µg/ml of SiO2 NPs 
  









Figure 6-14 (A): LSCM—Clot Structure Formed from Plasma Samples on Human Umbilical 
Vein Endothelial Cells after Treatment with Different Concentrations of SiO2 NPs;  
Figure 6-15 (B): LSCM—Number of Fibre Bundles from Plasma Samples on Human 
Umbilical Vein Endothelial Cells after Treatment with Different Concentrations of SiO2 NPs 
(n=9)  
*p<0.05; **p<0.001 
The clots formed from plasma samples in the presence of cells exposed to SiO2 NPs s from 0 
to 50 µg/ml. The final concentrations of thrombin, CaCl2 and FITC were 0.5 U/ml, 15 mM and 
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Purified Fibrinogen Samples 
For the fibrinogen samples, the clots were formed with purified fibrinogen samples in the 
presence of treated endothelial cells. The data showed even after the cells treated with the 
highest concentration of those particles, the fibrin clot structure was similar as the control. In 
contrast to the clots formed from plasma, the clots formed from purified fibrinogen did not 
have any significant difference in the structure between treated and untreated cells. 
  




                Control                                        0.01 µg/ml of SiO2 NPs 
  
                            0.1 µg/ml of SiO2 NPs                               1 µg/ml of SiO2 NPs 
  









Figure 6-16 (A): LSCM—Clot Structure Formed from Purified Fibrinogen on Human Umbilical 
Vein Endothelial Cells after Treatment with Different Concentrations of SiO2 NPs;  
Figure 6-17 (B): LSCM—Number of Fibre Bundles from Purified Fibrinogen on Human 
Umbilical Vein Endothelial Cells after Treatment with Different Concentrations of SiO2 NPs 
(n=9) 
The clots formed from purified fibrinogen in the presence of cells exposed to SiO2 NPs s from 
0 to 50 µg/ml. The final concentrations of fibrinogen, thrombin, CaCl2 and FITC were 1 mg/ml, 
0.5 U/ml, 15 mM and 50 µg/ml respectively. 
 
RT-PCR 
Real time polymerase chain reaction was used to quantify the genes of interests that released 
from endothelial cells after incubation with silicon dioxide nanoparticles for 24 hours. Two 





























Concentrations of  SiO2 NPs
B
Page 226 of 265 
 
Tissue Factor 
Tissue factor is a transmembrane glycoprotein. After endothelial cells were incubated with 
the particles for 24 hours, the gene expression of tissue factor was quantified by RT-PCR. 
Concentrations of SiO2 NPs were 0.01 µg/ml, 0.1 µg/ml, 1 µg/ml, 10 µg/ml and 50 µg/ml were 
used. Compared to control, there were no significant difference in the TF gene expression 
after HUVEC treated with SiO2 NPs. 
 
 
Figure 6-18. Relative Gene Expression Level of Tissue Factor (TF) in Human Umbilical Vein 
Endothelial Cells after Treatment with Different Concentrations of SiO2 NPs (n=3)  
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Thrombomodulin 
Thrombomodulin is produced by endothelial cells. After the cells were treated with SiO2 NPs, 
increased concentrations of SiO2 NPs caused decreased thrombomodulin mRNA secretion 
with a dose-dependent manner. From 10 µg/ml of SiO2 NPs, the level of THBD gene expression 
was decreased significantly compared to control. Figure 6-15 showed that SiO2 NPs inhibited 
the THBD gene expression on HUVEC. 
 
 
Figure 6-19. Relative Gene Expression Level of Thrombomodulin (THBD) in Human Umbilical 
Vein Endothelial Cells after Treatment with Different Concentrations of SiO2 NPs (n=3)  
Relative gene expression level of thrombomodulin was determined by real-time polymerase 
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ELISA 
ELISA was used to quantify the protein level of von Willebrand factor and plasminogen 
activator inhibitor-1 produced by endothelial cells after the stimuli by air pollution particles.  
 
Von Willebrand Factor 
HUVEC were treated with different concentrations of SiO2 NPs for 24 hours. The cell 
supernatant was taken for the measurement of protein levels of VWF produced by cells. 
Figure 6-12 showed that after 10 µg/ml of SiO2 NPs treatment, endothelial cells produced 
significantly high levels of VWF with concentration of 9.8 ng/ml. From 0.01 µg/ml to 50 µg/ml 
of SiO2 NPs, VWF secretion increased gradually in a dose-dependent manner. 
  




Figure 6-20. ELISA -- Concentrations of Von Willebrand Factor (VWF) from Human Umbilical 
Vein Endothelial Cells after 24h Treatment with Different Concentrations of SiO2 NPs (n=3) 
**p<0.001 
ELISA was used to measure the VWF protein levels. After the cells were treated different 
concentrations of SiO2 NPs for 24 hours, the cell supernatant was taken and measured the 
concentrations of VWF released from cells. From 10 µg/ml, SiO2 NPs induced significantly 
more VWF secretion from endothelial cells. 
 
Plasminogen Activator Inhibitor - 1 
After the endothelial cells were treated with different concentrations of silica nanoparticles, 
PAI-1 was produced at similar levels. There were no significant higher concentrations of PAI-
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Figure 6-21. ELISA -- Concentrations of Plasminogen Activator Inhibitor-1 (PAI-1) from 
Human Umbilical Vein Endothelial Cells after 24h Treatment with Different Concentrations 
of SiO2 NPs (n=3) 
ELISA was used to measure the PAI-1 protein levels. After the cells were treated different 
concentrations of SiO2 NPs for 24 hours, the cell supernatant was taken and measured the 
concentrations of PAI-1 released from cells.  
 
6.4 Discussion 
Silicon dioxide nanoparticles caused denser fibrin structure in clots made from normal pooled 
plasma, but not from purified fibrinogen. The plasma turbidity results showed that as the 
concentrations of particles increased, the OD values decreased. Combined the results from 
confocal microscope, plasma samples formed increased denser fibrin clot structure with 
increased concentrations of SiO2 NPs. It indicated that the lower OD value represented 
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pollution particles. Air particulate matter and diesel particles showed plasma samples formed 
denser fibrin clot structure with higher OD value. Compared with previous data, there was a 
discrepancy in the results linking clot maximum absorbance with network density and there 
are two potential explanations for this. Clot maximum absorbance is a composite measure of 
both clot density and fibre thickness; therefore lower maximum absorbance does not 
necessarily mean less compact clots but may simply reflect thinner fibres. Alternatively, it is 
possible the SiO2 NPs directly affect clot maximum absorbance, resulting in this discrepancy. 
These findings further emphasise the importance of complementing turbidimetric analyses 
with clot visualisation techniques such as confocal microscopy. The fibrin clot lysis time was 
prolonged as the concentration of silica NP increased in plasma samples. In the in vitro cell 
work, silica NPs induced significantly endothelial cell death from 10 µg/ml with a dose-
dependent manner. In addition, fibrin clots formed from normal pooled plasma in the 
presence of SiO2 NPs treated cells were getting denser as the concentrations of NPs increased 
and showed prothrombotic tendency. Real time PCR results indicated that the gene 
expression of thrombomodulin was inhibited by SiO2 NPs, but there were no significant 
difference in the tissue factor mRNA expression between control and treated cells. ELISA 
results showed silica NPs caused increased concentration of von Willebrand factor produced 
by endothelial cells, however, PAI-1 was not influenced by SiO2 NPs. 
Plasma contains not only fibrinogen, but also other coagulation factors, such as cascade 
initiators, factor XII. These factors may interact with the nanoparticles and induced the denser 
fibrin clot structure formation and longer fibrin lysis time. FXII was chosen to be tested as FXII 
can be activated by negatively charged surfaces such as silica and glass. However, FXIIa did 
not interact with SiO2 NPs.  
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According to the literature, silicon dioxide nanoparticles are able to trigger oxidative stress 
(Duan et al., 2013a; Eom and Choi, 2009; Liu and Sun, 2010; Park and Park, 2009), therefore, 
plasmid strand break assay was used to detect the free radicals releasing from SiO2 NPs. The 
results showed that silica did not produce significantly more free radicals compared to control 
which means that SiO2 NPs may cause ROS through other pathways.  
The effects of SiO2 NPs on human umbilical vein endothelial cells were also investigated. 
Silicon dioxide nanoparticles were able to cause different extent of cell death according to 
the treatment time and different cell lines. For the human umbilical vein endothelial cell, 
Duan et al. found that SiO2 NPs caused cell death in a dose- and time-dependent manner. 
After 24 hours treatment, 50 µg/ml of SiO2 NPs triggered approximately 15% cell death (Duan 
et al., 2013a)  which was in accordance with the findings of the cytotoxicity of SiO2 NPs in this 
study. Similar results were found in another study that showed after 24 hours incubation with 
50 µg/ml of SiO2 NPs, HUVEC viability was 83.49% (Duan et al., 2013b). There is also a study 
that demonstrated that 50 µg/ml of SiO2 NPs exerted toxicity and led to 10% reduction of live 
cells after 48 hours treatment (Peters et al., 2004). Cuo et al. investigated the cytotoxicity of 
SiO2 NPs on HUVEC. The results showed that after 24 hours treatment, SiO2 NPs caused 
significant cell death at 25 µg/ml (Guo et al., 2015). In most of the studies, SiO2 NPs caused 
significantly endothelial cell death from 50 µg/ml after 24 hours treatment. Some studies 
confirmed that silicon dioxide nanoparticles are able to enter the cells easily through 
endocytosis (Corbalan et al., 2011; Guo et al., 2015; He et al., 2009). Silica NPs were 
internalised by the cells and distributed in the cytoplasm and deposited in mitochondria 
(Guarnieri et al., 2014). As the concentrations of particles increased, the endocytosis of 
endothelial cells increased (Guo et al., 2015). Duan et al. also mentioned that the endothelial 
Page 233 of 265 
 
cell death was caused by both apoptosis and necrosis, and that release of lactate 
dehydrogenase as an indicator of necrosis was increased from 25 µg/ml of SiO2 NPs treatment, 
while apoptosis rate was significantly elevated at 50 µg/ml of SiO2 NPs (Duan et al., 2014). 
Endothelial cells apoptosis significantly contributed to atherothrombosis (Duan et al., 2013; 
Tedgui & Mallat, 2003). 
It has been shown that endothelial cell death would cause the decrease of cell integrity and 
increased in vascular permeability. Monocytes and adhesion molecules will migrate into the 
vessels and increase the expression of chemokines, thus contributing to the initiation of 
atherosclerosis (Guo et al., 2015). Guo et al. (2015) and Duan et al. (2014) indicated that SiO2 
NPs induced inflammatory response as the mRNA expression for IL-1β, IL-6, IL-8, TNF-α, ICAM-
1, VCAM-1, and MCP-1 by endothelial cells were increased after the treatment (Guo et al., 
2015; Duan et al., 2014). IL-6 not only increases CRP in the liver but also fibrinogen and PAI-1. 
IL-1 also triggers the synthesis of PAI-1 (Esper et al., 2006).  
In this study, there was no significantly increased free radicals release detected from SiO2 NPs, 
but many studies demonstrated that SiO2 NPs induced oxidative stress. According to the 
literature, silica NPs lead to redox imbalance and inflammation response which is possibly 
through other pathways, such as MARK-Nrf2 and Nf-kB signalling pathway (Guo et al., 2015).  
The fibrin clots were produced on top of endothelial cells after treatment with different 
concentrations of SiO2 NPs. The clots formed with plasma samples in the presence of treated 
cells were getting denser as the concentrations of treatment increased. There was no 
difference in the clots formed from purified fibrinogen between control and treated cells. To 
get a closer insight into the Silica NPs effects, real time PCR and ELISA were used for further 
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investigation on the effects of SiO2 NPs on endothelial cells and the mechanisms of denser 
fibrin clot structure formation as endothelial dysfunction can be evaluated by quantifying 
circulation adhesion molecules, proatherogenic substances and antifibrinolytics (Esper et al., 
2006). Von Willebrand factor, tissue factor, and plasminogen activator inhibitors are all 
procoagulant proteins secreted by endothelial cells. In this study, silica NPs had no effects on 
tissue factor mRNA and PAI-1 protein expression even in cells exposed to the highest 
concentration 50 µg/ml for 24 hours. Von Willebrand factor increased after particle treatment 
and the gene expression of thrombomodulin decreased in a dose-dependent manner. 
Significantly decreased mRNA thrombomodulin and increased VWF expression indicated the 
endothelial dysfunction after HUVEC were exposed to SiO2 NPs. Increased level of VWF 
promotes coagulation and platelets activation and aggregation. The reduced level of 
thrombomodulin caused low level of activated protein C (Sofat et al., 2010). VWF plays an 
important role in haemostasis and thrombosis. VWF not only stabilizes the FVIII activities, but 
also promotes platelet aggregation (Wu and Thiagarajan, 1996). Especially at high shear stress, 
VWF binds to platelets glycoprotein IIb-IIIa to support agonist-induced platelet aggregation 
(Wu and Thiagarajan, 1996). In addition, thrombomodulin is able to inhibit a number of 
procoagulant activities of thrombin, for example, fibrinogen, activation of FV and FXIII, and 
inactivation of protein S. Therefore, increased VWF protein expression and decreased 
thrombomodulin both may lead to denser fibrin clot structure formation. 
In conclusion, SiO2 nanoparticles caused alterations of fibrin clot structure with denser clot 
structure, more compact arrangement, and prolonged lysis time from normal pooled plasma. 
There was no effects found in purified fibrinogen. In the in vitro cell work, silica NPs triggered 
significant endothelial cell death from 10 µg/ml in a dose-dependent manner. In addition, 
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fibrin clots formed from normal pooled plasma in the presence of SiO2 NPs treated cells were 
getting denser as the concentrations of NPs increased and showed prothrombotic tendency. 
The gene expression of thrombomodulin was inhibited by SiO2 NPs, but there were no 
significant difference in the tissue factor mRNA expression between control and treated cells. 
Silica NPs caused increased concentrations of von Willebrand factor produced by endothelial 
cells, PAI-1 was not influenced by SiO2 NPs. This adds to existing evidence as to the hazards 
associated with such NPs.
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 Discussion 
A number of pathological mechanisms by which air pollution exposure may impact 
cardiovascular disease have been proposed, with the most relevant being the induction of 
oxidative stress, systemic inflammation, endothelial dysfunction, atherothrombosis, and 
arrhythmogenesis (Newby et al., 2014).  
There are three possible pathways that the exposure to particles may be capable of affecting 
remote cardiovascular territories. Pathway 1: after exposure to the particles, pro-
oxidative/proinflammatory mediators (e.g. cytokines or activated immune cells) and 
vasculoactive molecules (e.g. histamine or microparticles) are released from the lungs, which 
in turn have indirect effects on cardiovascular system. Pathway 2: an imbalance of the 
autonomic nervous system (parasympathetic nervous system withdraw and/or sympathetic 
nervous system activation) is caused by the interaction between particles and nerves. 
Pathway 3: nano-sized particles, soluble PM and particles constituents (e.g. organic 
compounds or metals) may directly get into the blood circulation (Brook, 2008). 
These three pathways may be activated at different time points or overlap temporally, also 
can act alone or together to prompt some cardiovascular event (Brook, 2008).  Hyperacutely 
(within minutes to hours), pulmonary inflammation and autonomic system imbalance are the 
most probable dominant pathways. Acute and sub-acute responses (hours to days) may be 
applied through pathways 2 and 3 firstly and induce systemic oxidative stress and 
inflammation secondarily. The chronic actions, such as enhancement of atherosclerosis and 
thrombosis generation, are plausibly induced by the chronic pro-oxidative and pro-
inflammatory state.  
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Particles’ sizes and types also can determine the pathways. Ultrafine particles and the soluble 
components of larger particles may be able to get into the circulation directly. Whereas the 
coarse particles or larger fine particles may have effects on the cardiovascular system only 
through acquired secondary pro-oxidative or inflammatory responses  by activation and 
irritation of the lung alveolae (Brook, 2008). 
The investigations from this study focused on the first and third pathway. For the first 
pathway, air pollution may contribute to the development of thrombosis involve local 
pulmonary inflammatory and oxidative responses with the release of prothrombotic factors 
and inflammatory cytokines into the circulation after the inhalation of particles (Emmerechts 
and Hoylaerts, 2012; Mills et al., 2009; Newby et al., 2014). Previous animal studies showed 
that PM10 caused lung inflammation following intrapulmonary instillation of PM and 
inhalation of concentrated ambient particles (Donaldson et al., 2005; Elder et al., 2004; Mills 
et al., 2009). In clinical studies, pulmonary inflammation occurred after inhalation of both 
concentrated ambient particulate matter and dilute diesel particles (Donaldson et al., 2005; 
Fujii et al., 2002; Mills et al., 2009). After exposure, plasma concentrations of pro-
inflammatory cytokines such as interleukin (IL) - 1β, IL-6 and tumour necrosis factor-α 
increased (Elder et al., 2004; Mills et al., 2009; Schwartz, 2001). In both animal and clinical 
studies, exposure of PM also led to the elevation of fibrinogen concentrations. High 
concentrations of fibrinogen shorten the lag phase of polymerisation, increase branch point 
densities, fibre thickness and clot rigidity, with concurrent increases in the resistance of the 
clot to fibrinolysis (Scott et al., 2004; Weisel, 2007).  
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For the third pathway, airborne particles are capable direct translocation from the pulmonary 
alveoli into the blood circulation, crossing the pulmonary epithelium and vascular 
endothelium barrier (Emmerechts and Hoylaerts, 2012; Mills et al., 2009; Newby et al., 2014). 
PM and diesel particles would affect fibrin clot structure and interfere with endothelial cells. 
Particles with diameters less than 10 μm can be inhaled deeply into the lungs. A number of 
other factors may influence the possible translocation of PM, including charge, chemical 
composition, and propensity to form aggregates (Mills et al., 2009). The size and shape of the 
particles could affect the region of deposition in the respiratory system, with smaller sized 
particles penetrating deeper into the lung. Macrophages may not be able to recognize 
particles with a diameter less than 500 nm, and for this reason, ultrafine PM may enter the 
blood or lymphatic systems more easily and transfer to different organs (Teow et al., 2011). 
Once in the circulation, the particles could interact with vascular endothelial cells and have 
direct effects on the atherosclerotic plaque, platelets and fibrin clot formation, structure and 
stability (Lauer et al., 2009; Mills et al., 2009).  
In this study, the effects of PM10, PM0.2, total diesel particles and filtered diesel particles on 
fibrin clot structure were investigated. Standard Reference Materials were used in the study 
which were directly purchased from NIST. There are some advantages to use SRMs for the 
investigation. Firstly, the components of the SRMs had been measured and certified. Secondly, 
based on the collection method of SRMs, several studies had confirmed that SRMs were able 
to represent the urban/diesel PM (Akhtar et al., 2010; Boland et al., 2001; Hetland et al., 2004). 
Thirdly, compared to the particles that were obtained from different areas in various studies, 
SRMs were more homogenous, thus increasing the consistency in the measurement of 
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different biological endpoints and promoting the reproducibility of the same biological 
endpoint (Akhtar et al., 2010).  
It is difficult to compare airborne exposure concentrations with concentrations used in in vitro 
experiments. According to the World Health Organisation statistics, the guideline values for 
PM10 and PM2.5 are 50 μg/m3 and 25 μg/m3 for the 24-hour mean concentration; 20 
μg/m3 and 10 μg/m3 for the annual concentration (World Health Organisation, 2011). The 
PM10 level in the Great Smog in London in 1952 was from 3,000 to 14,000 µg/m3. Some in 
vitro studies chose concentrations of air pollution particles above 50 µg/ml which is too high 
compared to the level at which people may be exposed. Therefore, based on those data, the 
concentrations of PM chosen to investigate the effects on fibrin clot structure and human 
endothelial cells in this study were from very low concentrations (0.01 μg/ml) to intermediate 
and high, which may better reflect environmental exposures.  
In this study, the effects of PM10, PM0.2, total diesel particles and filtered diesel particles on 
fibrin clot structure were investigated. Three methods were applied to study the effects of 
particles from air pollution, turbidity assay, turbidity lysis assay and laser scanning confocal 
microscopy in both normal pooled plasma and purified fibrinogen system. The experiments 
results from turbidity assay and LSCM assay showed that for clots formed from pooled plasma, 
there was a trend that higher concentrations of particles led to denser fibrin clot structure 
formation compared to control. The results from turbidity lysis provided more obvious 
consequences that as the concentrations of particles increased, the fibres formed from 
plasma were getting less sensitive to fibrinolysis and times to 50% lysis were significantly 
longer at 50 µg/ml of these four particles compared to control. In terms of the purified 
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fibrinogen system, the clots had similar structure as control even at the highest concentration 
50 µg/ml of those particles. The results demonstrated these four particles were able to alter 
the fibrin clot structure. Filtered PM (PM0.2) and filtered diesel particles with diameter than 
less than 200 nm represented the ultrafine particles which were able to get into the 
circulation (Nemmar et al., 2002). These two types of filtered particles had less effect on fibrin 
clot structure alterations and endothelial dysfunction compared to the larger particles, as 
PM0.2 and filtered diesel particles occupied 30% and 35% of PM10 and total diesel particles, 
respectively.  
In view of the associations between thrombosis and fibrin structure, the effects of particulate 
matter on fibrin clot structure have previously been investigated in this laboratory. It was 
found that diesel PM caused changes in fibrin clot structure and function in clots formed from 
both purified fibrinogen and from human plasma (Metassanet al., 2010a). However, no 
changes in fibrin clot structure were observed in clots formed from plasma taken from healthy 
individuals after 2 hours exposure to PM while performing moderate exercise (Metassan, et 
al., 2010b). The exposure in the latter study was of short duration, so the possibility remained 
that fibrin clot structure could be affected by long-term exposure to high levels of air pollution, 
or that susceptible subjects, such as patients with thrombosis could respond differently to the 
healthy young subjects in the earlier study.  
To test this possibility, a sub-study was performed using samples from a large cohort study in 
the Lombardy Region of Italy (Baccarelli et al. 2007; Baccarelli et al. 2009; Baccarelli et al. 
2008), which had reported that every 10 μg/m3 elevation of PM10 exposure was associated 
with a 67% increased risk of DVT. The aim of the sub-study was, therefore, to investigate the 
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possible association between fibrin clot structure and PM10 levels in a well-characterized 
group of patients with DVT and healthy controls. The sub-study results showed that after 
long-term and high-level exposure to air pollution (PM10 concentrations over 45.6 µg/m3), 
patients with DVT had significantly denser fibrin clot structure compared to those living in 
areas with lower levels of exposure (PM10 less than 45.6 µg/m3). In the high exposure group, 
clots from patients contained thicker fibres, more compact fibre arrangements and less 
permeable clot structure. There were no significant differences in fibrin clot structure 
between the two exposure levels in healthy subjects. This shows that patients with existing 
prothrombotic susceptibility may be affected by PM exposure. This raises the possibility that 
high PM exposure contributes to the onset of the DVT through changes to clot structure. The 
observation in this and a previous study (Metassan et al., 2010b) that there were no changes 
in clot structure in healthy individuals suggests that only people with an existing risk show 
changes to clot structure in response to PM exposure. 
As the endothelial cell plays an important role in modulating thrombosis in blood vessels, the 
effects of PM exposure on endothelial cells was studied. At 50 µg/ml of PM that did not induce 
significant cell death after 24 hours exposure, the fibrin clots formed from pooled plasma on 
the treated cells were altered compared to the controls. For the clots formed from purified 
fibrinogen samples, there were no significant differences on the clot structure between 
treated and untreated cells. Changes in expression of TF, THBD, VWF and PAI-1 following PM 
exposure of HUVECs were consistent with changes observed in clot structure, which adds 
evidence for PM affecting thrombosis via influences on endothelial cells. 
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Whilst there is an acknowledged risk of increased CVD associated with air pollution, and PM 
in particular, there is currently no epidemiological evidence of risk associated with engineered 
nanoparticles in the same size range. Nevertheless, there is a body of data showing that 
engineered nanoparticles such as silica NPs induce toxicity, including cytotoxicity and 
genotoxicity, and silica nanoparticles are widely used in many industries. It was therefore 
decided to investigate whether silica NPs induced changes to clot structure similar to those 
seen for PM.  
Silica nanoparticles caused denser fibrin structure in clots formed only from normal pooled 
plasma, but not from purified fibrinogen. Also, the fibrin clot lysis time was prolonged as the 
concentration of silica NP increased in plasma samples. These results are consistent with 
those seen for PM, which suggests the potential for silica NPs to be toxic to the cardiovascular 
system in an analogous manner. In the cell experiments, silica NPs induced significant 
endothelial cell death from 10 µg/ml in a dose-dependent manner. In addition, fibrin clots 
formed from normal pooled plasma in the presence of SiO2 NPs treated cells were getting 
denser as the concentrations of NPs increased and showing a prothrombotic tendency. Real 
time PCR results indicated that the gene expression of thrombomodulin was inhibited by SiO2 
NPs, but there were no significant difference in the TF mRNA expression between control and 
treated cells. ELISA results showed silica NPs caused increased concentration of VWF 
produced by endothelial cells, but PAI-1 was not influenced by SiO2 NPs. It can be seen that 
not all results mirrored those seen with diesel PM, but there were some similar results, raising 
the potential for toxicity of silica NPs on these cells. It is known that PM can release free 
radicals in solution, as a result of metal ions associated with the PM. This was confirmed for 
the PM used in this study, raising the possibility that oxidative stress could be one mechanism 
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responsible for changes induced in endothelial cells. Such free radical production was not 
observed in solution for the silica NPs, but it may be that free radicals were released within 
the cellular environment as this was not measured in this study. 
The comparison of effects of air particulate matter and silicon dioxide nanoparticles are 
shown as following tables. 
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No difference˄ No difference˄ No difference˄ No difference˄ 
Decreased 
From 10 µg/ml¶ 
Lysis Time 
Increased 
From 10 µg/ml¶ 
Increased 
From 50 µg/ml¶ 
Increased 
From 10 µg/ml¶  
Increased 
From 50 µg/ml¶  
No difference˄ 
Fibre Number No difference˄ No difference˄ No difference˄ No difference˄ 
Increased 




No difference˄ No difference˄ No difference˄ No difference˄  No difference˄ 
Lysis Time No difference˄ No difference˄ No difference˄ No difference˄ No difference˄ 
Fibre Number No difference˄ No difference˄ No difference˄ No difference˄ No difference˄ 
Table 7-1. Summary of Parameters of Fibrin Clot formed from Plasma or Purified Fibrinogen Samples 
¶ Concentrations: Parameters significantly increased/decreased after different concentrations of particles treatment 
˄There were no significant difference found after particles treatment from control. 
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 PM10 PM0.2 Total Diesel Particles Filtered Diesel Particles SiO2 NPs 
Von Willebrand Factor 
Increased 
From 0.1 µg/ml¶ 
Increased 
From 0.1 µg/ml¶ 
Increased  
From 0.1 µg/ml¶  
Increased 
From 1 µg/ml¶  
Increased 
From 1 µg/ml¶ 
Plasminogen Activator Inhibitor-1 
Increased 
From 0.1 µg/ml¶ 
Increased 
From 10 µg/ml¶ 
Increased 
From 1 µg/ml¶  
Increased 
From 10 µg/ml¶  
No difference˄ 
Tissue Factor mRNA 
Increased 
From 0.1 µg/ml¶ 
Increased 
From 1 µg/ml¶ 
Increased 
From 0.1 µg/ml¶ 
Increased 




From 0.1 µg/ml¶ 
Decreased 
From 0.1 µg/ml¶  
Decreased 
From 0.1 µg/ml¶  
Decreased 
From 1 µg/ml¶  
Decreased 
From 10 µg/ml¶  
Free Radicals 
Increased 
From 10 µg/ml¶ 
Increased 
From 50 µg/ml¶ 
Increased 
From 50 µg/ml¶  
Increased 




From 10 µg/ml¶ 
Increased 
From 10 µg/ml¶ 
Increased 
From 10 µg/ml¶ 
Increased 
From 10 µg/ml¶ 
Increased 
From 1 µg/ml¶ 
Fibre Number--Fibrinogen No difference˄ No difference˄ No difference˄ No difference˄ No difference˄ 
Table 7-2. Summary of Proteins/Gene Expression and Fibrin Clot Structure of HUVEC after Treatment with Different Particles 
¶ Concentrations of Particles: Proteins/Gene expressions or fibre numbers significantly increased or decreased after different concentrations of 
particles treatment 
˄There were no significant difference found after particles treatment from control.
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There is increasing recognition that PM in air pollution is associated with cardiovascular 
mortality and morbidity. The results presented here show that PM can induce changes to clot 
structure and function, and that changes in gene expression induced in endothelial cells may 
be a mechanism by which a prothrombotic state is induced in response to PM exposure. 
Furthermore, some, but not all, similar changes were observed in clots and cells exposed to 
silica NPs, raising the possibility that such engineered nanoparticles may also have the 
potential to contribute to cardiovascular toxicity. This adds to existing evidence as to the 
hazards associated with such NPs. 
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